6	TAFINLAR.xml:S1:4:1	O
ADVERSE	TAFINLAR.xml:S1:6:7	O
REACTIONS	TAFINLAR.xml:S1:14:9	O

The	TAFINLAR.xml:S1:27:3	O
following	TAFINLAR.xml:S1:31:9	O
adverse	TAFINLAR.xml:S1:41:7	O
reactions	TAFINLAR.xml:S1:49:9	O
are	TAFINLAR.xml:S1:59:3	O
discussed	TAFINLAR.xml:S1:63:9	O
in	TAFINLAR.xml:S1:73:2	O
greater	TAFINLAR.xml:S1:76:7	O
detail	TAFINLAR.xml:S1:84:6	O
in	TAFINLAR.xml:S1:91:2	O
another	TAFINLAR.xml:S1:94:7	O
section	TAFINLAR.xml:S1:102:7	O
of	TAFINLAR.xml:S1:110:2	O
the	TAFINLAR.xml:S1:113:3	O
label	TAFINLAR.xml:S1:117:5	O
:	TAFINLAR.xml:S1:122:1	O

New	TAFINLAR.xml:S1:133:3	O
Primary	TAFINLAR.xml:S1:137:7	B-AdverseReaction
Malignancies	TAFINLAR.xml:S1:145:12	I-AdverseReaction
[	TAFINLAR.xml:S1:158:1	O
see	TAFINLAR.xml:S1:159:3	O
Warnings	TAFINLAR.xml:S1:163:8	O
and	TAFINLAR.xml:S1:172:3	O
Precautions	TAFINLAR.xml:S1:176:11	O
(	TAFINLAR.xml:S1:188:1	O
5.1	TAFINLAR.xml:S1:189:3	O
)]	TAFINLAR.xml:S1:192:2	O

Tumor	TAFINLAR.xml:S1:203:5	B-AdverseReaction
Promotion	TAFINLAR.xml:S1:209:9	I-AdverseReaction
in	TAFINLAR.xml:S1:219:2	I-AdverseReaction
BRAF	TAFINLAR.xml:S1:222:4	I-AdverseReaction
Wild	TAFINLAR.xml:S1:227:4	I-AdverseReaction
-	TAFINLAR.xml:S1:231:1	I-AdverseReaction
Type	TAFINLAR.xml:S1:232:4	I-AdverseReaction
Melanoma	TAFINLAR.xml:S1:237:8	I-AdverseReaction
[	TAFINLAR.xml:S1:246:1	O
see	TAFINLAR.xml:S1:247:3	O
Warnings	TAFINLAR.xml:S1:251:8	O
and	TAFINLAR.xml:S1:260:3	O
Precautions	TAFINLAR.xml:S1:264:11	O
(	TAFINLAR.xml:S1:276:1	O
5.2	TAFINLAR.xml:S1:277:3	O
)]	TAFINLAR.xml:S1:280:2	O

Hemorrhage	TAFINLAR.xml:S1:291:10	B-AdverseReaction
[	TAFINLAR.xml:S1:302:1	O
see	TAFINLAR.xml:S1:303:3	O
Warnings	TAFINLAR.xml:S1:307:8	O
and	TAFINLAR.xml:S1:316:3	O
Precautions	TAFINLAR.xml:S1:320:11	O
(	TAFINLAR.xml:S1:332:1	O
5.3	TAFINLAR.xml:S1:333:3	O
)]	TAFINLAR.xml:S1:336:2	O

Venous	TAFINLAR.xml:S1:347:6	B-AdverseReaction
Thromboembolism	TAFINLAR.xml:S1:354:15	I-AdverseReaction
[	TAFINLAR.xml:S1:370:1	O
see	TAFINLAR.xml:S1:371:3	O
Warnings	TAFINLAR.xml:S1:375:8	O
and	TAFINLAR.xml:S1:384:3	O
Precautions	TAFINLAR.xml:S1:388:11	O
(	TAFINLAR.xml:S1:400:1	O
5.4	TAFINLAR.xml:S1:401:3	O
)]	TAFINLAR.xml:S1:404:2	O

Cardiomyopathy	TAFINLAR.xml:S1:415:14	B-AdverseReaction
[	TAFINLAR.xml:S1:430:1	O
see	TAFINLAR.xml:S1:431:3	O
Warnings	TAFINLAR.xml:S1:435:8	O
and	TAFINLAR.xml:S1:444:3	O
Precautions	TAFINLAR.xml:S1:448:11	O
(	TAFINLAR.xml:S1:460:1	O
5.5	TAFINLAR.xml:S1:461:3	O
)]	TAFINLAR.xml:S1:464:2	O

Ocular	TAFINLAR.xml:S1:475:6	B-AdverseReaction
Toxicities	TAFINLAR.xml:S1:482:10	I-AdverseReaction
[	TAFINLAR.xml:S1:493:1	O
see	TAFINLAR.xml:S1:494:3	O
Warnings	TAFINLAR.xml:S1:498:8	O
and	TAFINLAR.xml:S1:507:3	O
Precautions	TAFINLAR.xml:S1:511:11	O
(	TAFINLAR.xml:S1:523:1	O
5.6	TAFINLAR.xml:S1:524:3	O
)]	TAFINLAR.xml:S1:527:2	O

Serious	TAFINLAR.xml:S1:538:7	B-Severity
Febrile	TAFINLAR.xml:S1:546:7	B-AdverseReaction
Reactions	TAFINLAR.xml:S1:554:9	I-AdverseReaction
[	TAFINLAR.xml:S1:564:1	O
see	TAFINLAR.xml:S1:565:3	O
Warnings	TAFINLAR.xml:S1:569:8	O
and	TAFINLAR.xml:S1:578:3	O
Precautions	TAFINLAR.xml:S1:582:11	O
(	TAFINLAR.xml:S1:594:1	O
5.7	TAFINLAR.xml:S1:595:3	O
)]	TAFINLAR.xml:S1:598:2	O

Serious	TAFINLAR.xml:S1:609:7	B-Severity
Skin	TAFINLAR.xml:S1:617:4	B-AdverseReaction
Toxicity	TAFINLAR.xml:S1:622:8	I-AdverseReaction
[	TAFINLAR.xml:S1:631:1	O
see	TAFINLAR.xml:S1:632:3	O
Warnings	TAFINLAR.xml:S1:636:8	O
and	TAFINLAR.xml:S1:645:3	O
Precautions	TAFINLAR.xml:S1:649:11	O
(	TAFINLAR.xml:S1:661:1	O
5.8	TAFINLAR.xml:S1:662:3	O
)]	TAFINLAR.xml:S1:665:2	O

Hyperglycemia	TAFINLAR.xml:S1:676:13	B-AdverseReaction
[	TAFINLAR.xml:S1:690:1	O
see	TAFINLAR.xml:S1:691:3	O
Warnings	TAFINLAR.xml:S1:695:8	O
and	TAFINLAR.xml:S1:704:3	O
Precautions	TAFINLAR.xml:S1:708:11	O
(	TAFINLAR.xml:S1:720:1	O
5.9	TAFINLAR.xml:S1:721:3	O
)]	TAFINLAR.xml:S1:724:2	O

Glucose	TAFINLAR.xml:S1:735:7	B-AdverseReaction
-	TAFINLAR.xml:S1:742:1	I-AdverseReaction
6	TAFINLAR.xml:S1:743:1	I-AdverseReaction
-	TAFINLAR.xml:S1:744:1	I-AdverseReaction
Phosphate	TAFINLAR.xml:S1:745:9	I-AdverseReaction
Dehydrogenase	TAFINLAR.xml:S1:755:13	I-AdverseReaction
Deficiency	TAFINLAR.xml:S1:769:10	I-AdverseReaction
[	TAFINLAR.xml:S1:780:1	O
see	TAFINLAR.xml:S1:781:3	O
Warnings	TAFINLAR.xml:S1:785:8	O
and	TAFINLAR.xml:S1:794:3	O
Precautions	TAFINLAR.xml:S1:798:11	O
(	TAFINLAR.xml:S1:810:1	O
5.10	TAFINLAR.xml:S1:811:4	O
)]	TAFINLAR.xml:S1:815:2	O

Most	TAFINLAR.xml:S1:828:4	O
common	TAFINLAR.xml:S1:833:6	O
adverse	TAFINLAR.xml:S1:840:7	O
reactions	TAFINLAR.xml:S1:848:9	O
(	TAFINLAR.xml:S1:858:1	O
20%	TAFINLAR.xml:S1:861:3	O
)	TAFINLAR.xml:S1:864:1	O
for	TAFINLAR.xml:S1:866:3	O
TAFINLAR	TAFINLAR.xml:S1:870:8	O
as	TAFINLAR.xml:S1:879:2	O
a	TAFINLAR.xml:S1:882:1	O
single	TAFINLAR.xml:S1:884:6	O
agent	TAFINLAR.xml:S1:891:5	O
are	TAFINLAR.xml:S1:897:3	O
hyperkeratosis	TAFINLAR.xml:S1:901:14	B-AdverseReaction
,	TAFINLAR.xml:S1:915:1	O
headache	TAFINLAR.xml:S1:917:8	B-AdverseReaction
,	TAFINLAR.xml:S1:925:1	O
pyrexia	TAFINLAR.xml:S1:927:7	B-AdverseReaction
,	TAFINLAR.xml:S1:934:1	O
arthralgia	TAFINLAR.xml:S1:936:10	B-AdverseReaction
,	TAFINLAR.xml:S1:946:1	O
papilloma	TAFINLAR.xml:S1:948:9	B-AdverseReaction
,	TAFINLAR.xml:S1:957:1	O
alopecia	TAFINLAR.xml:S1:959:8	B-AdverseReaction
,	TAFINLAR.xml:S1:967:1	O
and	TAFINLAR.xml:S1:969:3	O
palmar	TAFINLAR.xml:S1:973:6	B-AdverseReaction
-	TAFINLAR.xml:S1:979:1	I-AdverseReaction
plantar	TAFINLAR.xml:S1:980:7	I-AdverseReaction
erythrodysesthesia	TAFINLAR.xml:S1:988:18	I-AdverseReaction
syndrome	TAFINLAR.xml:S1:1007:8	I-AdverseReaction
.	TAFINLAR.xml:S1:1015:1	O

(	TAFINLAR.xml:S1:1017:1	O
6.1	TAFINLAR.xml:S1:1020:3	O
)	TAFINLAR.xml:S1:1025:1	O

Most	TAFINLAR.xml:S1:1034:4	O
common	TAFINLAR.xml:S1:1039:6	O
adverse	TAFINLAR.xml:S1:1046:7	O
reactions	TAFINLAR.xml:S1:1054:9	O
(	TAFINLAR.xml:S1:1064:1	O
20%	TAFINLAR.xml:S1:1067:3	O
)	TAFINLAR.xml:S1:1070:1	O
for	TAFINLAR.xml:S1:1072:3	O
TAFINLAR	TAFINLAR.xml:S1:1076:8	O
in	TAFINLAR.xml:S1:1085:2	O
combination	TAFINLAR.xml:S1:1088:11	O
with	TAFINLAR.xml:S1:1100:4	O
trametinib	TAFINLAR.xml:S1:1105:10	O
are	TAFINLAR.xml:S1:1116:3	O
pyrexia	TAFINLAR.xml:S1:1120:7	B-AdverseReaction
,	TAFINLAR.xml:S1:1127:1	O
chills	TAFINLAR.xml:S1:1129:6	B-AdverseReaction
,	TAFINLAR.xml:S1:1135:1	O
fatigue	TAFINLAR.xml:S1:1137:7	B-AdverseReaction
,	TAFINLAR.xml:S1:1144:1	O
rash	TAFINLAR.xml:S1:1146:4	B-AdverseReaction
,	TAFINLAR.xml:S1:1150:1	O
nausea	TAFINLAR.xml:S1:1152:6	B-AdverseReaction
,	TAFINLAR.xml:S1:1158:1	O
vomiting	TAFINLAR.xml:S1:1160:8	B-AdverseReaction
,	TAFINLAR.xml:S1:1168:1	O
diarrhea	TAFINLAR.xml:S1:1170:8	B-AdverseReaction
,	TAFINLAR.xml:S1:1178:1	O
abdominal	TAFINLAR.xml:S1:1180:9	B-AdverseReaction
pain	TAFINLAR.xml:S1:1190:4	I-AdverseReaction
,	TAFINLAR.xml:S1:1194:1	O
peripheral	TAFINLAR.xml:S1:1196:10	B-AdverseReaction
edema	TAFINLAR.xml:S1:1207:5	I-AdverseReaction
,	TAFINLAR.xml:S1:1212:1	O
cough	TAFINLAR.xml:S1:1214:5	B-AdverseReaction
,	TAFINLAR.xml:S1:1219:1	O
headache	TAFINLAR.xml:S1:1221:8	B-AdverseReaction
,	TAFINLAR.xml:S1:1229:1	O
arthralgia	TAFINLAR.xml:S1:1231:10	B-AdverseReaction
,	TAFINLAR.xml:S1:1241:1	O
night	TAFINLAR.xml:S1:1243:5	B-AdverseReaction
sweats	TAFINLAR.xml:S1:1249:6	I-AdverseReaction
,	TAFINLAR.xml:S1:1255:1	O
decreased	TAFINLAR.xml:S1:1257:9	B-AdverseReaction
appetite	TAFINLAR.xml:S1:1267:8	I-AdverseReaction
,	TAFINLAR.xml:S1:1275:1	O
constipation	TAFINLAR.xml:S1:1277:12	B-AdverseReaction
,	TAFINLAR.xml:S1:1289:1	O
and	TAFINLAR.xml:S1:1291:3	O
myalgia	TAFINLAR.xml:S1:1295:7	B-AdverseReaction
.	TAFINLAR.xml:S1:1302:1	O

(	TAFINLAR.xml:S1:1304:1	O
6.1	TAFINLAR.xml:S1:1307:3	O
)	TAFINLAR.xml:S1:1312:1	O

EXCERPT	TAFINLAR.xml:S1:1321:7	O
:	TAFINLAR.xml:S1:1328:1	O
To	TAFINLAR.xml:S1:1334:2	O
report	TAFINLAR.xml:S1:1337:6	O
SUSPECTED	TAFINLAR.xml:S1:1344:9	O
ADVERSE	TAFINLAR.xml:S1:1354:7	O
REACTIONS	TAFINLAR.xml:S1:1362:9	O
,	TAFINLAR.xml:S1:1371:1	O
contact	TAFINLAR.xml:S1:1373:7	O
GlaxoSmithKline	TAFINLAR.xml:S1:1381:15	O
at	TAFINLAR.xml:S1:1397:2	O
1	TAFINLAR.xml:S1:1400:1	O
-	TAFINLAR.xml:S1:1401:1	O
888	TAFINLAR.xml:S1:1402:3	O
-	TAFINLAR.xml:S1:1405:1	O
825	TAFINLAR.xml:S1:1406:3	O
-	TAFINLAR.xml:S1:1409:1	O
5249	TAFINLAR.xml:S1:1410:4	O
or	TAFINLAR.xml:S1:1415:2	O
FDA	TAFINLAR.xml:S1:1418:3	O
at	TAFINLAR.xml:S1:1422:2	O
1	TAFINLAR.xml:S1:1425:1	O
-	TAFINLAR.xml:S1:1426:1	O
800	TAFINLAR.xml:S1:1427:3	O
-	TAFINLAR.xml:S1:1430:1	O
FDA	TAFINLAR.xml:S1:1431:3	O
-	TAFINLAR.xml:S1:1434:1	O
1088	TAFINLAR.xml:S1:1435:4	O
or	TAFINLAR.xml:S1:1440:2	O
www	TAFINLAR.xml:S1:1446:3	O
.	TAFINLAR.xml:S1:1449:1	O
fda	TAFINLAR.xml:S1:1450:3	O
.	TAFINLAR.xml:S1:1453:1	O
gov	TAFINLAR.xml:S1:1454:3	O
medwatch	TAFINLAR.xml:S1:1458:8	O
.	TAFINLAR.xml:S1:1466:1	O

6.1	TAFINLAR.xml:S1:1478:3	O

Clinical	TAFINLAR.xml:S1:1482:8	O

Trials	TAFINLAR.xml:S1:1491:6	O
Experience	TAFINLAR.xml:S1:1498:10	O

Because	TAFINLAR.xml:S1:1512:7	O
clinical	TAFINLAR.xml:S1:1520:8	O
trials	TAFINLAR.xml:S1:1529:6	O
are	TAFINLAR.xml:S1:1536:3	O
conducted	TAFINLAR.xml:S1:1540:9	O
under	TAFINLAR.xml:S1:1550:5	O
widely	TAFINLAR.xml:S1:1556:6	O
varying	TAFINLAR.xml:S1:1563:7	O
conditions	TAFINLAR.xml:S1:1571:10	O
,	TAFINLAR.xml:S1:1581:1	O
adverse	TAFINLAR.xml:S1:1583:7	O
reaction	TAFINLAR.xml:S1:1591:8	O
rates	TAFINLAR.xml:S1:1600:5	O
observed	TAFINLAR.xml:S1:1606:8	O
in	TAFINLAR.xml:S1:1615:2	O
the	TAFINLAR.xml:S1:1618:3	O
clinical	TAFINLAR.xml:S1:1622:8	O
trials	TAFINLAR.xml:S1:1631:6	O
of	TAFINLAR.xml:S1:1638:2	O
a	TAFINLAR.xml:S1:1641:1	O
drug	TAFINLAR.xml:S1:1643:4	O
cannot	TAFINLAR.xml:S1:1648:6	O
be	TAFINLAR.xml:S1:1655:2	O
directly	TAFINLAR.xml:S1:1658:8	O
compared	TAFINLAR.xml:S1:1667:8	O
to	TAFINLAR.xml:S1:1676:2	O
rates	TAFINLAR.xml:S1:1679:5	O
in	TAFINLAR.xml:S1:1685:2	O
the	TAFINLAR.xml:S1:1688:3	O
clinical	TAFINLAR.xml:S1:1692:8	O
trials	TAFINLAR.xml:S1:1701:6	O
of	TAFINLAR.xml:S1:1708:2	O
another	TAFINLAR.xml:S1:1711:7	O
drug	TAFINLAR.xml:S1:1719:4	O
and	TAFINLAR.xml:S1:1724:3	O
may	TAFINLAR.xml:S1:1728:3	O
not	TAFINLAR.xml:S1:1732:3	O
reflect	TAFINLAR.xml:S1:1736:7	O
the	TAFINLAR.xml:S1:1744:3	O
rates	TAFINLAR.xml:S1:1748:5	O
observed	TAFINLAR.xml:S1:1754:8	O
in	TAFINLAR.xml:S1:1763:2	O
practice	TAFINLAR.xml:S1:1766:8	O
.	TAFINLAR.xml:S1:1774:1	O

The	TAFINLAR.xml:S1:1780:3	O
data	TAFINLAR.xml:S1:1784:4	O
described	TAFINLAR.xml:S1:1789:9	O
in	TAFINLAR.xml:S1:1799:2	O
the	TAFINLAR.xml:S1:1802:3	O
Warnings	TAFINLAR.xml:S1:1806:8	O
and	TAFINLAR.xml:S1:1815:3	O
Precautions	TAFINLAR.xml:S1:1819:11	O
section	TAFINLAR.xml:S1:1831:7	O
and	TAFINLAR.xml:S1:1839:3	O
below	TAFINLAR.xml:S1:1843:5	O
reflect	TAFINLAR.xml:S1:1849:7	O
exposure	TAFINLAR.xml:S1:1857:8	O
to	TAFINLAR.xml:S1:1866:2	O
TAFINLAR	TAFINLAR.xml:S1:1869:8	O
as	TAFINLAR.xml:S1:1878:2	O
a	TAFINLAR.xml:S1:1881:1	O
single	TAFINLAR.xml:S1:1883:6	O
agent	TAFINLAR.xml:S1:1890:5	O
and	TAFINLAR.xml:S1:1896:3	O
in	TAFINLAR.xml:S1:1900:2	O
combination	TAFINLAR.xml:S1:1903:11	O
with	TAFINLAR.xml:S1:1915:4	O
trametinib	TAFINLAR.xml:S1:1920:10	O
.	TAFINLAR.xml:S1:1930:1	O

BRAF	TAFINLAR.xml:S1:1938:4	O
V600E	TAFINLAR.xml:S1:1943:5	O
Unresectable	TAFINLAR.xml:S1:1949:12	O
or	TAFINLAR.xml:S1:1962:2	O
Metastatic	TAFINLAR.xml:S1:1965:10	O
Melanoma	TAFINLAR.xml:S1:1976:8	O
:	TAFINLAR.xml:S1:1984:1	O

The	TAFINLAR.xml:S1:1992:3	O
safety	TAFINLAR.xml:S1:1996:6	O
of	TAFINLAR.xml:S1:2003:2	O
TAFINLAR	TAFINLAR.xml:S1:2006:8	O
as	TAFINLAR.xml:S1:2015:2	O
a	TAFINLAR.xml:S1:2018:1	O
single	TAFINLAR.xml:S1:2020:6	O
agent	TAFINLAR.xml:S1:2027:5	O
was	TAFINLAR.xml:S1:2033:3	O
evaluated	TAFINLAR.xml:S1:2037:9	O
in	TAFINLAR.xml:S1:2047:2	O
586	TAFINLAR.xml:S1:2050:3	O
patients	TAFINLAR.xml:S1:2054:8	O
with	TAFINLAR.xml:S1:2063:4	O
BRAF	TAFINLAR.xml:S1:2068:4	O
V600	TAFINLAR.xml:S1:2073:4	O
mutation	TAFINLAR.xml:S1:2078:8	O
-	TAFINLAR.xml:S1:2086:1	O
positive	TAFINLAR.xml:S1:2087:8	O
unresectable	TAFINLAR.xml:S1:2096:12	O
or	TAFINLAR.xml:S1:2109:2	O
metastatic	TAFINLAR.xml:S1:2112:10	O
melanoma	TAFINLAR.xml:S1:2123:8	O
,	TAFINLAR.xml:S1:2131:1	O
previously	TAFINLAR.xml:S1:2133:10	O
treated	TAFINLAR.xml:S1:2144:7	O
or	TAFINLAR.xml:S1:2152:2	O
untreated	TAFINLAR.xml:S1:2155:9	O
,	TAFINLAR.xml:S1:2164:1	O
who	TAFINLAR.xml:S1:2166:3	O
received	TAFINLAR.xml:S1:2170:8	O
TAFINLAR	TAFINLAR.xml:S1:2179:8	O
150	TAFINLAR.xml:S1:2188:3	O
mg	TAFINLAR.xml:S1:2192:2	O
orally	TAFINLAR.xml:S1:2195:6	O
twice	TAFINLAR.xml:S1:2202:5	O
daily	TAFINLAR.xml:S1:2208:5	O
until	TAFINLAR.xml:S1:2214:5	O
disease	TAFINLAR.xml:S1:2220:7	O
progression	TAFINLAR.xml:S1:2228:11	O
or	TAFINLAR.xml:S1:2240:2	O
unacceptable	TAFINLAR.xml:S1:2243:12	O
toxicity	TAFINLAR.xml:S1:2256:8	O
,	TAFINLAR.xml:S1:2264:1	O
including	TAFINLAR.xml:S1:2266:9	O
181	TAFINLAR.xml:S1:2276:3	O
patients	TAFINLAR.xml:S1:2280:8	O
treated	TAFINLAR.xml:S1:2289:7	O
for	TAFINLAR.xml:S1:2297:3	O
at	TAFINLAR.xml:S1:2301:2	O
least	TAFINLAR.xml:S1:2304:5	O
6	TAFINLAR.xml:S1:2310:1	O
months	TAFINLAR.xml:S1:2312:6	O
and	TAFINLAR.xml:S1:2319:3	O
86	TAFINLAR.xml:S1:2323:2	O
additional	TAFINLAR.xml:S1:2326:10	O
patients	TAFINLAR.xml:S1:2337:8	O
treated	TAFINLAR.xml:S1:2346:7	O
for	TAFINLAR.xml:S1:2354:3	O
more	TAFINLAR.xml:S1:2358:4	O
than	TAFINLAR.xml:S1:2363:4	O
12	TAFINLAR.xml:S1:2368:2	O
months	TAFINLAR.xml:S1:2371:6	O
.	TAFINLAR.xml:S1:2377:1	O

TAFINLAR	TAFINLAR.xml:S1:2379:8	O
was	TAFINLAR.xml:S1:2388:3	O
studied	TAFINLAR.xml:S1:2392:7	O
in	TAFINLAR.xml:S1:2400:2	O
open	TAFINLAR.xml:S1:2403:4	O
-	TAFINLAR.xml:S1:2407:1	O
label	TAFINLAR.xml:S1:2408:5	O
,	TAFINLAR.xml:S1:2413:1	O
single	TAFINLAR.xml:S1:2415:6	O
-	TAFINLAR.xml:S1:2421:1	O
arm	TAFINLAR.xml:S1:2422:3	O
trials	TAFINLAR.xml:S1:2426:6	O
and	TAFINLAR.xml:S1:2433:3	O
in	TAFINLAR.xml:S1:2437:2	O
an	TAFINLAR.xml:S1:2440:2	O
open	TAFINLAR.xml:S1:2443:4	O
-	TAFINLAR.xml:S1:2447:1	O
label	TAFINLAR.xml:S1:2448:5	O
,	TAFINLAR.xml:S1:2453:1	O
randomized	TAFINLAR.xml:S1:2455:10	O
,	TAFINLAR.xml:S1:2465:1	O
active	TAFINLAR.xml:S1:2467:6	O
-	TAFINLAR.xml:S1:2473:1	O
controlled	TAFINLAR.xml:S1:2474:10	O
trial	TAFINLAR.xml:S1:2485:5	O
.	TAFINLAR.xml:S1:2490:1	O

The	TAFINLAR.xml:S1:2492:3	O
median	TAFINLAR.xml:S1:2496:6	O
daily	TAFINLAR.xml:S1:2503:5	O
dose	TAFINLAR.xml:S1:2509:4	O
of	TAFINLAR.xml:S1:2514:2	O
TAFINLAR	TAFINLAR.xml:S1:2517:8	O
was	TAFINLAR.xml:S1:2526:3	O
300	TAFINLAR.xml:S1:2530:3	O
mg	TAFINLAR.xml:S1:2534:2	O
(	TAFINLAR.xml:S1:2537:1	O
range	TAFINLAR.xml:S1:2538:5	O
:	TAFINLAR.xml:S1:2543:1	O
118	TAFINLAR.xml:S1:2545:3	O
to	TAFINLAR.xml:S1:2549:2	O
300	TAFINLAR.xml:S1:2552:3	O
mg	TAFINLAR.xml:S1:2556:2	O
)	TAFINLAR.xml:S1:2558:1	O
.	TAFINLAR.xml:S1:2559:1	O

Table	TAFINLAR.xml:S1:2565:5	O
3	TAFINLAR.xml:S1:2571:1	O
and	TAFINLAR.xml:S1:2573:3	O
Table	TAFINLAR.xml:S1:2577:5	O
4	TAFINLAR.xml:S1:2583:1	O
present	TAFINLAR.xml:S1:2585:7	O
adverse	TAFINLAR.xml:S1:2593:7	O
drug	TAFINLAR.xml:S1:2601:4	O
reactions	TAFINLAR.xml:S1:2606:9	O
and	TAFINLAR.xml:S1:2616:3	O
laboratory	TAFINLAR.xml:S1:2620:10	O
abnormalities	TAFINLAR.xml:S1:2631:13	O
identified	TAFINLAR.xml:S1:2645:10	O
from	TAFINLAR.xml:S1:2656:4	O
analyses	TAFINLAR.xml:S1:2661:8	O
of	TAFINLAR.xml:S1:2670:2	O
Trial	TAFINLAR.xml:S1:2673:5	O
1	TAFINLAR.xml:S1:2679:1	O
[	TAFINLAR.xml:S1:2682:1	O
see	TAFINLAR.xml:S1:2683:3	O
Clinical	TAFINLAR.xml:S1:2687:8	O
Studies	TAFINLAR.xml:S1:2696:7	O
(	TAFINLAR.xml:S1:2704:1	O
14.1	TAFINLAR.xml:S1:2705:4	O
)]	TAFINLAR.xml:S1:2709:2	O
.	TAFINLAR.xml:S1:2711:1	O

Trial	TAFINLAR.xml:S1:2714:5	O
1	TAFINLAR.xml:S1:2720:1	O
,	TAFINLAR.xml:S1:2721:1	O
a	TAFINLAR.xml:S1:2723:1	O
multicenter	TAFINLAR.xml:S1:2725:11	O
,	TAFINLAR.xml:S1:2736:1	O
international	TAFINLAR.xml:S1:2738:13	O
,	TAFINLAR.xml:S1:2751:1	O
open	TAFINLAR.xml:S1:2753:4	O
-	TAFINLAR.xml:S1:2757:1	O
label	TAFINLAR.xml:S1:2758:5	O
,	TAFINLAR.xml:S1:2763:1	O
randomized	TAFINLAR.xml:S1:2765:10	O
(	TAFINLAR.xml:S1:2776:1	O
3	TAFINLAR.xml:S1:2777:1	O
:	TAFINLAR.xml:S1:2778:1	O
1	TAFINLAR.xml:S1:2779:1	O
)	TAFINLAR.xml:S1:2780:1	O
,	TAFINLAR.xml:S1:2781:1	O
controlled	TAFINLAR.xml:S1:2783:10	O
trial	TAFINLAR.xml:S1:2794:5	O
allocated	TAFINLAR.xml:S1:2800:9	O
250	TAFINLAR.xml:S1:2810:3	O
patients	TAFINLAR.xml:S1:2814:8	O
with	TAFINLAR.xml:S1:2823:4	O
unresectable	TAFINLAR.xml:S1:2828:12	O
or	TAFINLAR.xml:S1:2841:2	O
metastatic	TAFINLAR.xml:S1:2844:10	O
BRAF	TAFINLAR.xml:S1:2855:4	O
V600E	TAFINLAR.xml:S1:2860:5	O
mutation	TAFINLAR.xml:S1:2866:8	O
-	TAFINLAR.xml:S1:2874:1	O
positive	TAFINLAR.xml:S1:2875:8	O
melanoma	TAFINLAR.xml:S1:2884:8	O
to	TAFINLAR.xml:S1:2893:2	O
receive	TAFINLAR.xml:S1:2896:7	O
TAFINLAR	TAFINLAR.xml:S1:2904:8	O
150	TAFINLAR.xml:S1:2913:3	O
mg	TAFINLAR.xml:S1:2917:2	O
orally	TAFINLAR.xml:S1:2920:6	O
twice	TAFINLAR.xml:S1:2927:5	O
daily	TAFINLAR.xml:S1:2933:5	O
(	TAFINLAR.xml:S1:2939:1	O
n	TAFINLAR.xml:S1:2940:1	O
187	TAFINLAR.xml:S1:2944:3	O
)	TAFINLAR.xml:S1:2947:1	O
or	TAFINLAR.xml:S1:2949:2	O
dacarbazine	TAFINLAR.xml:S1:2952:11	O
1	TAFINLAR.xml:S1:2964:1	O
,	TAFINLAR.xml:S1:2965:1	O
000	TAFINLAR.xml:S1:2966:3	O
mg	TAFINLAR.xml:S1:2970:2	O
m	TAFINLAR.xml:S1:2973:1	O
2	TAFINLAR.xml:S1:2976:1	O
intravenously	TAFINLAR.xml:S1:2979:13	O
every	TAFINLAR.xml:S1:2993:5	O
3	TAFINLAR.xml:S1:2999:1	O
weeks	TAFINLAR.xml:S1:3001:5	O
(	TAFINLAR.xml:S1:3007:1	O
n	TAFINLAR.xml:S1:3008:1	O
63	TAFINLAR.xml:S1:3012:2	O
)	TAFINLAR.xml:S1:3014:1	O
.	TAFINLAR.xml:S1:3015:1	O

The	TAFINLAR.xml:S1:3017:3	O
trial	TAFINLAR.xml:S1:3021:5	O
excluded	TAFINLAR.xml:S1:3027:8	O
patients	TAFINLAR.xml:S1:3036:8	O
with	TAFINLAR.xml:S1:3045:4	O
abnormal	TAFINLAR.xml:S1:3050:8	O
left	TAFINLAR.xml:S1:3059:4	O
ventricular	TAFINLAR.xml:S1:3064:11	O
ejection	TAFINLAR.xml:S1:3076:8	O
fraction	TAFINLAR.xml:S1:3085:8	O
or	TAFINLAR.xml:S1:3094:2	O
cardiac	TAFINLAR.xml:S1:3097:7	O
valve	TAFINLAR.xml:S1:3105:5	O
morphology	TAFINLAR.xml:S1:3111:10	O
(	TAFINLAR.xml:S1:3122:1	O
Grade	TAFINLAR.xml:S1:3125:5	O
2	TAFINLAR.xml:S1:3131:1	O
)	TAFINLAR.xml:S1:3132:1	O
,	TAFINLAR.xml:S1:3133:1	O
corrected	TAFINLAR.xml:S1:3135:9	O
QT	TAFINLAR.xml:S1:3145:2	O
interval	TAFINLAR.xml:S1:3148:8	O
480	TAFINLAR.xml:S1:3159:3	O
milliseconds	TAFINLAR.xml:S1:3163:12	O
on	TAFINLAR.xml:S1:3176:2	O
electrocardiogram	TAFINLAR.xml:S1:3179:17	O
,	TAFINLAR.xml:S1:3196:1	O
or	TAFINLAR.xml:S1:3198:2	O
a	TAFINLAR.xml:S1:3201:1	O
known	TAFINLAR.xml:S1:3203:5	O
history	TAFINLAR.xml:S1:3209:7	O
of	TAFINLAR.xml:S1:3217:2	O
glucose	TAFINLAR.xml:S1:3220:7	O
-	TAFINLAR.xml:S1:3227:1	O
6	TAFINLAR.xml:S1:3228:1	O
-	TAFINLAR.xml:S1:3229:1	O
phosphate	TAFINLAR.xml:S1:3230:9	O
dehydrogenase	TAFINLAR.xml:S1:3240:13	O
deficiency	TAFINLAR.xml:S1:3254:10	O
.	TAFINLAR.xml:S1:3264:1	O

The	TAFINLAR.xml:S1:3266:3	O
median	TAFINLAR.xml:S1:3270:6	O
duration	TAFINLAR.xml:S1:3277:8	O
on	TAFINLAR.xml:S1:3286:2	O
treatment	TAFINLAR.xml:S1:3289:9	O
was	TAFINLAR.xml:S1:3299:3	O
4.9	TAFINLAR.xml:S1:3303:3	O
months	TAFINLAR.xml:S1:3307:6	O
for	TAFINLAR.xml:S1:3314:3	O
patients	TAFINLAR.xml:S1:3318:8	O
treated	TAFINLAR.xml:S1:3327:7	O
with	TAFINLAR.xml:S1:3335:4	O
TAFINLAR	TAFINLAR.xml:S1:3340:8	O
and	TAFINLAR.xml:S1:3349:3	O
2.8	TAFINLAR.xml:S1:3353:3	O
months	TAFINLAR.xml:S1:3357:6	O
for	TAFINLAR.xml:S1:3364:3	O
dacarbazine	TAFINLAR.xml:S1:3368:11	O
-	TAFINLAR.xml:S1:3379:1	O
treated	TAFINLAR.xml:S1:3380:7	O
patients	TAFINLAR.xml:S1:3388:8	O
.	TAFINLAR.xml:S1:3396:1	O

The	TAFINLAR.xml:S1:3398:3	O
population	TAFINLAR.xml:S1:3402:10	O
exposed	TAFINLAR.xml:S1:3413:7	O
to	TAFINLAR.xml:S1:3421:2	O
TAFINLAR	TAFINLAR.xml:S1:3424:8	O
was	TAFINLAR.xml:S1:3433:3	O
60%	TAFINLAR.xml:S1:3437:3	O
male	TAFINLAR.xml:S1:3441:4	O
,	TAFINLAR.xml:S1:3445:1	O
99%	TAFINLAR.xml:S1:3447:3	O
white	TAFINLAR.xml:S1:3451:5	O
,	TAFINLAR.xml:S1:3456:1	O
and	TAFINLAR.xml:S1:3458:3	O
had	TAFINLAR.xml:S1:3462:3	O
a	TAFINLAR.xml:S1:3466:1	O
median	TAFINLAR.xml:S1:3468:6	O
age	TAFINLAR.xml:S1:3475:3	O
of	TAFINLAR.xml:S1:3479:2	O
53	TAFINLAR.xml:S1:3482:2	O
years	TAFINLAR.xml:S1:3485:5	O
.	TAFINLAR.xml:S1:3490:1	O

The	TAFINLAR.xml:S1:3496:3	O
most	TAFINLAR.xml:S1:3500:4	O
commonly	TAFINLAR.xml:S1:3505:8	O
occurring	TAFINLAR.xml:S1:3514:9	O
adverse	TAFINLAR.xml:S1:3524:7	O
reactions	TAFINLAR.xml:S1:3532:9	O
(	TAFINLAR.xml:S1:3542:1	O
20%	TAFINLAR.xml:S1:3545:3	O
)	TAFINLAR.xml:S1:3548:1	O
in	TAFINLAR.xml:S1:3550:2	O
patients	TAFINLAR.xml:S1:3553:8	O
treated	TAFINLAR.xml:S1:3562:7	O
with	TAFINLAR.xml:S1:3570:4	O
TAFINLAR	TAFINLAR.xml:S1:3575:8	O
were	TAFINLAR.xml:S1:3584:4	O
,	TAFINLAR.xml:S1:3588:1	O
in	TAFINLAR.xml:S1:3590:2	O
order	TAFINLAR.xml:S1:3593:5	O
of	TAFINLAR.xml:S1:3599:2	O
decreasing	TAFINLAR.xml:S1:3602:10	O
frequency	TAFINLAR.xml:S1:3613:9	O
:	TAFINLAR.xml:S1:3622:1	O
hyperkeratosis	TAFINLAR.xml:S1:3624:14	B-AdverseReaction
,	TAFINLAR.xml:S1:3638:1	O
headache	TAFINLAR.xml:S1:3640:8	B-AdverseReaction
,	TAFINLAR.xml:S1:3648:1	O
pyrexia	TAFINLAR.xml:S1:3650:7	B-AdverseReaction
,	TAFINLAR.xml:S1:3657:1	O
arthralgia	TAFINLAR.xml:S1:3659:10	B-AdverseReaction
,	TAFINLAR.xml:S1:3669:1	O
papilloma	TAFINLAR.xml:S1:3671:9	B-AdverseReaction
,	TAFINLAR.xml:S1:3680:1	O
alopecia	TAFINLAR.xml:S1:3682:8	B-AdverseReaction
,	TAFINLAR.xml:S1:3690:1	O
and	TAFINLAR.xml:S1:3692:3	O
palmar	TAFINLAR.xml:S1:3696:6	B-AdverseReaction
-	TAFINLAR.xml:S1:3702:1	I-AdverseReaction
plantar	TAFINLAR.xml:S1:3703:7	I-AdverseReaction
erythrodysesthesia	TAFINLAR.xml:S1:3711:18	I-AdverseReaction
syndrome	TAFINLAR.xml:S1:3730:8	I-AdverseReaction
(	TAFINLAR.xml:S1:3739:1	O
PPES	TAFINLAR.xml:S1:3740:4	B-AdverseReaction
)	TAFINLAR.xml:S1:3744:1	O
.	TAFINLAR.xml:S1:3745:1	O

The	TAFINLAR.xml:S1:3751:3	O
incidence	TAFINLAR.xml:S1:3755:9	O
of	TAFINLAR.xml:S1:3765:2	O
adverse	TAFINLAR.xml:S1:3768:7	O
events	TAFINLAR.xml:S1:3776:6	O
resulting	TAFINLAR.xml:S1:3783:9	O
in	TAFINLAR.xml:S1:3793:2	O
permanent	TAFINLAR.xml:S1:3796:9	O
discontinuation	TAFINLAR.xml:S1:3806:15	O
of	TAFINLAR.xml:S1:3822:2	O
study	TAFINLAR.xml:S1:3825:5	O
medication	TAFINLAR.xml:S1:3831:10	O
in	TAFINLAR.xml:S1:3842:2	O
Trial	TAFINLAR.xml:S1:3845:5	O
1	TAFINLAR.xml:S1:3851:1	O
was	TAFINLAR.xml:S1:3853:3	O
3%	TAFINLAR.xml:S1:3857:2	O
for	TAFINLAR.xml:S1:3860:3	O
patients	TAFINLAR.xml:S1:3864:8	O
treated	TAFINLAR.xml:S1:3873:7	O
with	TAFINLAR.xml:S1:3881:4	O
TAFINLAR	TAFINLAR.xml:S1:3886:8	O
and	TAFINLAR.xml:S1:3895:3	O
3%	TAFINLAR.xml:S1:3899:2	O
for	TAFINLAR.xml:S1:3902:3	O
patients	TAFINLAR.xml:S1:3906:8	O
treated	TAFINLAR.xml:S1:3915:7	O
with	TAFINLAR.xml:S1:3923:4	O
dacarbazine	TAFINLAR.xml:S1:3928:11	O
.	TAFINLAR.xml:S1:3939:1	O

The	TAFINLAR.xml:S1:3941:3	O
most	TAFINLAR.xml:S1:3945:4	O
frequent	TAFINLAR.xml:S1:3950:8	O
(	TAFINLAR.xml:S1:3959:1	O
2%	TAFINLAR.xml:S1:3962:2	O
)	TAFINLAR.xml:S1:3964:1	O
adverse	TAFINLAR.xml:S1:3966:7	O
reactions	TAFINLAR.xml:S1:3974:9	O
leading	TAFINLAR.xml:S1:3984:7	O
to	TAFINLAR.xml:S1:3992:2	O
dose	TAFINLAR.xml:S1:3995:4	O
reduction	TAFINLAR.xml:S1:4000:9	O
of	TAFINLAR.xml:S1:4010:2	O
TAFINLAR	TAFINLAR.xml:S1:4013:8	O
were	TAFINLAR.xml:S1:4022:4	O
pyrexia	TAFINLAR.xml:S1:4027:7	B-AdverseReaction
(	TAFINLAR.xml:S1:4035:1	O
9%	TAFINLAR.xml:S1:4036:2	O
)	TAFINLAR.xml:S1:4038:1	O
,	TAFINLAR.xml:S1:4039:1	O
PPES	TAFINLAR.xml:S1:4041:4	B-AdverseReaction
(	TAFINLAR.xml:S1:4046:1	O
3%	TAFINLAR.xml:S1:4047:2	O
)	TAFINLAR.xml:S1:4049:1	O
,	TAFINLAR.xml:S1:4050:1	O
chills	TAFINLAR.xml:S1:4052:6	B-AdverseReaction
(	TAFINLAR.xml:S1:4059:1	O
3%	TAFINLAR.xml:S1:4060:2	O
)	TAFINLAR.xml:S1:4062:1	O
,	TAFINLAR.xml:S1:4063:1	O
fatigue	TAFINLAR.xml:S1:4065:7	B-AdverseReaction
(	TAFINLAR.xml:S1:4073:1	O
2%	TAFINLAR.xml:S1:4074:2	O
)	TAFINLAR.xml:S1:4076:1	O
,	TAFINLAR.xml:S1:4077:1	O
and	TAFINLAR.xml:S1:4079:3	O
headache	TAFINLAR.xml:S1:4083:8	B-AdverseReaction
(	TAFINLAR.xml:S1:4092:1	O
2%	TAFINLAR.xml:S1:4093:2	O
)	TAFINLAR.xml:S1:4095:1	O
.	TAFINLAR.xml:S1:4096:1	O

Table	TAFINLAR.xml:S1:4102:5	O
3	TAFINLAR.xml:S1:4108:1	O
.	TAFINLAR.xml:S1:4109:1	O

Selected	TAFINLAR.xml:S1:4111:8	O
Common	TAFINLAR.xml:S1:4120:6	O
Adverse	TAFINLAR.xml:S1:4127:7	O
Reactions	TAFINLAR.xml:S1:4135:9	O
Occurring	TAFINLAR.xml:S1:4145:9	O
in	TAFINLAR.xml:S1:4155:2	O
10%	TAFINLAR.xml:S1:4160:3	O
(	TAFINLAR.xml:S1:4164:1	O
All	TAFINLAR.xml:S1:4165:3	O
Grades	TAFINLAR.xml:S1:4169:6	O
)	TAFINLAR.xml:S1:4175:1	O
or	TAFINLAR.xml:S1:4177:2	O
2%	TAFINLAR.xml:S1:4182:2	O
(	TAFINLAR.xml:S1:4185:1	O
Grades	TAFINLAR.xml:S1:4186:6	O
3	TAFINLAR.xml:S1:4193:1	O
or	TAFINLAR.xml:S1:4195:2	O
4	TAFINLAR.xml:S1:4198:1	O
)	TAFINLAR.xml:S1:4199:1	O
of	TAFINLAR.xml:S1:4201:2	O
Patients	TAFINLAR.xml:S1:4204:8	O
Treated	TAFINLAR.xml:S1:4213:7	O
With	TAFINLAR.xml:S1:4221:4	O
TAFINLARa	TAFINLAR.xml:S1:4226:9	O

TAFINLARN	TAFINLAR.xml:S1:4301:9	O
187	TAFINLAR.xml:S1:4313:3	O
Dacarbazine	TAFINLAR.xml:S1:4320:11	O
N	TAFINLAR.xml:S1:4332:1	O
59	TAFINLAR.xml:S1:4336:2	O

Primary	TAFINLAR.xml:S1:4345:7	O
System	TAFINLAR.xml:S1:4353:6	O
Organ	TAFINLAR.xml:S1:4360:5	O
Class	TAFINLAR.xml:S1:4366:5	O
Preferred	TAFINLAR.xml:S1:4373:9	O
Term	TAFINLAR.xml:S1:4383:4	O
All	TAFINLAR.xml:S1:4407:3	O
Grades	TAFINLAR.xml:S1:4412:6	O
(	TAFINLAR.xml:S1:4419:1	O
)	TAFINLAR.xml:S1:4421:1	O
Grades	TAFINLAR.xml:S1:4426:6	O
3	TAFINLAR.xml:S1:4434:1	O
and	TAFINLAR.xml:S1:4436:3	O
4	TAFINLAR.xml:S1:4440:1	O
b	TAFINLAR.xml:S1:4441:1	O
(	TAFINLAR.xml:S1:4444:1	O
)	TAFINLAR.xml:S1:4446:1	O
All	TAFINLAR.xml:S1:4451:3	O
Grades	TAFINLAR.xml:S1:4456:6	O
(	TAFINLAR.xml:S1:4463:1	O
)	TAFINLAR.xml:S1:4465:1	O
Grades	TAFINLAR.xml:S1:4470:6	O
3	TAFINLAR.xml:S1:4478:1	O
and	TAFINLAR.xml:S1:4480:3	O
4	TAFINLAR.xml:S1:4484:1	O
(	TAFINLAR.xml:S1:4487:1	O
)	TAFINLAR.xml:S1:4489:1	O

Skin	TAFINLAR.xml:S1:4497:4	O
and	TAFINLAR.xml:S1:4502:3	O
subcutaneous	TAFINLAR.xml:S1:4506:12	O
tissue	TAFINLAR.xml:S1:4519:6	O
disorders	TAFINLAR.xml:S1:4526:9	O

Hyperkeratosis	TAFINLAR.xml:S1:4670:14	B-AdverseReaction

37	TAFINLAR.xml:S1:4858:2	O
1	TAFINLAR.xml:S1:4871:1	O
0	TAFINLAR.xml:S1:4882:1	O
0	TAFINLAR.xml:S1:4895:1	O

Alopecia	TAFINLAR.xml:S1:4969:8	B-AdverseReaction

22	TAFINLAR.xml:S1:5157:2	O
NAf	TAFINLAR.xml:S1:5170:3	O
2	TAFINLAR.xml:S1:5181:1	O
NAf	TAFINLAR.xml:S1:5194:3	O

Palmar	TAFINLAR.xml:S1:5268:6	B-AdverseReaction
-	TAFINLAR.xml:S1:5274:1	I-AdverseReaction
plantar	TAFINLAR.xml:S1:5275:7	I-AdverseReaction
erythrodysesthesia	TAFINLAR.xml:S1:5283:18	I-AdverseReaction
syndrome	TAFINLAR.xml:S1:5302:8	I-AdverseReaction

20	TAFINLAR.xml:S1:5456:2	O
2	TAFINLAR.xml:S1:5469:1	O
2	TAFINLAR.xml:S1:5480:1	O
0	TAFINLAR.xml:S1:5493:1	O

Rash	TAFINLAR.xml:S1:5567:4	B-AdverseReaction

17	TAFINLAR.xml:S1:5755:2	O
0	TAFINLAR.xml:S1:5768:1	O
0	TAFINLAR.xml:S1:5779:1	O
0	TAFINLAR.xml:S1:5792:1	O

Nervous	TAFINLAR.xml:S1:5805:7	O
system	TAFINLAR.xml:S1:5813:6	O
disorders	TAFINLAR.xml:S1:5820:9	O

Headache	TAFINLAR.xml:S1:5978:8	B-AdverseReaction

32	TAFINLAR.xml:S1:6166:2	O
0	TAFINLAR.xml:S1:6179:1	O
8	TAFINLAR.xml:S1:6190:1	O
0	TAFINLAR.xml:S1:6203:1	O

General	TAFINLAR.xml:S1:6216:7	O
disorders	TAFINLAR.xml:S1:6224:9	O
and	TAFINLAR.xml:S1:6234:3	O
administration	TAFINLAR.xml:S1:6238:14	O
site	TAFINLAR.xml:S1:6253:4	O
conditions	TAFINLAR.xml:S1:6258:10	O

Pyrexia	TAFINLAR.xml:S1:6389:7	B-AdverseReaction

28	TAFINLAR.xml:S1:6577:2	O
3	TAFINLAR.xml:S1:6590:1	O
10	TAFINLAR.xml:S1:6601:2	O
0	TAFINLAR.xml:S1:6614:1	O

Musculoskeletal	TAFINLAR.xml:S1:6627:15	O
and	TAFINLAR.xml:S1:6643:3	O
connective	TAFINLAR.xml:S1:6647:10	O
tissue	TAFINLAR.xml:S1:6658:6	O
disorders	TAFINLAR.xml:S1:6665:9	O

Arthralgia	TAFINLAR.xml:S1:6800:10	B-AdverseReaction

27	TAFINLAR.xml:S1:6988:2	O
1	TAFINLAR.xml:S1:7001:1	O
2	TAFINLAR.xml:S1:7012:1	O
0	TAFINLAR.xml:S1:7025:1	O

Back	TAFINLAR.xml:S1:7099:4	B-AdverseReaction
pain	TAFINLAR.xml:S1:7104:4	I-AdverseReaction

12	TAFINLAR.xml:S1:7287:2	O
3	TAFINLAR.xml:S1:7300:1	O
7	TAFINLAR.xml:S1:7311:1	O
0	TAFINLAR.xml:S1:7324:1	O

Myalgia	TAFINLAR.xml:S1:7398:7	B-AdverseReaction

11	TAFINLAR.xml:S1:7586:2	O
0	TAFINLAR.xml:S1:7599:1	O
0	TAFINLAR.xml:S1:7610:1	O
0	TAFINLAR.xml:S1:7623:1	O

Neoplasms	TAFINLAR.xml:S1:7636:9	O
benign	TAFINLAR.xml:S1:7646:6	O
,	TAFINLAR.xml:S1:7652:1	O
malignant	TAFINLAR.xml:S1:7654:9	O
,	TAFINLAR.xml:S1:7663:1	O
and	TAFINLAR.xml:S1:7665:3	O
unspecified	TAFINLAR.xml:S1:7669:11	O
(	TAFINLAR.xml:S1:7681:1	O
including	TAFINLAR.xml:S1:7682:9	O
cysts	TAFINLAR.xml:S1:7692:5	O
and	TAFINLAR.xml:S1:7698:3	O
polyps	TAFINLAR.xml:S1:7702:6	O
)	TAFINLAR.xml:S1:7708:1	O

Papilloma	TAFINLAR.xml:S1:7824:9	B-AdverseReaction
c	TAFINLAR.xml:S1:7835:1	O

27	TAFINLAR.xml:S1:8012:2	O
0	TAFINLAR.xml:S1:8025:1	O
2	TAFINLAR.xml:S1:8036:1	O
0	TAFINLAR.xml:S1:8049:1	O

cuSCC	TAFINLAR.xml:S1:8123:5	B-AdverseReaction
d	TAFINLAR.xml:S1:8130:1	O
,	TAFINLAR.xml:S1:8131:1	O
e	TAFINLAR.xml:S1:8133:1	O

7	TAFINLAR.xml:S1:8311:1	O
4	TAFINLAR.xml:S1:8324:1	O
0	TAFINLAR.xml:S1:8335:1	O
0	TAFINLAR.xml:S1:8348:1	O

Respiratory	TAFINLAR.xml:S1:8361:11	O
,	TAFINLAR.xml:S1:8372:1	O
thoracic	TAFINLAR.xml:S1:8374:8	O
,	TAFINLAR.xml:S1:8382:1	O
and	TAFINLAR.xml:S1:8384:3	O
mediastinal	TAFINLAR.xml:S1:8388:11	O
disorders	TAFINLAR.xml:S1:8400:9	O

Cough	TAFINLAR.xml:S1:8534:5	B-AdverseReaction

12	TAFINLAR.xml:S1:8722:2	O
0	TAFINLAR.xml:S1:8735:1	O
5	TAFINLAR.xml:S1:8746:1	O
0	TAFINLAR.xml:S1:8759:1	O

Gastrointestinal	TAFINLAR.xml:S1:8772:16	O
disorders	TAFINLAR.xml:S1:8789:9	O

Constipation	TAFINLAR.xml:S1:8945:12	B-AdverseReaction

11	TAFINLAR.xml:S1:9133:2	O
2	TAFINLAR.xml:S1:9146:1	O
14	TAFINLAR.xml:S1:9157:2	O
0	TAFINLAR.xml:S1:9170:1	O

Infections	TAFINLAR.xml:S1:9183:10	O
and	TAFINLAR.xml:S1:9194:3	O
infestations	TAFINLAR.xml:S1:9198:12	O

Nasopharyngitis	TAFINLAR.xml:S1:9356:15	B-AdverseReaction

10	TAFINLAR.xml:S1:9544:2	O
0	TAFINLAR.xml:S1:9557:1	O
3	TAFINLAR.xml:S1:9568:1	O
0	TAFINLAR.xml:S1:9581:1	O

a	TAFINLAR.xml:S1:9605:1	O
Adverse	TAFINLAR.xml:S1:9608:7	O
drug	TAFINLAR.xml:S1:9616:4	O
reactions	TAFINLAR.xml:S1:9621:9	O
,	TAFINLAR.xml:S1:9630:1	O
reported	TAFINLAR.xml:S1:9632:8	O
using	TAFINLAR.xml:S1:9641:5	O
MedDRA	TAFINLAR.xml:S1:9647:6	O
and	TAFINLAR.xml:S1:9654:3	O
graded	TAFINLAR.xml:S1:9658:6	O
using	TAFINLAR.xml:S1:9665:5	O
CTCAE	TAFINLAR.xml:S1:9671:5	O
version	TAFINLAR.xml:S1:9677:7	O
4.0	TAFINLAR.xml:S1:9685:3	O
for	TAFINLAR.xml:S1:9689:3	O
assessment	TAFINLAR.xml:S1:9693:10	O
of	TAFINLAR.xml:S1:9704:2	O
toxicity	TAFINLAR.xml:S1:9707:8	O
.	TAFINLAR.xml:S1:9715:1	O

b	TAFINLAR.xml:S1:9723:1	O

Grade	TAFINLAR.xml:S1:9726:5	B-Severity
4	TAFINLAR.xml:S1:9732:1	I-Severity
adverse	TAFINLAR.xml:S1:9734:7	O
reactions	TAFINLAR.xml:S1:9742:9	O
limited	TAFINLAR.xml:S1:9752:7	O
to	TAFINLAR.xml:S1:9760:2	O
hyperkeratosis	TAFINLAR.xml:S1:9763:14	B-AdverseReaction
(	TAFINLAR.xml:S1:9778:1	O
n	TAFINLAR.xml:S1:9779:1	O
1	TAFINLAR.xml:S1:9783:1	O
)	TAFINLAR.xml:S1:9784:1	O
and	TAFINLAR.xml:S1:9786:3	O
constipation	TAFINLAR.xml:S1:9790:12	B-AdverseReaction
(	TAFINLAR.xml:S1:9803:1	O
n	TAFINLAR.xml:S1:9804:1	O
1	TAFINLAR.xml:S1:9808:1	O
)	TAFINLAR.xml:S1:9809:1	O
.	TAFINLAR.xml:S1:9810:1	O

c	TAFINLAR.xml:S1:9818:1	O
Includes	TAFINLAR.xml:S1:9821:8	O
skin	TAFINLAR.xml:S1:9830:4	B-AdverseReaction
papilloma	TAFINLAR.xml:S1:9835:9	I-AdverseReaction
and	TAFINLAR.xml:S1:9845:3	O
papilloma	TAFINLAR.xml:S1:9849:9	B-AdverseReaction
.	TAFINLAR.xml:S1:9858:1	O

d	TAFINLAR.xml:S1:9866:1	O
Includes	TAFINLAR.xml:S1:9869:8	O
squamous	TAFINLAR.xml:S1:9878:8	B-AdverseReaction
cell	TAFINLAR.xml:S1:9887:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S1:9892:9	I-AdverseReaction
of	TAFINLAR.xml:S1:9902:2	I-AdverseReaction
the	TAFINLAR.xml:S1:9905:3	I-AdverseReaction
skin	TAFINLAR.xml:S1:9909:4	I-AdverseReaction
and	TAFINLAR.xml:S1:9914:3	O
keratoacanthoma	TAFINLAR.xml:S1:9918:15	B-AdverseReaction
.	TAFINLAR.xml:S1:9933:1	O

e	TAFINLAR.xml:S1:9941:1	O
Cases	TAFINLAR.xml:S1:9944:5	O
of	TAFINLAR.xml:S1:9950:2	O
cutaneous	TAFINLAR.xml:S1:9953:9	B-AdverseReaction
squamous	TAFINLAR.xml:S1:9963:8	I-AdverseReaction
cell	TAFINLAR.xml:S1:9972:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S1:9977:9	I-AdverseReaction
were	TAFINLAR.xml:S1:9987:4	O
required	TAFINLAR.xml:S1:9992:8	O
to	TAFINLAR.xml:S1:10001:2	O
be	TAFINLAR.xml:S1:10004:2	O
reported	TAFINLAR.xml:S1:10007:8	O
as	TAFINLAR.xml:S1:10016:2	O
Grade	TAFINLAR.xml:S1:10019:5	B-Severity
3	TAFINLAR.xml:S1:10025:1	I-Severity
per	TAFINLAR.xml:S1:10027:3	O
protocol	TAFINLAR.xml:S1:10031:8	O
.	TAFINLAR.xml:S1:10039:1	O

f	TAFINLAR.xml:S1:10047:1	O
NA	TAFINLAR.xml:S1:10050:2	O
not	TAFINLAR.xml:S1:10055:3	O
applicable	TAFINLAR.xml:S1:10059:10	O
.	TAFINLAR.xml:S1:10069:1	O

Table	TAFINLAR.xml:S1:10075:5	O
4	TAFINLAR.xml:S1:10081:1	O
.	TAFINLAR.xml:S1:10082:1	O

Incidence	TAFINLAR.xml:S1:10084:9	O
of	TAFINLAR.xml:S1:10094:2	O
Laboratory	TAFINLAR.xml:S1:10097:10	O
Abnormalities	TAFINLAR.xml:S1:10108:13	O
Increased	TAFINLAR.xml:S1:10122:9	O
From	TAFINLAR.xml:S1:10132:4	O
Baseline	TAFINLAR.xml:S1:10137:8	O
Occurring	TAFINLAR.xml:S1:10146:9	O
at	TAFINLAR.xml:S1:10156:2	O
a	TAFINLAR.xml:S1:10159:1	O
Higher	TAFINLAR.xml:S1:10161:6	O
Incidence	TAFINLAR.xml:S1:10168:9	O
in	TAFINLAR.xml:S1:10178:2	O
Patients	TAFINLAR.xml:S1:10181:8	O
Treated	TAFINLAR.xml:S1:10190:7	O
With	TAFINLAR.xml:S1:10198:4	O
TAFINLAR	TAFINLAR.xml:S1:10203:8	O
in	TAFINLAR.xml:S1:10212:2	O
Trial	TAFINLAR.xml:S1:10215:5	O
1	TAFINLAR.xml:S1:10221:1	O
[	TAFINLAR.xml:S1:10223:1	O
Between	TAFINLAR.xml:S1:10224:7	O
-	TAFINLAR.xml:S1:10231:1	O
Arm	TAFINLAR.xml:S1:10232:3	O
Difference	TAFINLAR.xml:S1:10236:10	O
of	TAFINLAR.xml:S1:10247:2	O
5%	TAFINLAR.xml:S1:10252:2	O
(	TAFINLAR.xml:S1:10255:1	O
All	TAFINLAR.xml:S1:10256:3	O
Grades	TAFINLAR.xml:S1:10260:6	O
)	TAFINLAR.xml:S1:10266:1	O
or	TAFINLAR.xml:S1:10268:2	O
2%	TAFINLAR.xml:S1:10273:2	O
(	TAFINLAR.xml:S1:10276:1	O
Grades	TAFINLAR.xml:S1:10277:6	O
3	TAFINLAR.xml:S1:10284:1	O
or	TAFINLAR.xml:S1:10286:2	O
4	TAFINLAR.xml:S1:10289:1	O
)]	TAFINLAR.xml:S1:10290:2	O

Test	TAFINLAR.xml:S1:10296:4	O
TAFINLAR	TAFINLAR.xml:S1:10343:8	O
N	TAFINLAR.xml:S1:10353:1	O
187	TAFINLAR.xml:S1:10357:3	O
DTIC	TAFINLAR.xml:S1:10364:4	O
N	TAFINLAR.xml:S1:10370:1	O
59	TAFINLAR.xml:S1:10374:2	O

All	TAFINLAR.xml:S1:10383:3	O
Grades	TAFINLAR.xml:S1:10388:6	O
(	TAFINLAR.xml:S1:10396:1	O
)	TAFINLAR.xml:S1:10398:1	O
Grades	TAFINLAR.xml:S1:10430:6	O
3	TAFINLAR.xml:S1:10438:1	O
and	TAFINLAR.xml:S1:10440:3	O
4	TAFINLAR.xml:S1:10444:1	O
(	TAFINLAR.xml:S1:10447:1	O
)	TAFINLAR.xml:S1:10449:1	O
All	TAFINLAR.xml:S1:10454:3	O
Grades	TAFINLAR.xml:S1:10459:6	O
(	TAFINLAR.xml:S1:10467:1	O
)	TAFINLAR.xml:S1:10469:1	O
Grades	TAFINLAR.xml:S1:10474:6	O
3	TAFINLAR.xml:S1:10482:1	O
and	TAFINLAR.xml:S1:10484:3	O
4	TAFINLAR.xml:S1:10488:1	O
(	TAFINLAR.xml:S1:10491:1	O
)	TAFINLAR.xml:S1:10493:1	O

Hyperglycemia	TAFINLAR.xml:S1:10501:13	B-AdverseReaction
50	TAFINLAR.xml:S1:10548:2	O
6	TAFINLAR.xml:S1:10564:1	O
43	TAFINLAR.xml:S1:10580:2	O
0	TAFINLAR.xml:S1:10596:1	O

Hypophosphatemia	TAFINLAR.xml:S1:10615:16	B-AdverseReaction
37	TAFINLAR.xml:S1:10662:2	O
6	TAFINLAR.xml:S1:10678:1	O
a	TAFINLAR.xml:S1:10679:1	O
14	TAFINLAR.xml:S1:10694:2	O
2	TAFINLAR.xml:S1:10710:1	O

Increased	TAFINLAR.xml:S1:10729:9	B-AdverseReaction
alkaline	TAFINLAR.xml:S1:10739:8	I-AdverseReaction
phosphatase	TAFINLAR.xml:S1:10748:11	I-AdverseReaction
19	TAFINLAR.xml:S1:10776:2	O
0	TAFINLAR.xml:S1:10792:1	O
14	TAFINLAR.xml:S1:10808:2	O
2	TAFINLAR.xml:S1:10824:1	O

Hyponatremia	TAFINLAR.xml:S1:10843:12	B-AdverseReaction
8	TAFINLAR.xml:S1:10890:1	O
2	TAFINLAR.xml:S1:10906:1	O
3	TAFINLAR.xml:S1:10922:1	O
0	TAFINLAR.xml:S1:10938:1	O

a	TAFINLAR.xml:S1:10968:1	O
Grade	TAFINLAR.xml:S1:10971:5	B-Severity
4	TAFINLAR.xml:S1:10977:1	I-Severity
laboratory	TAFINLAR.xml:S1:10979:10	O
abnormality	TAFINLAR.xml:S1:10990:11	O
limited	TAFINLAR.xml:S1:11002:7	O
to	TAFINLAR.xml:S1:11010:2	O
hypophosphatemia	TAFINLAR.xml:S1:11013:16	B-AdverseReaction
(	TAFINLAR.xml:S1:11030:1	O
n	TAFINLAR.xml:S1:11031:1	O
1	TAFINLAR.xml:S1:11035:1	O
)	TAFINLAR.xml:S1:11036:1	O
.	TAFINLAR.xml:S1:11037:1	O

Other	TAFINLAR.xml:S1:11043:5	O

clinically	TAFINLAR.xml:S1:11049:10	O
important	TAFINLAR.xml:S1:11060:9	O
adverse	TAFINLAR.xml:S1:11070:7	O
reactions	TAFINLAR.xml:S1:11078:9	O
observed	TAFINLAR.xml:S1:11088:8	O
in	TAFINLAR.xml:S1:11097:2	O
10%	TAFINLAR.xml:S1:11101:3	O
of	TAFINLAR.xml:S1:11105:2	O
patients	TAFINLAR.xml:S1:11108:8	O
(	TAFINLAR.xml:S1:11117:1	O
N	TAFINLAR.xml:S1:11118:1	O
586	TAFINLAR.xml:S1:11122:3	O
)	TAFINLAR.xml:S1:11125:1	O
treated	TAFINLAR.xml:S1:11127:7	O
with	TAFINLAR.xml:S1:11135:4	O
TAFINLAR	TAFINLAR.xml:S1:11140:8	O
were	TAFINLAR.xml:S1:11149:4	O
:	TAFINLAR.xml:S1:11153:1	O

Gastrointestinal	TAFINLAR.xml:S1:11161:16	O
Disorders	TAFINLAR.xml:S1:11178:9	O
:	TAFINLAR.xml:S1:11187:1	O
Pancreatitis	TAFINLAR.xml:S1:11190:12	B-AdverseReaction
.	TAFINLAR.xml:S1:11202:1	O

Immune	TAFINLAR.xml:S1:11210:6	O
System	TAFINLAR.xml:S1:11217:6	O
Disorders	TAFINLAR.xml:S1:11224:9	O
:	TAFINLAR.xml:S1:11233:1	O
Hypersensitivity	TAFINLAR.xml:S1:11236:16	B-AdverseReaction
manifesting	TAFINLAR.xml:S1:11253:11	O
as	TAFINLAR.xml:S1:11265:2	O
bullous	TAFINLAR.xml:S1:11268:7	B-AdverseReaction
rash	TAFINLAR.xml:S1:11276:4	I-AdverseReaction
.	TAFINLAR.xml:S1:11280:1	O

Renal	TAFINLAR.xml:S1:11288:5	O
and	TAFINLAR.xml:S1:11294:3	O
Urinary	TAFINLAR.xml:S1:11298:7	O
Disorders	TAFINLAR.xml:S1:11306:9	O
:	TAFINLAR.xml:S1:11315:1	O
Interstitial	TAFINLAR.xml:S1:11318:12	B-AdverseReaction
nephritis	TAFINLAR.xml:S1:11331:9	I-AdverseReaction
.	TAFINLAR.xml:S1:11340:1	O

BRAF	TAFINLAR.xml:S1:11348:4	O
V600E	TAFINLAR.xml:S1:11353:5	O
or	TAFINLAR.xml:S1:11359:2	O
V600K	TAFINLAR.xml:S1:11362:5	O
Unresectable	TAFINLAR.xml:S1:11368:12	O
or	TAFINLAR.xml:S1:11381:2	O
Metastatic	TAFINLAR.xml:S1:11384:10	O
Melanoma	TAFINLAR.xml:S1:11395:8	O
:	TAFINLAR.xml:S1:11403:1	O

The	TAFINLAR.xml:S1:11411:3	O
safety	TAFINLAR.xml:S1:11415:6	O
of	TAFINLAR.xml:S1:11422:2	O
TAFINLAR	TAFINLAR.xml:S1:11425:8	O
in	TAFINLAR.xml:S1:11434:2	O
combination	TAFINLAR.xml:S1:11437:11	O
with	TAFINLAR.xml:S1:11449:4	O
trametinib	TAFINLAR.xml:S1:11454:10	O
was	TAFINLAR.xml:S1:11465:3	O
evaluated	TAFINLAR.xml:S1:11469:9	O
in	TAFINLAR.xml:S1:11479:2	O
Trial	TAFINLAR.xml:S1:11482:5	O
2	TAFINLAR.xml:S1:11488:1	O
and	TAFINLAR.xml:S1:11490:3	O
other	TAFINLAR.xml:S1:11494:5	O
trials	TAFINLAR.xml:S1:11500:6	O
consisting	TAFINLAR.xml:S1:11507:10	O
of	TAFINLAR.xml:S1:11518:2	O
a	TAFINLAR.xml:S1:11521:1	O
total	TAFINLAR.xml:S1:11523:5	O
of	TAFINLAR.xml:S1:11529:2	O
202	TAFINLAR.xml:S1:11532:3	O
patients	TAFINLAR.xml:S1:11536:8	O
with	TAFINLAR.xml:S1:11545:4	O
BRAF	TAFINLAR.xml:S1:11550:4	O
V600	TAFINLAR.xml:S1:11555:4	O
mutation	TAFINLAR.xml:S1:11560:8	O
-	TAFINLAR.xml:S1:11568:1	O
positive	TAFINLAR.xml:S1:11569:8	O
unresectable	TAFINLAR.xml:S1:11578:12	O
or	TAFINLAR.xml:S1:11591:2	O
metastatic	TAFINLAR.xml:S1:11594:10	O
melanoma	TAFINLAR.xml:S1:11605:8	O
who	TAFINLAR.xml:S1:11614:3	O
received	TAFINLAR.xml:S1:11618:8	O
TAFINLAR	TAFINLAR.xml:S1:11627:8	O
150	TAFINLAR.xml:S1:11636:3	O
mg	TAFINLAR.xml:S1:11640:2	O
orally	TAFINLAR.xml:S1:11643:6	O
twice	TAFINLAR.xml:S1:11650:5	O
daily	TAFINLAR.xml:S1:11656:5	O
in	TAFINLAR.xml:S1:11662:2	O
combination	TAFINLAR.xml:S1:11665:11	O
with	TAFINLAR.xml:S1:11677:4	O
trametinib	TAFINLAR.xml:S1:11682:10	O
2	TAFINLAR.xml:S1:11693:1	O
mg	TAFINLAR.xml:S1:11695:2	O
orally	TAFINLAR.xml:S1:11698:6	O
once	TAFINLAR.xml:S1:11705:4	O
daily	TAFINLAR.xml:S1:11710:5	O
until	TAFINLAR.xml:S1:11716:5	O
disease	TAFINLAR.xml:S1:11722:7	O
progression	TAFINLAR.xml:S1:11730:11	O
or	TAFINLAR.xml:S1:11742:2	O
unacceptable	TAFINLAR.xml:S1:11745:12	O
toxicity	TAFINLAR.xml:S1:11758:8	O
.	TAFINLAR.xml:S1:11766:1	O

Among	TAFINLAR.xml:S1:11768:5	O
these	TAFINLAR.xml:S1:11774:5	O
202	TAFINLAR.xml:S1:11780:3	O
patients	TAFINLAR.xml:S1:11784:8	O
,	TAFINLAR.xml:S1:11792:1	O
66	TAFINLAR.xml:S1:11794:2	O
(	TAFINLAR.xml:S1:11797:1	O
33%	TAFINLAR.xml:S1:11798:3	O
)	TAFINLAR.xml:S1:11801:1	O
were	TAFINLAR.xml:S1:11803:4	O
exposed	TAFINLAR.xml:S1:11808:7	O
to	TAFINLAR.xml:S1:11816:2	O
TAFINLAR	TAFINLAR.xml:S1:11819:8	O
and	TAFINLAR.xml:S1:11828:3	O
68	TAFINLAR.xml:S1:11832:2	O
(	TAFINLAR.xml:S1:11835:1	O
34%	TAFINLAR.xml:S1:11836:3	O
)	TAFINLAR.xml:S1:11839:1	O
were	TAFINLAR.xml:S1:11841:4	O
exposed	TAFINLAR.xml:S1:11846:7	O
to	TAFINLAR.xml:S1:11854:2	O
trametinib	TAFINLAR.xml:S1:11857:10	O
for	TAFINLAR.xml:S1:11868:3	O
greater	TAFINLAR.xml:S1:11872:7	O
than	TAFINLAR.xml:S1:11880:4	O
6	TAFINLAR.xml:S1:11885:1	O
to	TAFINLAR.xml:S1:11887:2	O
12	TAFINLAR.xml:S1:11890:2	O
months	TAFINLAR.xml:S1:11893:6	O
while	TAFINLAR.xml:S1:11900:5	O
40	TAFINLAR.xml:S1:11906:2	O
(	TAFINLAR.xml:S1:11909:1	O
20%	TAFINLAR.xml:S1:11910:3	O
)	TAFINLAR.xml:S1:11913:1	O
were	TAFINLAR.xml:S1:11915:4	O
exposed	TAFINLAR.xml:S1:11920:7	O
to	TAFINLAR.xml:S1:11928:2	O
TAFINLAR	TAFINLAR.xml:S1:11931:8	O
and	TAFINLAR.xml:S1:11940:3	O
36	TAFINLAR.xml:S1:11944:2	O
(	TAFINLAR.xml:S1:11947:1	O
18%	TAFINLAR.xml:S1:11948:3	O
)	TAFINLAR.xml:S1:11951:1	O
were	TAFINLAR.xml:S1:11953:4	O
exposed	TAFINLAR.xml:S1:11958:7	O
to	TAFINLAR.xml:S1:11966:2	O
trametinib	TAFINLAR.xml:S1:11969:10	O
for	TAFINLAR.xml:S1:11980:3	O
greater	TAFINLAR.xml:S1:11984:7	O
than	TAFINLAR.xml:S1:11992:4	O
one	TAFINLAR.xml:S1:11997:3	O
year	TAFINLAR.xml:S1:12001:4	O
.	TAFINLAR.xml:S1:12005:1	O

The	TAFINLAR.xml:S1:12007:3	O
median	TAFINLAR.xml:S1:12011:6	O
age	TAFINLAR.xml:S1:12018:3	O
was	TAFINLAR.xml:S1:12022:3	O
54	TAFINLAR.xml:S1:12026:2	O
years	TAFINLAR.xml:S1:12029:5	O
,	TAFINLAR.xml:S1:12034:1	O
57%	TAFINLAR.xml:S1:12036:3	O
were	TAFINLAR.xml:S1:12040:4	O
male	TAFINLAR.xml:S1:12045:4	O
,	TAFINLAR.xml:S1:12049:1	O
and	TAFINLAR.xml:S1:12051:3	O
99%	TAFINLAR.xml:S1:12056:3	O
were	TAFINLAR.xml:S1:12060:4	O
white	TAFINLAR.xml:S1:12065:5	O
.	TAFINLAR.xml:S1:12070:1	O

Table	TAFINLAR.xml:S1:12076:5	O
5	TAFINLAR.xml:S1:12082:1	O
presents	TAFINLAR.xml:S1:12084:8	O
adverse	TAFINLAR.xml:S1:12093:7	O
reactions	TAFINLAR.xml:S1:12101:9	O
from	TAFINLAR.xml:S1:12111:4	O
Trial	TAFINLAR.xml:S1:12116:5	O
2	TAFINLAR.xml:S1:12122:1	O
,	TAFINLAR.xml:S1:12123:1	O
a	TAFINLAR.xml:S1:12125:1	O
multicenter	TAFINLAR.xml:S1:12127:11	O
,	TAFINLAR.xml:S1:12138:1	O
open	TAFINLAR.xml:S1:12140:4	O
-	TAFINLAR.xml:S1:12144:1	O
label	TAFINLAR.xml:S1:12145:5	O
,	TAFINLAR.xml:S1:12150:1	O
randomized	TAFINLAR.xml:S1:12152:10	O
trial	TAFINLAR.xml:S1:12163:5	O
of	TAFINLAR.xml:S1:12169:2	O
162	TAFINLAR.xml:S1:12172:3	O
patients	TAFINLAR.xml:S1:12176:8	O
with	TAFINLAR.xml:S1:12185:4	O
BRAF	TAFINLAR.xml:S1:12190:4	O
V600E	TAFINLAR.xml:S1:12195:5	O
or	TAFINLAR.xml:S1:12201:2	O
V600K	TAFINLAR.xml:S1:12204:5	O
mutation	TAFINLAR.xml:S1:12210:8	O
-	TAFINLAR.xml:S1:12218:1	O
positive	TAFINLAR.xml:S1:12219:8	O
melanoma	TAFINLAR.xml:S1:12228:8	O
receiving	TAFINLAR.xml:S1:12237:9	O
TAFINLAR	TAFINLAR.xml:S1:12247:8	O
150	TAFINLAR.xml:S1:12256:3	O
mg	TAFINLAR.xml:S1:12260:2	O
twice	TAFINLAR.xml:S1:12263:5	O
daily	TAFINLAR.xml:S1:12269:5	O
in	TAFINLAR.xml:S1:12275:2	O
combination	TAFINLAR.xml:S1:12278:11	O
with	TAFINLAR.xml:S1:12290:4	O
trametinib	TAFINLAR.xml:S1:12295:10	O
2	TAFINLAR.xml:S1:12306:1	O
mg	TAFINLAR.xml:S1:12308:2	O
orally	TAFINLAR.xml:S1:12311:6	O
once	TAFINLAR.xml:S1:12318:4	O
daily	TAFINLAR.xml:S1:12323:5	O
(	TAFINLAR.xml:S1:12329:1	O
n	TAFINLAR.xml:S1:12330:1	O
55	TAFINLAR.xml:S1:12334:2	O
)	TAFINLAR.xml:S1:12336:1	O
,	TAFINLAR.xml:S1:12337:1	O
TAFINLAR	TAFINLAR.xml:S1:12339:8	O
150	TAFINLAR.xml:S1:12348:3	O
mg	TAFINLAR.xml:S1:12352:2	O
orally	TAFINLAR.xml:S1:12355:6	O
twice	TAFINLAR.xml:S1:12362:5	O
daily	TAFINLAR.xml:S1:12368:5	O
in	TAFINLAR.xml:S1:12374:2	O
combination	TAFINLAR.xml:S1:12377:11	O
with	TAFINLAR.xml:S1:12389:4	O
trametinib	TAFINLAR.xml:S1:12394:10	O
1	TAFINLAR.xml:S1:12405:1	O
mg	TAFINLAR.xml:S1:12407:2	O
once	TAFINLAR.xml:S1:12410:4	O
daily	TAFINLAR.xml:S1:12415:5	O
(	TAFINLAR.xml:S1:12421:1	O
n	TAFINLAR.xml:S1:12422:1	O
54	TAFINLAR.xml:S1:12426:2	O
)	TAFINLAR.xml:S1:12428:1	O
,	TAFINLAR.xml:S1:12429:1	O
and	TAFINLAR.xml:S1:12431:3	O
TAFINLAR	TAFINLAR.xml:S1:12435:8	O
as	TAFINLAR.xml:S1:12444:2	O
a	TAFINLAR.xml:S1:12447:1	O
single	TAFINLAR.xml:S1:12449:6	O
agent	TAFINLAR.xml:S1:12456:5	O
150	TAFINLAR.xml:S1:12462:3	O
mg	TAFINLAR.xml:S1:12466:2	O
orally	TAFINLAR.xml:S1:12469:6	O
twice	TAFINLAR.xml:S1:12476:5	O
daily	TAFINLAR.xml:S1:12482:5	O
(	TAFINLAR.xml:S1:12488:1	O
n	TAFINLAR.xml:S1:12489:1	O
53	TAFINLAR.xml:S1:12493:2	O
)	TAFINLAR.xml:S1:12495:1	O
[	TAFINLAR.xml:S1:12498:1	O
see	TAFINLAR.xml:S1:12499:3	O
Clinical	TAFINLAR.xml:S1:12503:8	O
Studies	TAFINLAR.xml:S1:12512:7	O
(	TAFINLAR.xml:S1:12520:1	O
14.2	TAFINLAR.xml:S1:12521:4	O
)]	TAFINLAR.xml:S1:12525:2	O
.	TAFINLAR.xml:S1:12529:1	O

Patients	TAFINLAR.xml:S1:12531:8	O
with	TAFINLAR.xml:S1:12540:4	O
abnormal	TAFINLAR.xml:S1:12545:8	O
LVEF	TAFINLAR.xml:S1:12554:4	O
,	TAFINLAR.xml:S1:12558:1	O
history	TAFINLAR.xml:S1:12560:7	O
of	TAFINLAR.xml:S1:12568:2	O
acute	TAFINLAR.xml:S1:12571:5	O
coronary	TAFINLAR.xml:S1:12577:8	O
syndrome	TAFINLAR.xml:S1:12586:8	O
within	TAFINLAR.xml:S1:12595:6	O
6	TAFINLAR.xml:S1:12602:1	O
months	TAFINLAR.xml:S1:12604:6	O
,	TAFINLAR.xml:S1:12610:1	O
current	TAFINLAR.xml:S1:12612:7	O
evidence	TAFINLAR.xml:S1:12620:8	O
of	TAFINLAR.xml:S1:12629:2	O
Class	TAFINLAR.xml:S1:12632:5	O
II	TAFINLAR.xml:S1:12638:2	O
or	TAFINLAR.xml:S1:12641:2	O
greater	TAFINLAR.xml:S1:12644:7	O
congestive	TAFINLAR.xml:S1:12652:10	O
heart	TAFINLAR.xml:S1:12663:5	O
failure	TAFINLAR.xml:S1:12669:7	O
(	TAFINLAR.xml:S1:12677:1	O
New	TAFINLAR.xml:S1:12678:3	O
York	TAFINLAR.xml:S1:12682:4	O
Heart	TAFINLAR.xml:S1:12687:5	O
Association	TAFINLAR.xml:S1:12693:11	O
)	TAFINLAR.xml:S1:12704:1	O
,	TAFINLAR.xml:S1:12705:1	O
history	TAFINLAR.xml:S1:12707:7	O
RVO	TAFINLAR.xml:S1:12715:3	O
or	TAFINLAR.xml:S1:12719:2	O
RPED	TAFINLAR.xml:S1:12722:4	O
,	TAFINLAR.xml:S1:12726:1	O
QTc	TAFINLAR.xml:S1:12728:3	O
interval	TAFINLAR.xml:S1:12732:8	O
480	TAFINLAR.xml:S1:12743:3	O
msec	TAFINLAR.xml:S1:12747:4	O
,	TAFINLAR.xml:S1:12751:1	O
treatment	TAFINLAR.xml:S1:12753:9	O
refractory	TAFINLAR.xml:S1:12763:10	O
hypertension	TAFINLAR.xml:S1:12774:12	O
,	TAFINLAR.xml:S1:12786:1	O
uncontrolled	TAFINLAR.xml:S1:12788:12	O
arrhythmias	TAFINLAR.xml:S1:12801:11	O
,	TAFINLAR.xml:S1:12812:1	O
history	TAFINLAR.xml:S1:12814:7	O
of	TAFINLAR.xml:S1:12822:2	O
pneumonitis	TAFINLAR.xml:S1:12825:11	O
or	TAFINLAR.xml:S1:12837:2	O
interstitial	TAFINLAR.xml:S1:12840:12	O
lung	TAFINLAR.xml:S1:12853:4	O
disease	TAFINLAR.xml:S1:12858:7	O
,	TAFINLAR.xml:S1:12865:1	O
or	TAFINLAR.xml:S1:12867:2	O
a	TAFINLAR.xml:S1:12870:1	O
known	TAFINLAR.xml:S1:12872:5	O
history	TAFINLAR.xml:S1:12878:7	O
of	TAFINLAR.xml:S1:12886:2	O
G6PD	TAFINLAR.xml:S1:12889:4	O
deficiency	TAFINLAR.xml:S1:12894:10	O
were	TAFINLAR.xml:S1:12905:4	O
excluded	TAFINLAR.xml:S1:12910:8	O
.	TAFINLAR.xml:S1:12918:1	O

The	TAFINLAR.xml:S1:12920:3	O
median	TAFINLAR.xml:S1:12924:6	O
duration	TAFINLAR.xml:S1:12931:8	O
of	TAFINLAR.xml:S1:12940:2	O
treatment	TAFINLAR.xml:S1:12943:9	O
was	TAFINLAR.xml:S1:12953:3	O
10.9	TAFINLAR.xml:S1:12957:4	O
months	TAFINLAR.xml:S1:12962:6	O
for	TAFINLAR.xml:S1:12969:3	O
both	TAFINLAR.xml:S1:12973:4	O
TAFINLAR	TAFINLAR.xml:S1:12978:8	O
and	TAFINLAR.xml:S1:12987:3	O
trametinib	TAFINLAR.xml:S1:12991:10	O
(	TAFINLAR.xml:S1:13002:1	O
2	TAFINLAR.xml:S1:13003:1	O
-	TAFINLAR.xml:S1:13004:1	O
mg	TAFINLAR.xml:S1:13005:2	O
orally	TAFINLAR.xml:S1:13008:6	O
once	TAFINLAR.xml:S1:13015:4	O
-	TAFINLAR.xml:S1:13019:1	O
daily	TAFINLAR.xml:S1:13020:5	O
treatment	TAFINLAR.xml:S1:13026:9	O
group	TAFINLAR.xml:S1:13036:5	O
)	TAFINLAR.xml:S1:13041:1	O
when	TAFINLAR.xml:S1:13043:4	O
used	TAFINLAR.xml:S1:13048:4	O
in	TAFINLAR.xml:S1:13053:2	O
combination	TAFINLAR.xml:S1:13056:11	O
,	TAFINLAR.xml:S1:13067:1	O
10.6	TAFINLAR.xml:S1:13069:4	O
months	TAFINLAR.xml:S1:13074:6	O
for	TAFINLAR.xml:S1:13081:3	O
both	TAFINLAR.xml:S1:13085:4	O
TAFINLAR	TAFINLAR.xml:S1:13090:8	O
and	TAFINLAR.xml:S1:13099:3	O
trametinib	TAFINLAR.xml:S1:13103:10	O
(	TAFINLAR.xml:S1:13114:1	O
1	TAFINLAR.xml:S1:13115:1	O
-	TAFINLAR.xml:S1:13116:1	O
mg	TAFINLAR.xml:S1:13117:2	O
orally	TAFINLAR.xml:S1:13120:6	O
once	TAFINLAR.xml:S1:13127:4	O
-	TAFINLAR.xml:S1:13131:1	O
daily	TAFINLAR.xml:S1:13132:5	O
treatment	TAFINLAR.xml:S1:13138:9	O
group	TAFINLAR.xml:S1:13148:5	O
)	TAFINLAR.xml:S1:13153:1	O
when	TAFINLAR.xml:S1:13155:4	O
used	TAFINLAR.xml:S1:13160:4	O
in	TAFINLAR.xml:S1:13165:2	O
combination	TAFINLAR.xml:S1:13168:11	O
,	TAFINLAR.xml:S1:13179:1	O
and	TAFINLAR.xml:S1:13181:3	O
6.1	TAFINLAR.xml:S1:13185:3	O
months	TAFINLAR.xml:S1:13189:6	O
for	TAFINLAR.xml:S1:13196:3	O
TAFINLAR	TAFINLAR.xml:S1:13200:8	O
as	TAFINLAR.xml:S1:13209:2	O
a	TAFINLAR.xml:S1:13212:1	O
single	TAFINLAR.xml:S1:13214:6	O
agent	TAFINLAR.xml:S1:13221:5	O
.	TAFINLAR.xml:S1:13226:1	O

In	TAFINLAR.xml:S1:13232:2	O
Trial	TAFINLAR.xml:S1:13235:5	O
2	TAFINLAR.xml:S1:13241:1	O
,	TAFINLAR.xml:S1:13242:1	O
13%	TAFINLAR.xml:S1:13244:3	O
of	TAFINLAR.xml:S1:13248:2	O
patients	TAFINLAR.xml:S1:13251:8	O
receiving	TAFINLAR.xml:S1:13260:9	O
TAFINLAR	TAFINLAR.xml:S1:13270:8	O
in	TAFINLAR.xml:S1:13279:2	O
combination	TAFINLAR.xml:S1:13282:11	O
with	TAFINLAR.xml:S1:13294:4	O
trametinib	TAFINLAR.xml:S1:13299:10	O
experienced	TAFINLAR.xml:S1:13310:11	O
adverse	TAFINLAR.xml:S1:13322:7	O
reactions	TAFINLAR.xml:S1:13330:9	O
resulting	TAFINLAR.xml:S1:13340:9	O
in	TAFINLAR.xml:S1:13350:2	O
permanent	TAFINLAR.xml:S1:13353:9	O
discontinuation	TAFINLAR.xml:S1:13363:15	O
of	TAFINLAR.xml:S1:13379:2	O
trial	TAFINLAR.xml:S1:13382:5	O
medication	TAFINLAR.xml:S1:13388:10	O
(	TAFINLAR.xml:S1:13398:1	O
s	TAFINLAR.xml:S1:13399:1	O
)	TAFINLAR.xml:S1:13400:1	O
.	TAFINLAR.xml:S1:13401:1	O

The	TAFINLAR.xml:S1:13403:3	O
most	TAFINLAR.xml:S1:13407:4	O
common	TAFINLAR.xml:S1:13412:6	O
adverse	TAFINLAR.xml:S1:13419:7	O
reaction	TAFINLAR.xml:S1:13427:8	O
resulting	TAFINLAR.xml:S1:13436:9	O
in	TAFINLAR.xml:S1:13446:2	O
permanent	TAFINLAR.xml:S1:13449:9	O
discontinuation	TAFINLAR.xml:S1:13459:15	O
was	TAFINLAR.xml:S1:13475:3	O
pyrexia	TAFINLAR.xml:S1:13479:7	B-AdverseReaction
(	TAFINLAR.xml:S1:13487:1	O
4%	TAFINLAR.xml:S1:13488:2	O
)	TAFINLAR.xml:S1:13490:1	O
.	TAFINLAR.xml:S1:13491:1	O

Adverse	TAFINLAR.xml:S1:13493:7	O
reactions	TAFINLAR.xml:S1:13501:9	O
led	TAFINLAR.xml:S1:13511:3	O
to	TAFINLAR.xml:S1:13515:2	O
dose	TAFINLAR.xml:S1:13518:4	O
reductions	TAFINLAR.xml:S1:13523:10	O
in	TAFINLAR.xml:S1:13534:2	O
49%	TAFINLAR.xml:S1:13537:3	O
and	TAFINLAR.xml:S1:13541:3	O
dose	TAFINLAR.xml:S1:13545:4	O
interruptions	TAFINLAR.xml:S1:13550:13	O
in	TAFINLAR.xml:S1:13564:2	O
67%	TAFINLAR.xml:S1:13567:3	O
of	TAFINLAR.xml:S1:13571:2	O
patients	TAFINLAR.xml:S1:13574:8	O
treated	TAFINLAR.xml:S1:13583:7	O
with	TAFINLAR.xml:S1:13591:4	O
TAFINLAR	TAFINLAR.xml:S1:13596:8	O
in	TAFINLAR.xml:S1:13605:2	O
combination	TAFINLAR.xml:S1:13608:11	O
with	TAFINLAR.xml:S1:13620:4	O
trametinib	TAFINLAR.xml:S1:13625:10	O
.	TAFINLAR.xml:S1:13635:1	O

Pyrexia	TAFINLAR.xml:S1:13637:7	B-AdverseReaction
,	TAFINLAR.xml:S1:13644:1	O
chills	TAFINLAR.xml:S1:13646:6	B-AdverseReaction
,	TAFINLAR.xml:S1:13652:1	O
and	TAFINLAR.xml:S1:13654:3	O
nausea	TAFINLAR.xml:S1:13658:6	B-AdverseReaction
were	TAFINLAR.xml:S1:13665:4	O
the	TAFINLAR.xml:S1:13670:3	O
most	TAFINLAR.xml:S1:13674:4	O
common	TAFINLAR.xml:S1:13679:6	O
reasons	TAFINLAR.xml:S1:13686:7	O
cited	TAFINLAR.xml:S1:13694:5	O
for	TAFINLAR.xml:S1:13700:3	O
dose	TAFINLAR.xml:S1:13704:4	O
reductions	TAFINLAR.xml:S1:13709:10	O
and	TAFINLAR.xml:S1:13720:3	O
pyrexia	TAFINLAR.xml:S1:13724:7	B-AdverseReaction
,	TAFINLAR.xml:S1:13731:1	O
chills	TAFINLAR.xml:S1:13733:6	B-AdverseReaction
,	TAFINLAR.xml:S1:13739:1	O
and	TAFINLAR.xml:S1:13741:3	O
decreased	TAFINLAR.xml:S1:13745:9	B-AdverseReaction
ejection	TAFINLAR.xml:S1:13755:8	I-AdverseReaction
fraction	TAFINLAR.xml:S1:13764:8	I-AdverseReaction
were	TAFINLAR.xml:S1:13773:4	O
the	TAFINLAR.xml:S1:13778:3	O
most	TAFINLAR.xml:S1:13782:4	O
common	TAFINLAR.xml:S1:13787:6	O
reasons	TAFINLAR.xml:S1:13794:7	O
cited	TAFINLAR.xml:S1:13802:5	O
for	TAFINLAR.xml:S1:13808:3	O
dose	TAFINLAR.xml:S1:13812:4	O
interruptions	TAFINLAR.xml:S1:13817:13	O
of	TAFINLAR.xml:S1:13831:2	O
TAFINLAR	TAFINLAR.xml:S1:13834:8	O
and	TAFINLAR.xml:S1:13843:3	O
trametinib	TAFINLAR.xml:S1:13847:10	O
when	TAFINLAR.xml:S1:13858:4	O
used	TAFINLAR.xml:S1:13863:4	O
in	TAFINLAR.xml:S1:13868:2	O
combination	TAFINLAR.xml:S1:13871:11	O
.	TAFINLAR.xml:S1:13882:1	O

Table	TAFINLAR.xml:S1:13888:5	O
5	TAFINLAR.xml:S1:13894:1	O
.	TAFINLAR.xml:S1:13895:1	O

Common	TAFINLAR.xml:S1:13897:6	O
Adverse	TAFINLAR.xml:S1:13904:7	O
Drug	TAFINLAR.xml:S1:13912:4	O
Reactions	TAFINLAR.xml:S1:13917:9	O
Occurring	TAFINLAR.xml:S1:13927:9	O
in	TAFINLAR.xml:S1:13937:2	O
10%	TAFINLAR.xml:S1:13942:3	O
at	TAFINLAR.xml:S1:13946:2	O
(	TAFINLAR.xml:S1:13949:1	O
All	TAFINLAR.xml:S1:13950:3	O
Grades	TAFINLAR.xml:S1:13954:6	O
)	TAFINLAR.xml:S1:13960:1	O
or	TAFINLAR.xml:S1:13962:2	O
5%	TAFINLAR.xml:S1:13967:2	O
(	TAFINLAR.xml:S1:13970:1	O
Grades	TAFINLAR.xml:S1:13971:6	O
3	TAFINLAR.xml:S1:13978:1	O
or	TAFINLAR.xml:S1:13980:2	O
4	TAFINLAR.xml:S1:13983:1	O
)	TAFINLAR.xml:S1:13984:1	O
of	TAFINLAR.xml:S1:13986:2	O
Patients	TAFINLAR.xml:S1:13989:8	O
Treated	TAFINLAR.xml:S1:13998:7	O
With	TAFINLAR.xml:S1:14006:4	O
TAFINLAR	TAFINLAR.xml:S1:14011:8	O
in	TAFINLAR.xml:S1:14020:2	O
Combination	TAFINLAR.xml:S1:14023:11	O
With	TAFINLAR.xml:S1:14035:4	O
Trametinib	TAFINLAR.xml:S1:14040:10	O
in	TAFINLAR.xml:S1:14051:2	O
Trial	TAFINLAR.xml:S1:14054:5	O
2	TAFINLAR.xml:S1:14060:1	O

Adverse	TAFINLAR.xml:S1:14065:7	O
Reactions	TAFINLAR.xml:S1:14073:9	O
TAFINLAR	TAFINLAR.xml:S1:14092:8	O
plus	TAFINLAR.xml:S1:14101:4	O
Trametinib	TAFINLAR.xml:S1:14106:10	O
2	TAFINLAR.xml:S1:14117:1	O
mg	TAFINLAR.xml:S1:14119:2	O
N	TAFINLAR.xml:S1:14123:1	O
55	TAFINLAR.xml:S1:14127:2	O
TAFINLAR	TAFINLAR.xml:S1:14133:8	O
plus	TAFINLAR.xml:S1:14142:4	O
Trametinib	TAFINLAR.xml:S1:14147:10	O
1	TAFINLAR.xml:S1:14158:1	O
mg	TAFINLAR.xml:S1:14160:2	O
N	TAFINLAR.xml:S1:14164:1	O
54	TAFINLAR.xml:S1:14168:2	O
TAFINLAR	TAFINLAR.xml:S1:14174:8	O
N	TAFINLAR.xml:S1:14184:1	O
53	TAFINLAR.xml:S1:14188:2	O

All	TAFINLAR.xml:S1:14197:3	O
Gradesa	TAFINLAR.xml:S1:14201:7	O
Grades	TAFINLAR.xml:S1:14224:6	O
3	TAFINLAR.xml:S1:14232:1	O
and	TAFINLAR.xml:S1:14234:3	O
4	TAFINLAR.xml:S1:14238:1	O
All	TAFINLAR.xml:S1:14243:3	O
Gradesa	TAFINLAR.xml:S1:14247:7	O
Grades	TAFINLAR.xml:S1:14258:6	O
3	TAFINLAR.xml:S1:14266:1	O
and	TAFINLAR.xml:S1:14268:3	O
4	TAFINLAR.xml:S1:14272:1	O
All	TAFINLAR.xml:S1:14277:3	O
Gradesa	TAFINLAR.xml:S1:14282:7	O
Grades	TAFINLAR.xml:S1:14293:6	O
3	TAFINLAR.xml:S1:14301:1	O
and	TAFINLAR.xml:S1:14303:3	O
4	TAFINLAR.xml:S1:14307:1	O

General	TAFINLAR.xml:S1:14315:7	O
disorders	TAFINLAR.xml:S1:14323:9	O
and	TAFINLAR.xml:S1:14333:3	O
administrative	TAFINLAR.xml:S1:14337:14	O
site	TAFINLAR.xml:S1:14352:4	O
conditions	TAFINLAR.xml:S1:14357:10	O

Pyrexia	TAFINLAR.xml:S1:14400:7	B-AdverseReaction

71	TAFINLAR.xml:S1:14483:2	O
5	TAFINLAR.xml:S1:14502:1	O
69	TAFINLAR.xml:S1:14516:2	O
9	TAFINLAR.xml:S1:14535:1	O
26	TAFINLAR.xml:S1:14549:2	O
0	TAFINLAR.xml:S1:14560:1	O

Chills	TAFINLAR.xml:S1:14599:6	B-AdverseReaction

58	TAFINLAR.xml:S1:14682:2	O
2	TAFINLAR.xml:S1:14701:1	O
50	TAFINLAR.xml:S1:14715:2	O
2	TAFINLAR.xml:S1:14734:1	O
17	TAFINLAR.xml:S1:14748:2	O
0	TAFINLAR.xml:S1:14759:1	O

Fatigue	TAFINLAR.xml:S1:14798:7	B-AdverseReaction

53	TAFINLAR.xml:S1:14881:2	O
4	TAFINLAR.xml:S1:14900:1	O
57	TAFINLAR.xml:S1:14914:2	O
2	TAFINLAR.xml:S1:14933:1	O
40	TAFINLAR.xml:S1:14947:2	O
6	TAFINLAR.xml:S1:14958:1	O

Edema	TAFINLAR.xml:S1:14997:5	B-AdverseReaction
peripheral	TAFINLAR.xml:S1:15003:10	I-AdverseReaction
b	TAFINLAR.xml:S1:15015:1	O

31	TAFINLAR.xml:S1:15080:2	O
0	TAFINLAR.xml:S1:15099:1	O
28	TAFINLAR.xml:S1:15113:2	O
0	TAFINLAR.xml:S1:15132:1	O
17	TAFINLAR.xml:S1:15146:2	O
0	TAFINLAR.xml:S1:15157:1	O

Skin	TAFINLAR.xml:S1:15170:4	O
and	TAFINLAR.xml:S1:15175:3	O
subcutaneous	TAFINLAR.xml:S1:15179:12	O
tissue	TAFINLAR.xml:S1:15192:6	O
disorders	TAFINLAR.xml:S1:15199:9	O

Rash	TAFINLAR.xml:S1:15241:4	B-AdverseReaction
c	TAFINLAR.xml:S1:15247:1	O

45	TAFINLAR.xml:S1:15324:2	O
0	TAFINLAR.xml:S1:15343:1	O
43	TAFINLAR.xml:S1:15357:2	O
2	TAFINLAR.xml:S1:15376:1	O
53	TAFINLAR.xml:S1:15390:2	O
0	TAFINLAR.xml:S1:15401:1	O

Night	TAFINLAR.xml:S1:15440:5	B-AdverseReaction
Sweats	TAFINLAR.xml:S1:15446:6	I-AdverseReaction

24	TAFINLAR.xml:S1:15523:2	O
0	TAFINLAR.xml:S1:15542:1	O
15	TAFINLAR.xml:S1:15556:2	O
0	TAFINLAR.xml:S1:15575:1	O
6	TAFINLAR.xml:S1:15589:1	O
0	TAFINLAR.xml:S1:15600:1	O

Dry	TAFINLAR.xml:S1:15639:3	B-AdverseReaction
skin	TAFINLAR.xml:S1:15643:4	I-AdverseReaction

18	TAFINLAR.xml:S1:15722:2	O
0	TAFINLAR.xml:S1:15741:1	O
9	TAFINLAR.xml:S1:15755:1	O
0	TAFINLAR.xml:S1:15774:1	O
6	TAFINLAR.xml:S1:15788:1	O
0	TAFINLAR.xml:S1:15799:1	O

Dermatitis	TAFINLAR.xml:S1:15838:10	B-AdverseReaction
acneiform	TAFINLAR.xml:S1:15849:9	I-AdverseReaction

16	TAFINLAR.xml:S1:15921:2	O
0	TAFINLAR.xml:S1:15940:1	O
11	TAFINLAR.xml:S1:15954:2	O
0	TAFINLAR.xml:S1:15973:1	O
4	TAFINLAR.xml:S1:15987:1	O
0	TAFINLAR.xml:S1:15998:1	O

Actinic	TAFINLAR.xml:S1:16037:7	B-AdverseReaction
keratosis	TAFINLAR.xml:S1:16045:9	I-AdverseReaction

15	TAFINLAR.xml:S1:16120:2	O
0	TAFINLAR.xml:S1:16139:1	O
7	TAFINLAR.xml:S1:16153:1	O
0	TAFINLAR.xml:S1:16172:1	O
9	TAFINLAR.xml:S1:16186:1	O
0	TAFINLAR.xml:S1:16197:1	O

Erythema	TAFINLAR.xml:S1:16236:8	B-AdverseReaction

15	TAFINLAR.xml:S1:16319:2	O
0	TAFINLAR.xml:S1:16338:1	O
6	TAFINLAR.xml:S1:16352:1	O
0	TAFINLAR.xml:S1:16371:1	O
2	TAFINLAR.xml:S1:16385:1	O
0	TAFINLAR.xml:S1:16396:1	O

Pruritus	TAFINLAR.xml:S1:16435:8	B-AdverseReaction

11	TAFINLAR.xml:S1:16518:2	O
0	TAFINLAR.xml:S1:16537:1	O
11	TAFINLAR.xml:S1:16551:2	O
0	TAFINLAR.xml:S1:16570:1	O
13	TAFINLAR.xml:S1:16584:2	O
0	TAFINLAR.xml:S1:16595:1	O

Gastrointestinal	TAFINLAR.xml:S1:16608:16	O
disorders	TAFINLAR.xml:S1:16625:9	O

Nausea	TAFINLAR.xml:S1:16667:6	B-AdverseReaction

44	TAFINLAR.xml:S1:16750:2	O
2	TAFINLAR.xml:S1:16769:1	O
46	TAFINLAR.xml:S1:16783:2	O
6	TAFINLAR.xml:S1:16802:1	O
21	TAFINLAR.xml:S1:16816:2	O
0	TAFINLAR.xml:S1:16827:1	O

Vomiting	TAFINLAR.xml:S1:16866:8	B-AdverseReaction

40	TAFINLAR.xml:S1:16949:2	O
2	TAFINLAR.xml:S1:16968:1	O
43	TAFINLAR.xml:S1:16982:2	O
4	TAFINLAR.xml:S1:17001:1	O
15	TAFINLAR.xml:S1:17015:2	O
0	TAFINLAR.xml:S1:17026:1	O

Diarrhea	TAFINLAR.xml:S1:17065:8	B-AdverseReaction

36	TAFINLAR.xml:S1:17148:2	O
2	TAFINLAR.xml:S1:17167:1	O
26	TAFINLAR.xml:S1:17181:2	O
0	TAFINLAR.xml:S1:17200:1	O
28	TAFINLAR.xml:S1:17214:2	O
0	TAFINLAR.xml:S1:17225:1	O

Abdominal	TAFINLAR.xml:S1:17264:9	B-AdverseReaction
pain	TAFINLAR.xml:S1:17274:4	I-AdverseReaction
d	TAFINLAR.xml:S1:17280:1	O

33	TAFINLAR.xml:S1:17347:2	O
2	TAFINLAR.xml:S1:17366:1	O
24	TAFINLAR.xml:S1:17380:2	O
2	TAFINLAR.xml:S1:17399:1	O
21	TAFINLAR.xml:S1:17413:2	O
2	TAFINLAR.xml:S1:17424:1	O

Constipation	TAFINLAR.xml:S1:17463:12	B-AdverseReaction

22	TAFINLAR.xml:S1:17546:2	O
0	TAFINLAR.xml:S1:17565:1	O
17	TAFINLAR.xml:S1:17579:2	O
2	TAFINLAR.xml:S1:17598:1	O
11	TAFINLAR.xml:S1:17612:2	O
0	TAFINLAR.xml:S1:17623:1	O

Dry	TAFINLAR.xml:S1:17662:3	B-AdverseReaction
mouth	TAFINLAR.xml:S1:17666:5	I-AdverseReaction

11	TAFINLAR.xml:S1:17745:2	O
0	TAFINLAR.xml:S1:17764:1	O
11	TAFINLAR.xml:S1:17778:2	O
0	TAFINLAR.xml:S1:17797:1	O
6	TAFINLAR.xml:S1:17811:1	O
0	TAFINLAR.xml:S1:17822:1	O

Nervous	TAFINLAR.xml:S1:17835:7	O
system	TAFINLAR.xml:S1:17843:6	O
disorders	TAFINLAR.xml:S1:17850:9	O

Headache	TAFINLAR.xml:S1:17892:8	B-AdverseReaction

29	TAFINLAR.xml:S1:17975:2	O
0	TAFINLAR.xml:S1:17994:1	O
37	TAFINLAR.xml:S1:18008:2	O
2	TAFINLAR.xml:S1:18027:1	O
28	TAFINLAR.xml:S1:18041:2	O
0	TAFINLAR.xml:S1:18052:1	O

Dizziness	TAFINLAR.xml:S1:18091:9	B-AdverseReaction

16	TAFINLAR.xml:S1:18174:2	O
0	TAFINLAR.xml:S1:18193:1	O
13	TAFINLAR.xml:S1:18207:2	O
0	TAFINLAR.xml:S1:18226:1	O
9	TAFINLAR.xml:S1:18240:1	O
0	TAFINLAR.xml:S1:18251:1	O

Respiratory	TAFINLAR.xml:S1:18264:11	O
,	TAFINLAR.xml:S1:18275:1	O
thoracic	TAFINLAR.xml:S1:18277:8	O
,	TAFINLAR.xml:S1:18285:1	O
and	TAFINLAR.xml:S1:18287:3	O
mediastinal	TAFINLAR.xml:S1:18291:11	O
disorders	TAFINLAR.xml:S1:18303:9	O

Cough	TAFINLAR.xml:S1:18345:5	B-AdverseReaction

29	TAFINLAR.xml:S1:18428:2	O
0	TAFINLAR.xml:S1:18447:1	O
11	TAFINLAR.xml:S1:18461:2	O
0	TAFINLAR.xml:S1:18480:1	O
21	TAFINLAR.xml:S1:18494:2	O
0	TAFINLAR.xml:S1:18505:1	O

Oropharyngeal	TAFINLAR.xml:S1:18544:13	B-AdverseReaction
pain	TAFINLAR.xml:S1:18558:4	I-AdverseReaction

13	TAFINLAR.xml:S1:18627:2	O
0	TAFINLAR.xml:S1:18646:1	O
7	TAFINLAR.xml:S1:18660:1	O
0	TAFINLAR.xml:S1:18679:1	O
0	TAFINLAR.xml:S1:18693:1	O
0	TAFINLAR.xml:S1:18704:1	O

Musculoskeletal	TAFINLAR.xml:S1:18717:15	O
,	TAFINLAR.xml:S1:18732:1	O
connective	TAFINLAR.xml:S1:18734:10	O
tissue	TAFINLAR.xml:S1:18745:6	O
,	TAFINLAR.xml:S1:18751:1	O
and	TAFINLAR.xml:S1:18753:3	O
bone	TAFINLAR.xml:S1:18757:4	O
disorders	TAFINLAR.xml:S1:18762:9	O

Arthralgia	TAFINLAR.xml:S1:18804:10	B-AdverseReaction

27	TAFINLAR.xml:S1:18887:2	O
0	TAFINLAR.xml:S1:18906:1	O
44	TAFINLAR.xml:S1:18920:2	O
0	TAFINLAR.xml:S1:18939:1	O
34	TAFINLAR.xml:S1:18953:2	O
0	TAFINLAR.xml:S1:18964:1	O

Myalgia	TAFINLAR.xml:S1:19003:7	B-AdverseReaction

22	TAFINLAR.xml:S1:19086:2	O
2	TAFINLAR.xml:S1:19105:1	O
24	TAFINLAR.xml:S1:19119:2	O
0	TAFINLAR.xml:S1:19138:1	O
23	TAFINLAR.xml:S1:19152:2	O
2	TAFINLAR.xml:S1:19163:1	O

Back	TAFINLAR.xml:S1:19202:4	B-AdverseReaction
pain	TAFINLAR.xml:S1:19207:4	I-AdverseReaction

18	TAFINLAR.xml:S1:19285:2	O
5	TAFINLAR.xml:S1:19304:1	O
11	TAFINLAR.xml:S1:19318:2	O
0	TAFINLAR.xml:S1:19337:1	O
11	TAFINLAR.xml:S1:19351:2	O
2	TAFINLAR.xml:S1:19362:1	O

Muscle	TAFINLAR.xml:S1:19401:6	B-AdverseReaction
spasms	TAFINLAR.xml:S1:19408:6	I-AdverseReaction

16	TAFINLAR.xml:S1:19484:2	O
0	TAFINLAR.xml:S1:19503:1	O
2	TAFINLAR.xml:S1:19517:1	O
0	TAFINLAR.xml:S1:19536:1	O
4	TAFINLAR.xml:S1:19550:1	O
0	TAFINLAR.xml:S1:19561:1	O

Pain	TAFINLAR.xml:S1:19600:4	B-AdverseReaction
in	TAFINLAR.xml:S1:19605:2	I-AdverseReaction
extremity	TAFINLAR.xml:S1:19608:9	I-AdverseReaction

16	TAFINLAR.xml:S1:19683:2	O
0	TAFINLAR.xml:S1:19702:1	O
11	TAFINLAR.xml:S1:19716:2	O
2	TAFINLAR.xml:S1:19735:1	O
19	TAFINLAR.xml:S1:19749:2	O
0	TAFINLAR.xml:S1:19760:1	O

Metabolism	TAFINLAR.xml:S1:19773:10	O
and	TAFINLAR.xml:S1:19784:3	O
nutritional	TAFINLAR.xml:S1:19788:11	O
disorders	TAFINLAR.xml:S1:19800:9	O

Decreased	TAFINLAR.xml:S1:19842:9	B-AdverseReaction
appetite	TAFINLAR.xml:S1:19852:8	I-AdverseReaction

22	TAFINLAR.xml:S1:19925:2	O
0	TAFINLAR.xml:S1:19944:1	O
30	TAFINLAR.xml:S1:19958:2	O
0	TAFINLAR.xml:S1:19977:1	O
19	TAFINLAR.xml:S1:19991:2	O
0	TAFINLAR.xml:S1:20002:1	O

Dehydration	TAFINLAR.xml:S1:20041:11	B-AdverseReaction

11	TAFINLAR.xml:S1:20124:2	O
0	TAFINLAR.xml:S1:20143:1	O
6	TAFINLAR.xml:S1:20157:1	O
2	TAFINLAR.xml:S1:20176:1	O
2	TAFINLAR.xml:S1:20190:1	O
0	TAFINLAR.xml:S1:20201:1	O

Psychiatric	TAFINLAR.xml:S1:20214:11	O
Disorders	TAFINLAR.xml:S1:20226:9	O

Insomnia	TAFINLAR.xml:S1:20270:8	B-AdverseReaction

18	TAFINLAR.xml:S1:20353:2	O
0	TAFINLAR.xml:S1:20372:1	O
11	TAFINLAR.xml:S1:20386:2	O
0	TAFINLAR.xml:S1:20405:1	O
8	TAFINLAR.xml:S1:20419:1	O
2	TAFINLAR.xml:S1:20430:1	O

Vascular	TAFINLAR.xml:S1:20443:8	O
disorders	TAFINLAR.xml:S1:20452:9	O

Hemorrhage	TAFINLAR.xml:S1:20499:10	B-AdverseReaction
e	TAFINLAR.xml:S1:20511:1	O

16	TAFINLAR.xml:S1:20582:2	O
5	TAFINLAR.xml:S1:20601:1	O
11	TAFINLAR.xml:S1:20615:2	O
0	TAFINLAR.xml:S1:20634:1	O
2	TAFINLAR.xml:S1:20648:1	O
0	TAFINLAR.xml:S1:20659:1	O

Infections	TAFINLAR.xml:S1:20672:10	O
and	TAFINLAR.xml:S1:20683:3	O
infestations	TAFINLAR.xml:S1:20687:12	O

Urinary	TAFINLAR.xml:S1:20732:7	B-AdverseReaction
tract	TAFINLAR.xml:S1:20740:5	I-AdverseReaction
infection	TAFINLAR.xml:S1:20746:9	I-AdverseReaction

13	TAFINLAR.xml:S1:20815:2	O
2	TAFINLAR.xml:S1:20834:1	O
6	TAFINLAR.xml:S1:20848:1	O
0	TAFINLAR.xml:S1:20867:1	O
9	TAFINLAR.xml:S1:20881:1	O
2	TAFINLAR.xml:S1:20892:1	O

Renal	TAFINLAR.xml:S1:20905:5	O
and	TAFINLAR.xml:S1:20911:3	O
urinary	TAFINLAR.xml:S1:20915:7	O
disorders	TAFINLAR.xml:S1:20923:9	O

Renal	TAFINLAR.xml:S1:20965:5	B-AdverseReaction
failure	TAFINLAR.xml:S1:20971:7	I-AdverseReaction
f	TAFINLAR.xml:S1:20980:1	O

7	TAFINLAR.xml:S1:21048:1	O
7	TAFINLAR.xml:S1:21067:1	O
2	TAFINLAR.xml:S1:21081:1	O
0	TAFINLAR.xml:S1:21100:1	O
0	TAFINLAR.xml:S1:21114:1	O
0	TAFINLAR.xml:S1:21125:1	O

a	TAFINLAR.xml:S1:21151:1	O
National	TAFINLAR.xml:S1:21154:8	O
Cancer	TAFINLAR.xml:S1:21163:6	O
Institute	TAFINLAR.xml:S1:21170:9	O
Common	TAFINLAR.xml:S1:21180:6	O
Terminology	TAFINLAR.xml:S1:21187:11	O
Criteria	TAFINLAR.xml:S1:21199:8	O
for	TAFINLAR.xml:S1:21208:3	O
Adverse	TAFINLAR.xml:S1:21212:7	O
Events	TAFINLAR.xml:S1:21220:6	O
,	TAFINLAR.xml:S1:21226:1	O
version	TAFINLAR.xml:S1:21228:7	O
4	TAFINLAR.xml:S1:21236:1	O
.	TAFINLAR.xml:S1:21237:1	O

b	TAFINLAR.xml:S1:21245:1	O

Includes	TAFINLAR.xml:S1:21248:8	O
the	TAFINLAR.xml:S1:21257:3	O
following	TAFINLAR.xml:S1:21261:9	O
terms	TAFINLAR.xml:S1:21271:5	O
:	TAFINLAR.xml:S1:21276:1	O
peripheral	TAFINLAR.xml:S1:21278:10	B-AdverseReaction
edema	TAFINLAR.xml:S1:21289:5	I-AdverseReaction
,	TAFINLAR.xml:S1:21294:1	O
edema	TAFINLAR.xml:S1:21296:5	B-AdverseReaction
,	TAFINLAR.xml:S1:21301:1	O
and	TAFINLAR.xml:S1:21303:3	O
lymphedema	TAFINLAR.xml:S1:21307:10	B-AdverseReaction
.	TAFINLAR.xml:S1:21317:1	O

c	TAFINLAR.xml:S1:21325:1	O
Includes	TAFINLAR.xml:S1:21328:8	O
the	TAFINLAR.xml:S1:21337:3	O
following	TAFINLAR.xml:S1:21341:9	O
terms	TAFINLAR.xml:S1:21351:5	O
:	TAFINLAR.xml:S1:21356:1	O
rash	TAFINLAR.xml:S1:21358:4	B-AdverseReaction
,	TAFINLAR.xml:S1:21362:1	O
rash	TAFINLAR.xml:S1:21364:4	B-AdverseReaction
generalized	TAFINLAR.xml:S1:21369:11	I-AdverseReaction
,	TAFINLAR.xml:S1:21380:1	O
rash	TAFINLAR.xml:S1:21382:4	B-AdverseReaction
pruritic	TAFINLAR.xml:S1:21387:8	I-AdverseReaction
,	TAFINLAR.xml:S1:21395:1	O
rash	TAFINLAR.xml:S1:21397:4	B-AdverseReaction
erythematous	TAFINLAR.xml:S1:21402:12	I-AdverseReaction
,	TAFINLAR.xml:S1:21414:1	O
rash	TAFINLAR.xml:S1:21416:4	B-AdverseReaction
papular	TAFINLAR.xml:S1:21421:7	I-AdverseReaction
,	TAFINLAR.xml:S1:21428:1	O
rash	TAFINLAR.xml:S1:21430:4	B-AdverseReaction
vesicular	TAFINLAR.xml:S1:21435:9	I-AdverseReaction
,	TAFINLAR.xml:S1:21444:1	O
rash	TAFINLAR.xml:S1:21446:4	B-AdverseReaction
macular	TAFINLAR.xml:S1:21451:7	I-AdverseReaction
,	TAFINLAR.xml:S1:21458:1	O
and	TAFINLAR.xml:S1:21460:3	O
rash	TAFINLAR.xml:S1:21464:4	B-AdverseReaction
maculo	TAFINLAR.xml:S1:21469:6	I-AdverseReaction
-	TAFINLAR.xml:S1:21475:1	I-AdverseReaction
papular	TAFINLAR.xml:S1:21476:7	I-AdverseReaction
.	TAFINLAR.xml:S1:21483:1	O

d	TAFINLAR.xml:S1:21491:1	O
Includes	TAFINLAR.xml:S1:21494:8	O
the	TAFINLAR.xml:S1:21503:3	O
following	TAFINLAR.xml:S1:21507:9	O
terms	TAFINLAR.xml:S1:21517:5	O
:	TAFINLAR.xml:S1:21522:1	O
abdominal	TAFINLAR.xml:S1:21524:9	B-AdverseReaction
pain	TAFINLAR.xml:S1:21534:4	I-AdverseReaction
,	TAFINLAR.xml:S1:21538:1	O
abdominal	TAFINLAR.xml:S1:21540:9	B-AdverseReaction
pain	TAFINLAR.xml:S1:21550:4	I-AdverseReaction
upper	TAFINLAR.xml:S1:21555:5	I-AdverseReaction
,	TAFINLAR.xml:S1:21560:1	O
abdominal	TAFINLAR.xml:S1:21562:9	B-AdverseReaction
pain	TAFINLAR.xml:S1:21572:4	I-AdverseReaction
lower	TAFINLAR.xml:S1:21577:5	I-AdverseReaction
,	TAFINLAR.xml:S1:21582:1	O
and	TAFINLAR.xml:S1:21584:3	O
abdominal	TAFINLAR.xml:S1:21588:9	B-AdverseReaction
discomfort	TAFINLAR.xml:S1:21598:10	I-AdverseReaction
.	TAFINLAR.xml:S1:21608:1	O

e	TAFINLAR.xml:S1:21616:1	O
Includes	TAFINLAR.xml:S1:21619:8	O
the	TAFINLAR.xml:S1:21628:3	O
following	TAFINLAR.xml:S1:21632:9	O
terms	TAFINLAR.xml:S1:21642:5	O
:	TAFINLAR.xml:S1:21647:1	O
brain	TAFINLAR.xml:S1:21649:5	B-AdverseReaction
stem	TAFINLAR.xml:S1:21655:4	I-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21660:10	I-AdverseReaction
,	TAFINLAR.xml:S1:21670:1	O
cerebral	TAFINLAR.xml:S1:21672:8	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21681:10	I-AdverseReaction
,	TAFINLAR.xml:S1:21691:1	O
gastric	TAFINLAR.xml:S1:21693:7	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21701:10	I-AdverseReaction
,	TAFINLAR.xml:S1:21711:1	O
epistaxis	TAFINLAR.xml:S1:21713:9	B-AdverseReaction
,	TAFINLAR.xml:S1:21722:1	O
gingival	TAFINLAR.xml:S1:21724:8	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21733:10	I-AdverseReaction
,	TAFINLAR.xml:S1:21743:1	O
hematuria	TAFINLAR.xml:S1:21745:9	B-AdverseReaction
,	TAFINLAR.xml:S1:21754:1	O
vaginal	TAFINLAR.xml:S1:21756:7	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21764:10	I-AdverseReaction
,	TAFINLAR.xml:S1:21774:1	O
hemorrhage	TAFINLAR.xml:S1:21776:10	B-AdverseReaction
intracranial	TAFINLAR.xml:S1:21787:12	I-AdverseReaction
,	TAFINLAR.xml:S1:21799:1	O
eye	TAFINLAR.xml:S1:21801:3	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21805:10	I-AdverseReaction
,	TAFINLAR.xml:S1:21815:1	O
and	TAFINLAR.xml:S1:21817:3	O
vitreous	TAFINLAR.xml:S1:21821:8	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21830:10	I-AdverseReaction
.	TAFINLAR.xml:S1:21840:1	O

f	TAFINLAR.xml:S1:21848:1	O
Includes	TAFINLAR.xml:S1:21851:8	O
the	TAFINLAR.xml:S1:21860:3	O
following	TAFINLAR.xml:S1:21864:9	O
terms	TAFINLAR.xml:S1:21874:5	O
:	TAFINLAR.xml:S1:21879:1	O
renal	TAFINLAR.xml:S1:21881:5	B-AdverseReaction
failure	TAFINLAR.xml:S1:21887:7	I-AdverseReaction
and	TAFINLAR.xml:S1:21895:3	O
renal	TAFINLAR.xml:S1:21899:5	B-AdverseReaction
failure	TAFINLAR.xml:S1:21905:7	I-AdverseReaction
acute	TAFINLAR.xml:S1:21913:5	I-AdverseReaction
.	TAFINLAR.xml:S1:21918:1	O

Other	TAFINLAR.xml:S1:21924:5	O
clinically	TAFINLAR.xml:S1:21930:10	O
important	TAFINLAR.xml:S1:21941:9	O
adverse	TAFINLAR.xml:S1:21951:7	O
reactions	TAFINLAR.xml:S1:21959:9	O
(	TAFINLAR.xml:S1:21969:1	O
N	TAFINLAR.xml:S1:21970:1	O
202	TAFINLAR.xml:S1:21974:3	O
)	TAFINLAR.xml:S1:21977:1	O
observed	TAFINLAR.xml:S1:21979:8	O
in	TAFINLAR.xml:S1:21988:2	O
10%	TAFINLAR.xml:S1:21992:3	O
of	TAFINLAR.xml:S1:21996:2	O
patients	TAFINLAR.xml:S1:21999:8	O
treated	TAFINLAR.xml:S1:22008:7	O
with	TAFINLAR.xml:S1:22016:4	O
TAFINLAR	TAFINLAR.xml:S1:22021:8	O
in	TAFINLAR.xml:S1:22030:2	O
combination	TAFINLAR.xml:S1:22033:11	O
with	TAFINLAR.xml:S1:22045:4	O
trametinib	TAFINLAR.xml:S1:22050:10	O
were	TAFINLAR.xml:S1:22061:4	O
:	TAFINLAR.xml:S1:22065:1	O

Eye	TAFINLAR.xml:S1:22073:3	O
Disorders	TAFINLAR.xml:S1:22077:9	O
:	TAFINLAR.xml:S1:22086:1	O
Vision	TAFINLAR.xml:S1:22089:6	B-AdverseReaction
blurred	TAFINLAR.xml:S1:22096:7	I-AdverseReaction
,	TAFINLAR.xml:S1:22103:1	O
transient	TAFINLAR.xml:S1:22105:9	B-AdverseReaction
blindness	TAFINLAR.xml:S1:22115:9	I-AdverseReaction
.	TAFINLAR.xml:S1:22124:1	O

Gastrointestinal	TAFINLAR.xml:S1:22132:16	O
Disorders	TAFINLAR.xml:S1:22149:9	O
:	TAFINLAR.xml:S1:22158:1	O
Stomatitis	TAFINLAR.xml:S1:22161:10	B-AdverseReaction
,	TAFINLAR.xml:S1:22171:1	O
pancreatitis	TAFINLAR.xml:S1:22173:12	B-AdverseReaction
.	TAFINLAR.xml:S1:22185:1	O

General	TAFINLAR.xml:S1:22193:7	O
Disorders	TAFINLAR.xml:S1:22201:9	O
and	TAFINLAR.xml:S1:22211:3	O
Administration	TAFINLAR.xml:S1:22215:14	O
Site	TAFINLAR.xml:S1:22230:4	O
Conditions	TAFINLAR.xml:S1:22235:10	O
:	TAFINLAR.xml:S1:22245:1	O
Asthenia	TAFINLAR.xml:S1:22248:8	B-AdverseReaction
.	TAFINLAR.xml:S1:22256:1	O

Infections	TAFINLAR.xml:S1:22264:10	O
and	TAFINLAR.xml:S1:22275:3	O
Infestations	TAFINLAR.xml:S1:22279:12	O
:	TAFINLAR.xml:S1:22291:1	O
Cellulitis	TAFINLAR.xml:S1:22294:10	B-AdverseReaction
,	TAFINLAR.xml:S1:22304:1	O
folliculitis	TAFINLAR.xml:S1:22306:12	B-AdverseReaction
,	TAFINLAR.xml:S1:22318:1	O
paronychia	TAFINLAR.xml:S1:22320:10	B-AdverseReaction
,	TAFINLAR.xml:S1:22330:1	O
rash	TAFINLAR.xml:S1:22332:4	B-AdverseReaction
pustular	TAFINLAR.xml:S1:22337:8	I-AdverseReaction
.	TAFINLAR.xml:S1:22345:1	O

Neoplasms	TAFINLAR.xml:S1:22353:9	O
Benign	TAFINLAR.xml:S1:22363:6	O
,	TAFINLAR.xml:S1:22369:1	O
Malignant	TAFINLAR.xml:S1:22371:9	O
,	TAFINLAR.xml:S1:22380:1	O
and	TAFINLAR.xml:S1:22382:3	O
Unspecified	TAFINLAR.xml:S1:22386:11	O
(	TAFINLAR.xml:S1:22398:1	O
including	TAFINLAR.xml:S1:22399:9	O
cysts	TAFINLAR.xml:S1:22409:5	O
and	TAFINLAR.xml:S1:22415:3	O
polyps	TAFINLAR.xml:S1:22419:6	O
)	TAFINLAR.xml:S1:22425:1	O
:	TAFINLAR.xml:S1:22426:1	O
Skin	TAFINLAR.xml:S1:22429:4	B-AdverseReaction
papilloma	TAFINLAR.xml:S1:22434:9	I-AdverseReaction
.	TAFINLAR.xml:S1:22443:1	O

Skin	TAFINLAR.xml:S1:22451:4	O
and	TAFINLAR.xml:S1:22456:3	O
Subcutaneous	TAFINLAR.xml:S1:22460:12	O
Tissue	TAFINLAR.xml:S1:22473:6	O
Disorders	TAFINLAR.xml:S1:22480:9	O
:	TAFINLAR.xml:S1:22489:1	O
Palmar	TAFINLAR.xml:S1:22492:6	B-AdverseReaction
-	TAFINLAR.xml:S1:22498:1	I-AdverseReaction
plantar	TAFINLAR.xml:S1:22499:7	I-AdverseReaction
erythrodysesthesia	TAFINLAR.xml:S1:22507:18	I-AdverseReaction
syndrome	TAFINLAR.xml:S1:22526:8	I-AdverseReaction
,	TAFINLAR.xml:S1:22534:1	O
hyperkeratosis	TAFINLAR.xml:S1:22536:14	B-AdverseReaction
,	TAFINLAR.xml:S1:22550:1	O
hyperhidrosis	TAFINLAR.xml:S1:22552:13	B-AdverseReaction
.	TAFINLAR.xml:S1:22565:1	O

Vascular	TAFINLAR.xml:S1:22573:8	O
Disorders	TAFINLAR.xml:S1:22582:9	O
:	TAFINLAR.xml:S1:22591:1	O
Hypertension	TAFINLAR.xml:S1:22594:12	B-AdverseReaction
.	TAFINLAR.xml:S1:22606:1	O

Table	TAFINLAR.xml:S1:22612:5	O
6	TAFINLAR.xml:S1:22618:1	O
.	TAFINLAR.xml:S1:22619:1	O

Treatment	TAFINLAR.xml:S1:22621:9	O
-	TAFINLAR.xml:S1:22630:1	O
Emergent	TAFINLAR.xml:S1:22631:8	O
Laboratory	TAFINLAR.xml:S1:22640:10	O
Abnormalities	TAFINLAR.xml:S1:22651:13	O
Occurring	TAFINLAR.xml:S1:22665:9	O
at	TAFINLAR.xml:S1:22675:2	O
10%	TAFINLAR.xml:S1:22680:3	O
(	TAFINLAR.xml:S1:22684:1	O
All	TAFINLAR.xml:S1:22685:3	O
Grades	TAFINLAR.xml:S1:22689:6	O
)	TAFINLAR.xml:S1:22695:1	O
or	TAFINLAR.xml:S1:22697:2	O
2%	TAFINLAR.xml:S1:22702:2	O
(	TAFINLAR.xml:S1:22705:1	O
Grades	TAFINLAR.xml:S1:22706:6	O
3	TAFINLAR.xml:S1:22713:1	O
or	TAFINLAR.xml:S1:22715:2	O
4	TAFINLAR.xml:S1:22718:1	O
)]	TAFINLAR.xml:S1:22719:2	O
of	TAFINLAR.xml:S1:22722:2	O
Patients	TAFINLAR.xml:S1:22725:8	O
Treated	TAFINLAR.xml:S1:22734:7	O
With	TAFINLAR.xml:S1:22742:4	O
TAFINLAR	TAFINLAR.xml:S1:22747:8	O
in	TAFINLAR.xml:S1:22756:2	O
Combination	TAFINLAR.xml:S1:22759:11	O
With	TAFINLAR.xml:S1:22771:4	O
Trametinib	TAFINLAR.xml:S1:22776:10	O
in	TAFINLAR.xml:S1:22787:2	O
Trial	TAFINLAR.xml:S1:22790:5	O
2	TAFINLAR.xml:S1:22796:1	O

Tests	TAFINLAR.xml:S1:22801:5	O
TAFINLAR	TAFINLAR.xml:S1:22838:8	O
plus	TAFINLAR.xml:S1:22847:4	O
Trametinib	TAFINLAR.xml:S1:22852:10	O
2	TAFINLAR.xml:S1:22863:1	O
mg	TAFINLAR.xml:S1:22865:2	O
N	TAFINLAR.xml:S1:22869:1	O
55	TAFINLAR.xml:S1:22873:2	O
TAFINLAR	TAFINLAR.xml:S1:22879:8	O
plus	TAFINLAR.xml:S1:22888:4	O
Trametinib	TAFINLAR.xml:S1:22893:10	O
1	TAFINLAR.xml:S1:22904:1	O
mg	TAFINLAR.xml:S1:22906:2	O
N	TAFINLAR.xml:S1:22910:1	O
54	TAFINLAR.xml:S1:22914:2	O
TAFINLAR	TAFINLAR.xml:S1:22920:8	O
N	TAFINLAR.xml:S1:22930:1	O
53	TAFINLAR.xml:S1:22934:2	O

All	TAFINLAR.xml:S1:22943:3	O
Grades	TAFINLAR.xml:S1:22948:6	O
Grades	TAFINLAR.xml:S1:22980:6	O
3	TAFINLAR.xml:S1:22988:1	O
and	TAFINLAR.xml:S1:22990:3	O
4	TAFINLAR.xml:S1:22994:1	O
All	TAFINLAR.xml:S1:22999:3	O
Grades	TAFINLAR.xml:S1:23004:6	O
Grades	TAFINLAR.xml:S1:23014:6	O
3	TAFINLAR.xml:S1:23022:1	O
and	TAFINLAR.xml:S1:23024:3	O
4	TAFINLAR.xml:S1:23028:1	O
All	TAFINLAR.xml:S1:23033:3	O
Grades	TAFINLAR.xml:S1:23038:6	O
Grades	TAFINLAR.xml:S1:23048:6	O
3	TAFINLAR.xml:S1:23056:1	O
and	TAFINLAR.xml:S1:23058:3	O
4	TAFINLAR.xml:S1:23062:1	O
a	TAFINLAR.xml:S1:23063:1	O

Hematology	TAFINLAR.xml:S1:23071:10	O

Leukopenia	TAFINLAR.xml:S1:23147:10	B-AdverseReaction

62	TAFINLAR.xml:S1:23260:2	O
5	TAFINLAR.xml:S1:23274:1	O
46	TAFINLAR.xml:S1:23288:2	O
4	TAFINLAR.xml:S1:23302:1	O
21	TAFINLAR.xml:S1:23316:2	O
0	TAFINLAR.xml:S1:23326:1	O

Lymphopenia	TAFINLAR.xml:S1:23376:11	B-AdverseReaction

55	TAFINLAR.xml:S1:23489:2	O
22	TAFINLAR.xml:S1:23503:2	O
59	TAFINLAR.xml:S1:23517:2	O
19	TAFINLAR.xml:S1:23531:2	O
40	TAFINLAR.xml:S1:23545:2	O
6	TAFINLAR.xml:S1:23555:1	O

Neutropenia	TAFINLAR.xml:S1:23605:11	B-AdverseReaction

55	TAFINLAR.xml:S1:23718:2	O
13	TAFINLAR.xml:S1:23732:2	O
37	TAFINLAR.xml:S1:23746:2	O
2	TAFINLAR.xml:S1:23760:1	O
9	TAFINLAR.xml:S1:23774:1	O
2	TAFINLAR.xml:S1:23784:1	O

Anemia	TAFINLAR.xml:S1:23834:6	B-AdverseReaction

55	TAFINLAR.xml:S1:23947:2	O
4	TAFINLAR.xml:S1:23961:1	O
46	TAFINLAR.xml:S1:23975:2	O
7	TAFINLAR.xml:S1:23989:1	O
28	TAFINLAR.xml:S1:24003:2	O
0	TAFINLAR.xml:S1:24013:1	O

Thrombocytopenia	TAFINLAR.xml:S1:24063:16	B-AdverseReaction

31	TAFINLAR.xml:S1:24176:2	O
4	TAFINLAR.xml:S1:24190:1	O
31	TAFINLAR.xml:S1:24204:2	O
2	TAFINLAR.xml:S1:24218:1	O
8	TAFINLAR.xml:S1:24232:1	O
0	TAFINLAR.xml:S1:24242:1	O

Liver	TAFINLAR.xml:S1:24256:5	O
Function	TAFINLAR.xml:S1:24262:8	O
Tests	TAFINLAR.xml:S1:24271:5	O

Increased	TAFINLAR.xml:S1:24332:9	B-AdverseReaction
AST	TAFINLAR.xml:S1:24342:3	I-AdverseReaction

60	TAFINLAR.xml:S1:24445:2	O
5	TAFINLAR.xml:S1:24459:1	O
54	TAFINLAR.xml:S1:24473:2	O
0	TAFINLAR.xml:S1:24487:1	O
15	TAFINLAR.xml:S1:24501:2	O
0	TAFINLAR.xml:S1:24511:1	O

Increased	TAFINLAR.xml:S1:24561:9	B-AdverseReaction
alkaline	TAFINLAR.xml:S1:24571:8	I-AdverseReaction
phosphatase	TAFINLAR.xml:S1:24580:11	I-AdverseReaction

60	TAFINLAR.xml:S1:24674:2	O
2	TAFINLAR.xml:S1:24688:1	O
67	TAFINLAR.xml:S1:24702:2	O
6	TAFINLAR.xml:S1:24716:1	O
26	TAFINLAR.xml:S1:24730:2	O
2	TAFINLAR.xml:S1:24740:1	O

Increased	TAFINLAR.xml:S1:24790:9	B-AdverseReaction
ALT	TAFINLAR.xml:S1:24800:3	I-AdverseReaction

42	TAFINLAR.xml:S1:24903:2	O
4	TAFINLAR.xml:S1:24917:1	O
35	TAFINLAR.xml:S1:24931:2	O
4	TAFINLAR.xml:S1:24945:1	O
11	TAFINLAR.xml:S1:24959:2	O
0	TAFINLAR.xml:S1:24969:1	O

Hyperbilirubinemia	TAFINLAR.xml:S1:25019:18	B-AdverseReaction

15	TAFINLAR.xml:S1:25132:2	O
0	TAFINLAR.xml:S1:25146:1	O
7	TAFINLAR.xml:S1:25160:1	O
4	TAFINLAR.xml:S1:25174:1	O
0	TAFINLAR.xml:S1:25188:1	O
0	TAFINLAR.xml:S1:25198:1	O

Chemistry	TAFINLAR.xml:S1:25212:9	O

Hyperglycemia	TAFINLAR.xml:S1:25288:13	B-AdverseReaction

58	TAFINLAR.xml:S1:25401:2	O
5	TAFINLAR.xml:S1:25415:1	O
67	TAFINLAR.xml:S1:25429:2	O
6	TAFINLAR.xml:S1:25443:1	O
49	TAFINLAR.xml:S1:25457:2	O
2	TAFINLAR.xml:S1:25467:1	O

Increased	TAFINLAR.xml:S1:25517:9	B-AdverseReaction
GGT	TAFINLAR.xml:S1:25527:3	I-AdverseReaction

56	TAFINLAR.xml:S1:25630:2	O
11	TAFINLAR.xml:S1:25644:2	O
54	TAFINLAR.xml:S1:25658:2	O
17	TAFINLAR.xml:S1:25672:2	O
38	TAFINLAR.xml:S1:25686:2	O
2	TAFINLAR.xml:S1:25696:1	O

Hyponatremia	TAFINLAR.xml:S1:25746:12	B-AdverseReaction

55	TAFINLAR.xml:S1:25859:2	O
11	TAFINLAR.xml:S1:25873:2	O
48	TAFINLAR.xml:S1:25887:2	O
15	TAFINLAR.xml:S1:25901:2	O
36	TAFINLAR.xml:S1:25915:2	O
2	TAFINLAR.xml:S1:25925:1	O

Hypoalbuminemia	TAFINLAR.xml:S1:25975:15	B-AdverseReaction

53	TAFINLAR.xml:S1:26088:2	O
0	TAFINLAR.xml:S1:26102:1	O
43	TAFINLAR.xml:S1:26116:2	O
2	TAFINLAR.xml:S1:26130:1	O
23	TAFINLAR.xml:S1:26144:2	O
0	TAFINLAR.xml:S1:26154:1	O

Hypophosphatemia	TAFINLAR.xml:S1:26204:16	B-AdverseReaction

47	TAFINLAR.xml:S1:26317:2	O
5	TAFINLAR.xml:S1:26331:1	O
41	TAFINLAR.xml:S1:26345:2	O
11	TAFINLAR.xml:S1:26359:2	O
40	TAFINLAR.xml:S1:26373:2	O
0	TAFINLAR.xml:S1:26383:1	O

Hypokalemia	TAFINLAR.xml:S1:26433:11	B-AdverseReaction

29	TAFINLAR.xml:S1:26546:2	O
2	TAFINLAR.xml:S1:26560:1	O
15	TAFINLAR.xml:S1:26574:2	O
2	TAFINLAR.xml:S1:26588:1	O
23	TAFINLAR.xml:S1:26602:2	O
6	TAFINLAR.xml:S1:26612:1	O

Increased	TAFINLAR.xml:S1:26662:9	B-AdverseReaction
creatinine	TAFINLAR.xml:S1:26672:10	I-AdverseReaction

24	TAFINLAR.xml:S1:26775:2	O
5	TAFINLAR.xml:S1:26789:1	O
20	TAFINLAR.xml:S1:26803:2	O
2	TAFINLAR.xml:S1:26817:1	O
9	TAFINLAR.xml:S1:26831:1	O
0	TAFINLAR.xml:S1:26841:1	O

Hypomagnesemia	TAFINLAR.xml:S1:26891:14	B-AdverseReaction

18	TAFINLAR.xml:S1:27004:2	O
2	TAFINLAR.xml:S1:27018:1	O
2	TAFINLAR.xml:S1:27032:1	O
0	TAFINLAR.xml:S1:27046:1	O
6	TAFINLAR.xml:S1:27060:1	O
0	TAFINLAR.xml:S1:27070:1	O

Hyperkalemia	TAFINLAR.xml:S1:27120:12	B-AdverseReaction

18	TAFINLAR.xml:S1:27233:2	O
0	TAFINLAR.xml:S1:27247:1	O
22	TAFINLAR.xml:S1:27261:2	O
0	TAFINLAR.xml:S1:27275:1	O
15	TAFINLAR.xml:S1:27289:2	O
4	TAFINLAR.xml:S1:27299:1	O

Hypercalcemia	TAFINLAR.xml:S1:27349:13	B-AdverseReaction

15	TAFINLAR.xml:S1:27462:2	O
0	TAFINLAR.xml:S1:27476:1	O
19	TAFINLAR.xml:S1:27490:2	O
2	TAFINLAR.xml:S1:27504:1	O
4	TAFINLAR.xml:S1:27518:1	O
0	TAFINLAR.xml:S1:27528:1	O

Hypocalcemia	TAFINLAR.xml:S1:27578:12	B-AdverseReaction

13	TAFINLAR.xml:S1:27691:2	O
0	TAFINLAR.xml:S1:27705:1	O
20	TAFINLAR.xml:S1:27719:2	O
0	TAFINLAR.xml:S1:27733:1	O
9	TAFINLAR.xml:S1:27747:1	O
0	TAFINLAR.xml:S1:27757:1	O

a	TAFINLAR.xml:S1:27784:1	O
No	TAFINLAR.xml:S1:27787:2	O
Grade	TAFINLAR.xml:S1:27790:5	O
4	TAFINLAR.xml:S1:27796:1	O
events	TAFINLAR.xml:S1:27798:6	O
were	TAFINLAR.xml:S1:27805:4	O
reported	TAFINLAR.xml:S1:27810:8	O
in	TAFINLAR.xml:S1:27819:2	O
patients	TAFINLAR.xml:S1:27822:8	O
receiving	TAFINLAR.xml:S1:27831:9	O
TAFINLAR	TAFINLAR.xml:S1:27841:8	O
as	TAFINLAR.xml:S1:27850:2	O
a	TAFINLAR.xml:S1:27853:1	O
single	TAFINLAR.xml:S1:27855:6	O
agent	TAFINLAR.xml:S1:27862:5	O
.	TAFINLAR.xml:S1:27867:1	O

ALT	TAFINLAR.xml:S1:27873:3	O

Alanine	TAFINLAR.xml:S1:27879:7	O
aminotransferase	TAFINLAR.xml:S1:27887:16	O
;	TAFINLAR.xml:S1:27903:1	O
AST	TAFINLAR.xml:S1:27905:3	O
Aspartate	TAFINLAR.xml:S1:27911:9	O
aminotransferase	TAFINLAR.xml:S1:27921:16	O
;	TAFINLAR.xml:S1:27937:1	O
GGT	TAFINLAR.xml:S1:27939:3	O
Gamma	TAFINLAR.xml:S1:27945:5	O
glutamyltransferase	TAFINLAR.xml:S1:27951:19	O
.	TAFINLAR.xml:S1:27970:1	O

QT	TAFINLAR.xml:S1:27978:2	O
Prolongation	TAFINLAR.xml:S1:27981:12	O
:	TAFINLAR.xml:S1:27993:1	O
In	TAFINLAR.xml:S1:27996:2	O
Trial	TAFINLAR.xml:S1:27999:5	O
2	TAFINLAR.xml:S1:28005:1	O
,	TAFINLAR.xml:S1:28006:1	O
QTcF	TAFINLAR.xml:S1:28008:4	B-AdverseReaction
prolongation	TAFINLAR.xml:S1:28013:12	I-AdverseReaction
to	TAFINLAR.xml:S1:28026:2	O
500	TAFINLAR.xml:S1:28030:3	B-Severity
msec	TAFINLAR.xml:S1:28034:4	I-Severity
occurred	TAFINLAR.xml:S1:28039:8	O
in	TAFINLAR.xml:S1:28048:2	O
4%	TAFINLAR.xml:S1:28051:2	O
(	TAFINLAR.xml:S1:28054:1	O
2	TAFINLAR.xml:S1:28055:1	O
55	TAFINLAR.xml:S1:28057:2	O
)	TAFINLAR.xml:S1:28059:1	O
of	TAFINLAR.xml:S1:28061:2	O
patients	TAFINLAR.xml:S1:28064:8	O
treated	TAFINLAR.xml:S1:28073:7	O
with	TAFINLAR.xml:S1:28081:4	O
TAFINLAR	TAFINLAR.xml:S1:28086:8	O
in	TAFINLAR.xml:S1:28095:2	O
combination	TAFINLAR.xml:S1:28098:11	O
with	TAFINLAR.xml:S1:28110:4	O
trametinib	TAFINLAR.xml:S1:28115:10	O
and	TAFINLAR.xml:S1:28126:3	O
in	TAFINLAR.xml:S1:28130:2	O
2%	TAFINLAR.xml:S1:28133:2	O
(	TAFINLAR.xml:S1:28136:1	O
1	TAFINLAR.xml:S1:28137:1	O
53	TAFINLAR.xml:S1:28139:2	O
)	TAFINLAR.xml:S1:28141:1	O
of	TAFINLAR.xml:S1:28143:2	O
patients	TAFINLAR.xml:S1:28146:8	O
treated	TAFINLAR.xml:S1:28155:7	O
with	TAFINLAR.xml:S1:28163:4	O
TAFINLAR	TAFINLAR.xml:S1:28168:8	O
as	TAFINLAR.xml:S1:28177:2	O
a	TAFINLAR.xml:S1:28180:1	O
single	TAFINLAR.xml:S1:28182:6	O
agent	TAFINLAR.xml:S1:28189:5	O
.	TAFINLAR.xml:S1:28194:1	O

The	TAFINLAR.xml:S1:28196:3	O
QTcF	TAFINLAR.xml:S1:28200:4	B-AdverseReaction
was	TAFINLAR.xml:S1:28205:3	I-AdverseReaction
increased	TAFINLAR.xml:S1:28209:9	I-AdverseReaction
more	TAFINLAR.xml:S1:28219:4	O
than	TAFINLAR.xml:S1:28224:4	O
60	TAFINLAR.xml:S1:28229:2	B-Severity
msec	TAFINLAR.xml:S1:28232:4	I-Severity
from	TAFINLAR.xml:S1:28237:4	I-Severity
baseline	TAFINLAR.xml:S1:28242:8	I-Severity
in	TAFINLAR.xml:S1:28251:2	O
13%	TAFINLAR.xml:S1:28254:3	O
(	TAFINLAR.xml:S1:28258:1	O
7	TAFINLAR.xml:S1:28259:1	O
55	TAFINLAR.xml:S1:28261:2	O
)	TAFINLAR.xml:S1:28263:1	O
of	TAFINLAR.xml:S1:28265:2	O
patients	TAFINLAR.xml:S1:28268:8	O
treated	TAFINLAR.xml:S1:28277:7	O
with	TAFINLAR.xml:S1:28285:4	O
TAFINLAR	TAFINLAR.xml:S1:28290:8	O
in	TAFINLAR.xml:S1:28299:2	O
combination	TAFINLAR.xml:S1:28302:11	O
with	TAFINLAR.xml:S1:28314:4	O
trametinib	TAFINLAR.xml:S1:28319:10	O
and	TAFINLAR.xml:S1:28330:3	O
2%	TAFINLAR.xml:S1:28334:2	O
(	TAFINLAR.xml:S1:28337:1	O
1	TAFINLAR.xml:S1:28338:1	O
53	TAFINLAR.xml:S1:28340:2	O
)	TAFINLAR.xml:S1:28342:1	O
of	TAFINLAR.xml:S1:28344:2	O
patients	TAFINLAR.xml:S1:28347:8	O
treated	TAFINLAR.xml:S1:28356:7	O
with	TAFINLAR.xml:S1:28364:4	O
TAFINLAR	TAFINLAR.xml:S1:28369:8	O
as	TAFINLAR.xml:S1:28378:2	O
a	TAFINLAR.xml:S1:28381:1	O
single	TAFINLAR.xml:S1:28383:6	O
agent	TAFINLAR.xml:S1:28390:5	O
.	TAFINLAR.xml:S1:28395:1	O
5	TAFINLAR.xml:S2:4:1	O
WARNINGS	TAFINLAR.xml:S2:6:8	O
AND	TAFINLAR.xml:S2:15:3	O
PRECAUTIONS	TAFINLAR.xml:S2:19:11	O

Review	TAFINLAR.xml:S2:37:6	O
the	TAFINLAR.xml:S2:44:3	O
Full	TAFINLAR.xml:S2:48:4	O
Prescribing	TAFINLAR.xml:S2:53:11	O
Information	TAFINLAR.xml:S2:65:11	O
for	TAFINLAR.xml:S2:77:3	O
trametinib	TAFINLAR.xml:S2:81:10	O
prior	TAFINLAR.xml:S2:92:5	O
to	TAFINLAR.xml:S2:98:2	O
initiation	TAFINLAR.xml:S2:101:10	O
of	TAFINLAR.xml:S2:112:2	O
TAFINLAR	TAFINLAR.xml:S2:115:8	O
in	TAFINLAR.xml:S2:124:2	O
combination	TAFINLAR.xml:S2:127:11	O
with	TAFINLAR.xml:S2:139:4	O
trametinib	TAFINLAR.xml:S2:144:10	O
.	TAFINLAR.xml:S2:154:1	O

The	TAFINLAR.xml:S2:156:3	O
following	TAFINLAR.xml:S2:160:9	O
serious	TAFINLAR.xml:S2:170:7	O
adverse	TAFINLAR.xml:S2:178:7	O
reactions	TAFINLAR.xml:S2:186:9	O
of	TAFINLAR.xml:S2:196:2	O
trametinib	TAFINLAR.xml:S2:199:10	O
as	TAFINLAR.xml:S2:210:2	O
a	TAFINLAR.xml:S2:213:1	O
single	TAFINLAR.xml:S2:215:6	O
agent	TAFINLAR.xml:S2:222:5	O
,	TAFINLAR.xml:S2:227:1	O
which	TAFINLAR.xml:S2:229:5	O
may	TAFINLAR.xml:S2:235:3	O
occur	TAFINLAR.xml:S2:239:5	O
when	TAFINLAR.xml:S2:245:4	O
TAFINLAR	TAFINLAR.xml:S2:250:8	O
is	TAFINLAR.xml:S2:259:2	O
used	TAFINLAR.xml:S2:262:4	O
in	TAFINLAR.xml:S2:267:2	O
combination	TAFINLAR.xml:S2:270:11	O
with	TAFINLAR.xml:S2:282:4	O
trametinib	TAFINLAR.xml:S2:287:10	O
,	TAFINLAR.xml:S2:297:1	O
are	TAFINLAR.xml:S2:299:3	O
not	TAFINLAR.xml:S2:303:3	O
described	TAFINLAR.xml:S2:307:9	O
in	TAFINLAR.xml:S2:317:2	O
the	TAFINLAR.xml:S2:320:3	O
Full	TAFINLAR.xml:S2:324:4	O
Prescribing	TAFINLAR.xml:S2:329:11	O
Information	TAFINLAR.xml:S2:341:11	O
for	TAFINLAR.xml:S2:353:3	O
TAFINLAR	TAFINLAR.xml:S2:357:8	O
:	TAFINLAR.xml:S2:365:1	O

Retinal	TAFINLAR.xml:S2:379:7	B-AdverseReaction
vein	TAFINLAR.xml:S2:387:4	I-AdverseReaction
occlusion	TAFINLAR.xml:S2:392:9	I-AdverseReaction

Interstitial	TAFINLAR.xml:S2:411:12	B-AdverseReaction
lung	TAFINLAR.xml:S2:424:4	I-AdverseReaction
disease	TAFINLAR.xml:S2:429:7	I-AdverseReaction

New	TAFINLAR.xml:S2:447:3	O
primary	TAFINLAR.xml:S2:451:7	B-AdverseReaction
malignancies	TAFINLAR.xml:S2:459:12	I-AdverseReaction
,	TAFINLAR.xml:S2:471:1	I-AdverseReaction
cutaneous	TAFINLAR.xml:S2:473:9	I-AdverseReaction
and	TAFINLAR.xml:S2:483:3	O
non	TAFINLAR.xml:S2:487:3	I-AdverseReaction
-	TAFINLAR.xml:S2:490:1	I-AdverseReaction
cutaneous	TAFINLAR.xml:S2:491:9	I-AdverseReaction
,	TAFINLAR.xml:S2:500:1	O
can	TAFINLAR.xml:S2:502:3	B-Factor
occur	TAFINLAR.xml:S2:506:5	O
when	TAFINLAR.xml:S2:512:4	O
TAFINLAR	TAFINLAR.xml:S2:517:8	O
is	TAFINLAR.xml:S2:526:2	O
administered	TAFINLAR.xml:S2:529:12	O
as	TAFINLAR.xml:S2:542:2	O
a	TAFINLAR.xml:S2:545:1	O
single	TAFINLAR.xml:S2:547:6	O
agent	TAFINLAR.xml:S2:554:5	O
or	TAFINLAR.xml:S2:560:2	O
in	TAFINLAR.xml:S2:563:2	O
combination	TAFINLAR.xml:S2:566:11	O
with	TAFINLAR.xml:S2:578:4	O
trametinib	TAFINLAR.xml:S2:583:10	O
.	TAFINLAR.xml:S2:593:1	O

Monitor	TAFINLAR.xml:S2:595:7	O
patients	TAFINLAR.xml:S2:603:8	O
for	TAFINLAR.xml:S2:612:3	O
new	TAFINLAR.xml:S2:616:3	O
malignancies	TAFINLAR.xml:S2:620:12	O
prior	TAFINLAR.xml:S2:633:5	O
to	TAFINLAR.xml:S2:639:2	O
initiation	TAFINLAR.xml:S2:642:10	O
of	TAFINLAR.xml:S2:653:2	O
therapy	TAFINLAR.xml:S2:656:7	O
,	TAFINLAR.xml:S2:663:1	O
while	TAFINLAR.xml:S2:665:5	O
on	TAFINLAR.xml:S2:671:2	O
therapy	TAFINLAR.xml:S2:674:7	O
,	TAFINLAR.xml:S2:681:1	O
and	TAFINLAR.xml:S2:683:3	O
following	TAFINLAR.xml:S2:687:9	O
discontinuation	TAFINLAR.xml:S2:697:15	O
of	TAFINLAR.xml:S2:713:2	O
TAFINLAR	TAFINLAR.xml:S2:716:8	O
or	TAFINLAR.xml:S2:725:2	O
the	TAFINLAR.xml:S2:728:3	O
combination	TAFINLAR.xml:S2:732:11	O
therapy	TAFINLAR.xml:S2:744:7	O
.	TAFINLAR.xml:S2:751:1	O

(	TAFINLAR.xml:S2:753:1	O
5.1	TAFINLAR.xml:S2:756:3	O
,	TAFINLAR.xml:S2:761:1	O
2.3	TAFINLAR.xml:S2:764:3	O
)	TAFINLAR.xml:S2:769:1	O

Tumor	TAFINLAR.xml:S2:778:5	B-AdverseReaction
Promotion	TAFINLAR.xml:S2:784:9	I-AdverseReaction
in	TAFINLAR.xml:S2:794:2	I-AdverseReaction
BRAF	TAFINLAR.xml:S2:797:4	I-AdverseReaction
Wild	TAFINLAR.xml:S2:802:4	I-AdverseReaction
-	TAFINLAR.xml:S2:806:1	I-AdverseReaction
Type	TAFINLAR.xml:S2:807:4	I-AdverseReaction
Melanoma	TAFINLAR.xml:S2:812:8	I-AdverseReaction
:	TAFINLAR.xml:S2:820:1	O
Increased	TAFINLAR.xml:S2:822:9	B-AdverseReaction
cell	TAFINLAR.xml:S2:832:4	I-AdverseReaction
proliferation	TAFINLAR.xml:S2:837:13	I-AdverseReaction
can	TAFINLAR.xml:S2:851:3	O
occur	TAFINLAR.xml:S2:855:5	O
with	TAFINLAR.xml:S2:861:4	O
BRAF	TAFINLAR.xml:S2:866:4	B-DrugClass
inhibitors	TAFINLAR.xml:S2:871:10	I-DrugClass
.	TAFINLAR.xml:S2:881:1	O

(	TAFINLAR.xml:S2:883:1	O
5.2	TAFINLAR.xml:S2:886:3	O
)	TAFINLAR.xml:S2:891:1	O

Hemorrhage	TAFINLAR.xml:S2:900:10	B-AdverseReaction
:	TAFINLAR.xml:S2:910:1	O
Major	TAFINLAR.xml:S2:912:5	B-Severity
hemorrhagic	TAFINLAR.xml:S2:918:11	B-AdverseReaction
events	TAFINLAR.xml:S2:930:6	I-AdverseReaction
can	TAFINLAR.xml:S2:937:3	B-Factor
occur	TAFINLAR.xml:S2:941:5	O
in	TAFINLAR.xml:S2:947:2	O
patients	TAFINLAR.xml:S2:950:8	O
receiving	TAFINLAR.xml:S2:959:9	O
TAFINLAR	TAFINLAR.xml:S2:969:8	O
in	TAFINLAR.xml:S2:978:2	O
combination	TAFINLAR.xml:S2:981:11	O
with	TAFINLAR.xml:S2:993:4	O
trametinib	TAFINLAR.xml:S2:998:10	O
.	TAFINLAR.xml:S2:1008:1	O

Monitor	TAFINLAR.xml:S2:1010:7	O
for	TAFINLAR.xml:S2:1018:3	O
signs	TAFINLAR.xml:S2:1022:5	O
and	TAFINLAR.xml:S2:1028:3	O
symptoms	TAFINLAR.xml:S2:1032:8	O
of	TAFINLAR.xml:S2:1041:2	O
bleeding	TAFINLAR.xml:S2:1044:8	O
.	TAFINLAR.xml:S2:1052:1	O

(	TAFINLAR.xml:S2:1054:1	O
5.3	TAFINLAR.xml:S2:1057:3	O
)	TAFINLAR.xml:S2:1062:1	O

Venous	TAFINLAR.xml:S2:1071:6	B-AdverseReaction
Thromboembolism	TAFINLAR.xml:S2:1078:15	I-AdverseReaction
:	TAFINLAR.xml:S2:1093:1	O
Deep	TAFINLAR.xml:S2:1095:4	B-AdverseReaction
vein	TAFINLAR.xml:S2:1100:4	I-AdverseReaction
thrombosis	TAFINLAR.xml:S2:1105:10	I-AdverseReaction
and	TAFINLAR.xml:S2:1116:3	O
pulmonary	TAFINLAR.xml:S2:1120:9	B-AdverseReaction
embolism	TAFINLAR.xml:S2:1130:8	I-AdverseReaction
can	TAFINLAR.xml:S2:1139:3	B-Factor
occur	TAFINLAR.xml:S2:1143:5	O
in	TAFINLAR.xml:S2:1149:2	O
patients	TAFINLAR.xml:S2:1152:8	O
receiving	TAFINLAR.xml:S2:1161:9	O
TAFINLAR	TAFINLAR.xml:S2:1171:8	O
in	TAFINLAR.xml:S2:1180:2	O
combination	TAFINLAR.xml:S2:1183:11	O
with	TAFINLAR.xml:S2:1195:4	O
trametinib	TAFINLAR.xml:S2:1200:10	O
.	TAFINLAR.xml:S2:1210:1	O

(	TAFINLAR.xml:S2:1212:1	O
5.4	TAFINLAR.xml:S2:1215:3	O
,	TAFINLAR.xml:S2:1220:1	O
2.3	TAFINLAR.xml:S2:1223:3	O
)	TAFINLAR.xml:S2:1228:1	O

Cardiomyopathy	TAFINLAR.xml:S2:1237:14	B-AdverseReaction
:	TAFINLAR.xml:S2:1251:1	O
Assess	TAFINLAR.xml:S2:1253:6	O
LVEF	TAFINLAR.xml:S2:1260:4	O
before	TAFINLAR.xml:S2:1265:6	O
treatment	TAFINLAR.xml:S2:1272:9	O
with	TAFINLAR.xml:S2:1282:4	O
TAFINLAR	TAFINLAR.xml:S2:1287:8	O
in	TAFINLAR.xml:S2:1296:2	O
combination	TAFINLAR.xml:S2:1299:11	O
with	TAFINLAR.xml:S2:1311:4	O
trametinib	TAFINLAR.xml:S2:1316:10	O
,	TAFINLAR.xml:S2:1326:1	O
after	TAFINLAR.xml:S2:1328:5	O
one	TAFINLAR.xml:S2:1334:3	O
month	TAFINLAR.xml:S2:1338:5	O
of	TAFINLAR.xml:S2:1344:2	O
treatment	TAFINLAR.xml:S2:1347:9	O
,	TAFINLAR.xml:S2:1356:1	O
then	TAFINLAR.xml:S2:1358:4	O
every	TAFINLAR.xml:S2:1363:5	O
2	TAFINLAR.xml:S2:1369:1	O
to	TAFINLAR.xml:S2:1371:2	O
3	TAFINLAR.xml:S2:1374:1	O
months	TAFINLAR.xml:S2:1376:6	O
thereafter	TAFINLAR.xml:S2:1383:10	O
.	TAFINLAR.xml:S2:1393:1	O

(	TAFINLAR.xml:S2:1395:1	O
5.5	TAFINLAR.xml:S2:1398:3	O
,	TAFINLAR.xml:S2:1403:1	O
2.3	TAFINLAR.xml:S2:1406:3	O
)	TAFINLAR.xml:S2:1411:1	O

Ocular	TAFINLAR.xml:S2:1420:6	B-AdverseReaction
Toxicities	TAFINLAR.xml:S2:1427:10	I-AdverseReaction
:	TAFINLAR.xml:S2:1437:1	O
Perform	TAFINLAR.xml:S2:1439:7	O
ophthalmologic	TAFINLAR.xml:S2:1447:14	O
evaluation	TAFINLAR.xml:S2:1462:10	O
for	TAFINLAR.xml:S2:1473:3	O
any	TAFINLAR.xml:S2:1477:3	O
visual	TAFINLAR.xml:S2:1481:6	O
disturbances	TAFINLAR.xml:S2:1488:12	O
.	TAFINLAR.xml:S2:1500:1	O

(	TAFINLAR.xml:S2:1502:1	O
5.6	TAFINLAR.xml:S2:1505:3	O
,	TAFINLAR.xml:S2:1510:1	O
2.3	TAFINLAR.xml:S2:1513:3	O
)	TAFINLAR.xml:S2:1518:1	O

Serious	TAFINLAR.xml:S2:1527:7	B-Severity
Febrile	TAFINLAR.xml:S2:1535:7	B-AdverseReaction
Reactions	TAFINLAR.xml:S2:1543:9	I-AdverseReaction
:	TAFINLAR.xml:S2:1552:1	O
Incidence	TAFINLAR.xml:S2:1554:9	O
and	TAFINLAR.xml:S2:1564:3	O
severity	TAFINLAR.xml:S2:1568:8	O
of	TAFINLAR.xml:S2:1577:2	O
pyrexia	TAFINLAR.xml:S2:1580:7	B-AdverseReaction
are	TAFINLAR.xml:S2:1588:3	O
increased	TAFINLAR.xml:S2:1592:9	O
with	TAFINLAR.xml:S2:1602:4	O
TAFINLAR	TAFINLAR.xml:S2:1607:8	O
in	TAFINLAR.xml:S2:1616:2	O
combination	TAFINLAR.xml:S2:1619:11	O
with	TAFINLAR.xml:S2:1631:4	O
trametinib	TAFINLAR.xml:S2:1636:10	O
.	TAFINLAR.xml:S2:1646:1	O

(	TAFINLAR.xml:S2:1648:1	O
5.7	TAFINLAR.xml:S2:1651:3	O
,	TAFINLAR.xml:S2:1656:1	O
2.3	TAFINLAR.xml:S2:1659:3	O
)	TAFINLAR.xml:S2:1664:1	O

Serious	TAFINLAR.xml:S2:1673:7	B-Severity
Skin	TAFINLAR.xml:S2:1681:4	B-AdverseReaction
Toxicity	TAFINLAR.xml:S2:1686:8	I-AdverseReaction
:	TAFINLAR.xml:S2:1694:1	O
Monitor	TAFINLAR.xml:S2:1696:7	O
for	TAFINLAR.xml:S2:1704:3	O
skin	TAFINLAR.xml:S2:1708:4	O
toxicities	TAFINLAR.xml:S2:1713:10	O
and	TAFINLAR.xml:S2:1724:3	O
for	TAFINLAR.xml:S2:1728:3	O
secondary	TAFINLAR.xml:S2:1732:9	O
infections	TAFINLAR.xml:S2:1742:10	O
.	TAFINLAR.xml:S2:1752:1	O

Discontinue	TAFINLAR.xml:S2:1754:11	O
for	TAFINLAR.xml:S2:1766:3	O
intolerable	TAFINLAR.xml:S2:1770:11	O
Grade	TAFINLAR.xml:S2:1782:5	O
2	TAFINLAR.xml:S2:1788:1	O
,	TAFINLAR.xml:S2:1789:1	O
or	TAFINLAR.xml:S2:1791:2	O
Grade	TAFINLAR.xml:S2:1794:5	O
3	TAFINLAR.xml:S2:1800:1	O
or	TAFINLAR.xml:S2:1802:2	O
4	TAFINLAR.xml:S2:1805:1	O
rash	TAFINLAR.xml:S2:1807:4	O
not	TAFINLAR.xml:S2:1812:3	O
improving	TAFINLAR.xml:S2:1816:9	O
within	TAFINLAR.xml:S2:1826:6	O
3	TAFINLAR.xml:S2:1833:1	O
weeks	TAFINLAR.xml:S2:1835:5	O
despite	TAFINLAR.xml:S2:1841:7	O
interruption	TAFINLAR.xml:S2:1849:12	O
of	TAFINLAR.xml:S2:1862:2	O
TAFINLAR	TAFINLAR.xml:S2:1865:8	O
.	TAFINLAR.xml:S2:1873:1	O

(	TAFINLAR.xml:S2:1875:1	O
5.8	TAFINLAR.xml:S2:1878:3	O
,	TAFINLAR.xml:S2:1883:1	O
2.3	TAFINLAR.xml:S2:1886:3	O
)	TAFINLAR.xml:S2:1891:1	O

Hyperglycemia	TAFINLAR.xml:S2:1900:13	B-AdverseReaction
:	TAFINLAR.xml:S2:1913:1	O
Monitor	TAFINLAR.xml:S2:1915:7	O
serum	TAFINLAR.xml:S2:1923:5	O
glucose	TAFINLAR.xml:S2:1929:7	O
levels	TAFINLAR.xml:S2:1937:6	O
in	TAFINLAR.xml:S2:1944:2	O
patients	TAFINLAR.xml:S2:1947:8	O
with	TAFINLAR.xml:S2:1956:4	O
pre	TAFINLAR.xml:S2:1961:3	O
-	TAFINLAR.xml:S2:1964:1	O
existing	TAFINLAR.xml:S2:1965:8	O
diabetes	TAFINLAR.xml:S2:1974:8	O
or	TAFINLAR.xml:S2:1983:2	O
hyperglycemia	TAFINLAR.xml:S2:1986:13	O
.	TAFINLAR.xml:S2:1999:1	O

(	TAFINLAR.xml:S2:2001:1	O
5.9	TAFINLAR.xml:S2:2004:3	O
)	TAFINLAR.xml:S2:2009:1	O

Glucose	TAFINLAR.xml:S2:2018:7	B-AdverseReaction
-	TAFINLAR.xml:S2:2025:1	I-AdverseReaction
6	TAFINLAR.xml:S2:2026:1	I-AdverseReaction
-	TAFINLAR.xml:S2:2027:1	I-AdverseReaction
Phosphate	TAFINLAR.xml:S2:2028:9	I-AdverseReaction
Dehydrogenase	TAFINLAR.xml:S2:2038:13	I-AdverseReaction
Deficiency	TAFINLAR.xml:S2:2052:10	I-AdverseReaction
:	TAFINLAR.xml:S2:2062:1	O
Closely	TAFINLAR.xml:S2:2064:7	O
monitor	TAFINLAR.xml:S2:2072:7	O
for	TAFINLAR.xml:S2:2080:3	O
hemolytic	TAFINLAR.xml:S2:2084:9	O
anemia	TAFINLAR.xml:S2:2094:6	O
.	TAFINLAR.xml:S2:2100:1	O

(	TAFINLAR.xml:S2:2102:1	O
5.10	TAFINLAR.xml:S2:2105:4	O
)	TAFINLAR.xml:S2:2111:1	O

Embryofetal	TAFINLAR.xml:S2:2120:11	B-AdverseReaction
Toxicity	TAFINLAR.xml:S2:2132:8	I-AdverseReaction
:	TAFINLAR.xml:S2:2140:1	O
Can	TAFINLAR.xml:S2:2142:3	B-Factor
cause	TAFINLAR.xml:S2:2146:5	O
fetal	TAFINLAR.xml:S2:2152:5	B-AdverseReaction
harm	TAFINLAR.xml:S2:2158:4	I-AdverseReaction
.	TAFINLAR.xml:S2:2162:1	O

Advise	TAFINLAR.xml:S2:2164:6	O
females	TAFINLAR.xml:S2:2171:7	O
of	TAFINLAR.xml:S2:2179:2	O
reproductive	TAFINLAR.xml:S2:2182:12	O
potential	TAFINLAR.xml:S2:2195:9	O
of	TAFINLAR.xml:S2:2205:2	O
potential	TAFINLAR.xml:S2:2208:9	O
risk	TAFINLAR.xml:S2:2218:4	O
to	TAFINLAR.xml:S2:2223:2	O
a	TAFINLAR.xml:S2:2226:1	O
fetus	TAFINLAR.xml:S2:2228:5	O
.	TAFINLAR.xml:S2:2233:1	O

TAFINLAR	TAFINLAR.xml:S2:2235:8	O
may	TAFINLAR.xml:S2:2244:3	O
render	TAFINLAR.xml:S2:2248:6	O
hormonal	TAFINLAR.xml:S2:2255:8	O
contraceptives	TAFINLAR.xml:S2:2264:14	O
less	TAFINLAR.xml:S2:2279:4	O
effective	TAFINLAR.xml:S2:2284:9	O
and	TAFINLAR.xml:S2:2294:3	O
an	TAFINLAR.xml:S2:2298:2	O
alternative	TAFINLAR.xml:S2:2301:11	O
method	TAFINLAR.xml:S2:2313:6	O
of	TAFINLAR.xml:S2:2320:2	O
contraception	TAFINLAR.xml:S2:2323:13	O
should	TAFINLAR.xml:S2:2337:6	O
be	TAFINLAR.xml:S2:2344:2	O
used	TAFINLAR.xml:S2:2347:4	O
.	TAFINLAR.xml:S2:2351:1	O

(	TAFINLAR.xml:S2:2353:1	O
5.11	TAFINLAR.xml:S2:2356:4	O
,	TAFINLAR.xml:S2:2362:1	O
8.1	TAFINLAR.xml:S2:2365:3	O
)	TAFINLAR.xml:S2:2370:1	O

EXCERPT	TAFINLAR.xml:S2:2379:7	O
:	TAFINLAR.xml:S2:2386:1	O

5.1	TAFINLAR.xml:S2:2397:3	O

New	TAFINLAR.xml:S2:2401:3	O
Primary	TAFINLAR.xml:S2:2405:7	O
Malignancies	TAFINLAR.xml:S2:2413:12	O

New	TAFINLAR.xml:S2:2431:3	O
primary	TAFINLAR.xml:S2:2435:7	B-AdverseReaction
malignancies	TAFINLAR.xml:S2:2443:12	I-AdverseReaction
,	TAFINLAR.xml:S2:2455:1	I-AdverseReaction
cutaneous	TAFINLAR.xml:S2:2457:9	I-AdverseReaction
and	TAFINLAR.xml:S2:2467:3	O
non	TAFINLAR.xml:S2:2471:3	I-AdverseReaction
-	TAFINLAR.xml:S2:2474:1	I-AdverseReaction
cutaneous	TAFINLAR.xml:S2:2475:9	I-AdverseReaction
,	TAFINLAR.xml:S2:2484:1	O
can	TAFINLAR.xml:S2:2486:3	B-Factor
occur	TAFINLAR.xml:S2:2490:5	O
when	TAFINLAR.xml:S2:2496:4	O
TAFINLAR	TAFINLAR.xml:S2:2501:8	O
is	TAFINLAR.xml:S2:2510:2	O
administered	TAFINLAR.xml:S2:2513:12	O
as	TAFINLAR.xml:S2:2526:2	O
a	TAFINLAR.xml:S2:2529:1	O
single	TAFINLAR.xml:S2:2531:6	O
agent	TAFINLAR.xml:S2:2538:5	O
or	TAFINLAR.xml:S2:2544:2	O
when	TAFINLAR.xml:S2:2547:4	O
used	TAFINLAR.xml:S2:2552:4	O
in	TAFINLAR.xml:S2:2557:2	O
combination	TAFINLAR.xml:S2:2560:11	O
with	TAFINLAR.xml:S2:2572:4	O
trametinib	TAFINLAR.xml:S2:2577:10	O
.	TAFINLAR.xml:S2:2587:1	O

Cutaneous	TAFINLAR.xml:S2:2594:9	O
Malignancies	TAFINLAR.xml:S2:2604:12	O
:	TAFINLAR.xml:S2:2616:1	O

TAFINLAR	TAFINLAR.xml:S2:2624:8	O
results	TAFINLAR.xml:S2:2633:7	O
in	TAFINLAR.xml:S2:2641:2	O
an	TAFINLAR.xml:S2:2644:2	O
increased	TAFINLAR.xml:S2:2647:9	O
incidence	TAFINLAR.xml:S2:2657:9	O
of	TAFINLAR.xml:S2:2667:2	O
cutaneous	TAFINLAR.xml:S2:2670:9	B-AdverseReaction
squamous	TAFINLAR.xml:S2:2680:8	I-AdverseReaction
cell	TAFINLAR.xml:S2:2689:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:2694:9	I-AdverseReaction
,	TAFINLAR.xml:S2:2703:1	O
keratoacanthoma	TAFINLAR.xml:S2:2705:15	B-AdverseReaction
,	TAFINLAR.xml:S2:2720:1	O
and	TAFINLAR.xml:S2:2722:3	O
melanoma	TAFINLAR.xml:S2:2726:8	B-AdverseReaction
.	TAFINLAR.xml:S2:2734:1	O

TAFINLAR	TAFINLAR.xml:S2:2736:8	O
when	TAFINLAR.xml:S2:2745:4	O
used	TAFINLAR.xml:S2:2750:4	O
in	TAFINLAR.xml:S2:2755:2	O
combination	TAFINLAR.xml:S2:2758:11	O
with	TAFINLAR.xml:S2:2770:4	O
trametinib	TAFINLAR.xml:S2:2775:10	O
results	TAFINLAR.xml:S2:2786:7	O
in	TAFINLAR.xml:S2:2794:2	O
an	TAFINLAR.xml:S2:2797:2	O
increased	TAFINLAR.xml:S2:2800:9	O
incidence	TAFINLAR.xml:S2:2810:9	O
of	TAFINLAR.xml:S2:2820:2	O
basal	TAFINLAR.xml:S2:2823:5	B-AdverseReaction
cell	TAFINLAR.xml:S2:2829:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:2834:9	I-AdverseReaction
.	TAFINLAR.xml:S2:2843:1	O

In	TAFINLAR.xml:S2:2851:2	O
Trial	TAFINLAR.xml:S2:2854:5	O
1	TAFINLAR.xml:S2:2860:1	O
,	TAFINLAR.xml:S2:2861:1	O
cutaneous	TAFINLAR.xml:S2:2863:9	B-AdverseReaction
squamous	TAFINLAR.xml:S2:2873:8	I-AdverseReaction
cell	TAFINLAR.xml:S2:2882:4	I-AdverseReaction
carcinomas	TAFINLAR.xml:S2:2887:10	I-AdverseReaction
and	TAFINLAR.xml:S2:2898:3	O
keratoacanthomas	TAFINLAR.xml:S2:2902:16	B-AdverseReaction
(	TAFINLAR.xml:S2:2919:1	O
cuSCC	TAFINLAR.xml:S2:2920:5	B-AdverseReaction
)	TAFINLAR.xml:S2:2925:1	O
occurred	TAFINLAR.xml:S2:2927:8	O
in	TAFINLAR.xml:S2:2936:2	O
7%	TAFINLAR.xml:S2:2939:2	O
(	TAFINLAR.xml:S2:2942:1	O
14	TAFINLAR.xml:S2:2943:2	O
187	TAFINLAR.xml:S2:2946:3	O
)	TAFINLAR.xml:S2:2949:1	O
of	TAFINLAR.xml:S2:2951:2	O
patients	TAFINLAR.xml:S2:2954:8	O
treated	TAFINLAR.xml:S2:2963:7	O
with	TAFINLAR.xml:S2:2971:4	O
TAFINLAR	TAFINLAR.xml:S2:2976:8	O
and	TAFINLAR.xml:S2:2985:3	O
in	TAFINLAR.xml:S2:2989:2	O
none	TAFINLAR.xml:S2:2992:4	O
of	TAFINLAR.xml:S2:2997:2	O
the	TAFINLAR.xml:S2:3000:3	O
patients	TAFINLAR.xml:S2:3004:8	O
treated	TAFINLAR.xml:S2:3013:7	O
with	TAFINLAR.xml:S2:3021:4	O
dacarbazine	TAFINLAR.xml:S2:3026:11	O
.	TAFINLAR.xml:S2:3037:1	O

Across	TAFINLAR.xml:S2:3043:6	O
clinical	TAFINLAR.xml:S2:3050:8	O
trials	TAFINLAR.xml:S2:3059:6	O
of	TAFINLAR.xml:S2:3066:2	O
TAFINLAR	TAFINLAR.xml:S2:3069:8	O
(	TAFINLAR.xml:S2:3078:1	O
N	TAFINLAR.xml:S2:3079:1	O
586	TAFINLAR.xml:S2:3083:3	O
)	TAFINLAR.xml:S2:3086:1	O
,	TAFINLAR.xml:S2:3087:1	O
the	TAFINLAR.xml:S2:3089:3	O
incidence	TAFINLAR.xml:S2:3093:9	O
of	TAFINLAR.xml:S2:3103:2	O
cuSCC	TAFINLAR.xml:S2:3106:5	B-AdverseReaction
was	TAFINLAR.xml:S2:3112:3	O
11%	TAFINLAR.xml:S2:3116:3	O
.	TAFINLAR.xml:S2:3119:1	O

The	TAFINLAR.xml:S2:3121:3	O
median	TAFINLAR.xml:S2:3125:6	O
time	TAFINLAR.xml:S2:3132:4	O
to	TAFINLAR.xml:S2:3137:2	O
first	TAFINLAR.xml:S2:3140:5	O
cuSCC	TAFINLAR.xml:S2:3146:5	B-AdverseReaction
was	TAFINLAR.xml:S2:3152:3	O
9	TAFINLAR.xml:S2:3156:1	O
weeks	TAFINLAR.xml:S2:3158:5	O
(	TAFINLAR.xml:S2:3164:1	O
range	TAFINLAR.xml:S2:3165:5	O
:	TAFINLAR.xml:S2:3170:1	O
1	TAFINLAR.xml:S2:3172:1	O
to	TAFINLAR.xml:S2:3174:2	O
53	TAFINLAR.xml:S2:3177:2	O
weeks	TAFINLAR.xml:S2:3180:5	O
)	TAFINLAR.xml:S2:3185:1	O
.	TAFINLAR.xml:S2:3186:1	O

Of	TAFINLAR.xml:S2:3188:2	O
those	TAFINLAR.xml:S2:3191:5	O
patients	TAFINLAR.xml:S2:3197:8	O
who	TAFINLAR.xml:S2:3206:3	O
developed	TAFINLAR.xml:S2:3210:9	O
new	TAFINLAR.xml:S2:3220:3	O
cuSCC	TAFINLAR.xml:S2:3224:5	B-AdverseReaction
,	TAFINLAR.xml:S2:3229:1	O
approximately	TAFINLAR.xml:S2:3231:13	O
33%	TAFINLAR.xml:S2:3245:3	O
developed	TAFINLAR.xml:S2:3249:9	O
one	TAFINLAR.xml:S2:3259:3	O
or	TAFINLAR.xml:S2:3263:2	O
more	TAFINLAR.xml:S2:3266:4	O
cuSCC	TAFINLAR.xml:S2:3271:5	B-AdverseReaction
with	TAFINLAR.xml:S2:3277:4	O
continued	TAFINLAR.xml:S2:3282:9	O
administration	TAFINLAR.xml:S2:3292:14	O
of	TAFINLAR.xml:S2:3307:2	O
TAFINLAR	TAFINLAR.xml:S2:3310:8	O
.	TAFINLAR.xml:S2:3318:1	O

The	TAFINLAR.xml:S2:3320:3	O
median	TAFINLAR.xml:S2:3324:6	O
time	TAFINLAR.xml:S2:3331:4	O
between	TAFINLAR.xml:S2:3336:7	O
diagnosis	TAFINLAR.xml:S2:3344:9	O
of	TAFINLAR.xml:S2:3354:2	O
the	TAFINLAR.xml:S2:3357:3	O
first	TAFINLAR.xml:S2:3361:5	O
cuSCC	TAFINLAR.xml:S2:3367:5	B-AdverseReaction
and	TAFINLAR.xml:S2:3373:3	O
the	TAFINLAR.xml:S2:3377:3	O
second	TAFINLAR.xml:S2:3381:6	O
cuSCC	TAFINLAR.xml:S2:3388:5	B-AdverseReaction
was	TAFINLAR.xml:S2:3394:3	O
6	TAFINLAR.xml:S2:3398:1	O
weeks	TAFINLAR.xml:S2:3400:5	O
.	TAFINLAR.xml:S2:3405:1	O

In	TAFINLAR.xml:S2:3411:2	O
Trial	TAFINLAR.xml:S2:3414:5	O
1	TAFINLAR.xml:S2:3420:1	O
,	TAFINLAR.xml:S2:3421:1	O
the	TAFINLAR.xml:S2:3423:3	O
incidence	TAFINLAR.xml:S2:3427:9	O
of	TAFINLAR.xml:S2:3437:2	O
new	TAFINLAR.xml:S2:3440:3	O
primary	TAFINLAR.xml:S2:3444:7	B-AdverseReaction
malignant	TAFINLAR.xml:S2:3452:9	I-AdverseReaction
melanomas	TAFINLAR.xml:S2:3462:9	I-AdverseReaction
was	TAFINLAR.xml:S2:3472:3	O
2%	TAFINLAR.xml:S2:3476:2	O
(	TAFINLAR.xml:S2:3479:1	O
3	TAFINLAR.xml:S2:3480:1	O
187	TAFINLAR.xml:S2:3482:3	O
)	TAFINLAR.xml:S2:3485:1	O
for	TAFINLAR.xml:S2:3487:3	O
patients	TAFINLAR.xml:S2:3491:8	O
receiving	TAFINLAR.xml:S2:3500:9	O
TAFINLAR	TAFINLAR.xml:S2:3510:8	O
while	TAFINLAR.xml:S2:3519:5	O
no	TAFINLAR.xml:S2:3525:2	O
dacarbazine	TAFINLAR.xml:S2:3528:11	O
-	TAFINLAR.xml:S2:3539:1	O
treated	TAFINLAR.xml:S2:3540:7	O
patient	TAFINLAR.xml:S2:3548:7	O
was	TAFINLAR.xml:S2:3556:3	O
diagnosed	TAFINLAR.xml:S2:3560:9	O
with	TAFINLAR.xml:S2:3570:4	O
new	TAFINLAR.xml:S2:3575:3	O
primary	TAFINLAR.xml:S2:3579:7	O
malignant	TAFINLAR.xml:S2:3587:9	O
melanoma	TAFINLAR.xml:S2:3597:8	O
.	TAFINLAR.xml:S2:3605:1	O

In	TAFINLAR.xml:S2:3612:2	O
Trial	TAFINLAR.xml:S2:3615:5	O
2	TAFINLAR.xml:S2:3621:1	O
,	TAFINLAR.xml:S2:3622:1	O
the	TAFINLAR.xml:S2:3624:3	O
incidence	TAFINLAR.xml:S2:3628:9	O
of	TAFINLAR.xml:S2:3638:2	O
basal	TAFINLAR.xml:S2:3641:5	B-AdverseReaction
cell	TAFINLAR.xml:S2:3647:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:3652:9	I-AdverseReaction
was	TAFINLAR.xml:S2:3662:3	O
increased	TAFINLAR.xml:S2:3666:9	O
in	TAFINLAR.xml:S2:3676:2	O
patients	TAFINLAR.xml:S2:3679:8	O
receiving	TAFINLAR.xml:S2:3688:9	O
TAFINLAR	TAFINLAR.xml:S2:3698:8	O
in	TAFINLAR.xml:S2:3707:2	O
combination	TAFINLAR.xml:S2:3710:11	O
with	TAFINLAR.xml:S2:3722:4	O
trametinib	TAFINLAR.xml:S2:3727:10	O
:	TAFINLAR.xml:S2:3737:1	O
9%	TAFINLAR.xml:S2:3739:2	O
(	TAFINLAR.xml:S2:3742:1	O
5	TAFINLAR.xml:S2:3743:1	O
55	TAFINLAR.xml:S2:3745:2	O
)	TAFINLAR.xml:S2:3747:1	O
of	TAFINLAR.xml:S2:3749:2	O
patients	TAFINLAR.xml:S2:3752:8	O
receiving	TAFINLAR.xml:S2:3761:9	O
TAFINLAR	TAFINLAR.xml:S2:3771:8	O
in	TAFINLAR.xml:S2:3780:2	O
combination	TAFINLAR.xml:S2:3783:11	O
with	TAFINLAR.xml:S2:3795:4	O
trametinib	TAFINLAR.xml:S2:3800:10	O
compared	TAFINLAR.xml:S2:3811:8	O
with	TAFINLAR.xml:S2:3820:4	O
2%	TAFINLAR.xml:S2:3825:2	O
(	TAFINLAR.xml:S2:3828:1	O
1	TAFINLAR.xml:S2:3829:1	O
53	TAFINLAR.xml:S2:3831:2	O
)	TAFINLAR.xml:S2:3833:1	O
of	TAFINLAR.xml:S2:3835:2	O
patients	TAFINLAR.xml:S2:3838:8	O
receiving	TAFINLAR.xml:S2:3847:9	O
TAFINLAR	TAFINLAR.xml:S2:3857:8	O
as	TAFINLAR.xml:S2:3866:2	O
a	TAFINLAR.xml:S2:3869:1	O
single	TAFINLAR.xml:S2:3871:6	O
agent	TAFINLAR.xml:S2:3878:5	O
.	TAFINLAR.xml:S2:3883:1	O

The	TAFINLAR.xml:S2:3885:3	O
range	TAFINLAR.xml:S2:3889:5	O
of	TAFINLAR.xml:S2:3895:2	O
time	TAFINLAR.xml:S2:3898:4	O
to	TAFINLAR.xml:S2:3903:2	O
diagnosis	TAFINLAR.xml:S2:3906:9	O
of	TAFINLAR.xml:S2:3916:2	O
basal	TAFINLAR.xml:S2:3919:5	B-AdverseReaction
cell	TAFINLAR.xml:S2:3925:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:3930:9	I-AdverseReaction
was	TAFINLAR.xml:S2:3940:3	O
28	TAFINLAR.xml:S2:3944:2	O
to	TAFINLAR.xml:S2:3947:2	O
249	TAFINLAR.xml:S2:3950:3	O
days	TAFINLAR.xml:S2:3954:4	O
in	TAFINLAR.xml:S2:3959:2	O
patients	TAFINLAR.xml:S2:3962:8	O
receiving	TAFINLAR.xml:S2:3971:9	O
TAFINLAR	TAFINLAR.xml:S2:3981:8	O
in	TAFINLAR.xml:S2:3990:2	O
combination	TAFINLAR.xml:S2:3993:11	O
with	TAFINLAR.xml:S2:4005:4	O
trametinib	TAFINLAR.xml:S2:4010:10	O
and	TAFINLAR.xml:S2:4021:3	O
was	TAFINLAR.xml:S2:4025:3	O
197	TAFINLAR.xml:S2:4029:3	O
days	TAFINLAR.xml:S2:4033:4	O
for	TAFINLAR.xml:S2:4038:3	O
the	TAFINLAR.xml:S2:4042:3	O
patient	TAFINLAR.xml:S2:4046:7	O
receiving	TAFINLAR.xml:S2:4054:9	O
TAFINLAR	TAFINLAR.xml:S2:4064:8	O
as	TAFINLAR.xml:S2:4073:2	O
a	TAFINLAR.xml:S2:4076:1	O
single	TAFINLAR.xml:S2:4078:6	O
agent	TAFINLAR.xml:S2:4085:5	O
.	TAFINLAR.xml:S2:4090:1	O

Cutaneous	TAFINLAR.xml:S2:4099:9	B-AdverseReaction
squamous	TAFINLAR.xml:S2:4109:8	I-AdverseReaction
cell	TAFINLAR.xml:S2:4118:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:4123:9	I-AdverseReaction
(	TAFINLAR.xml:S2:4133:1	O
SCC	TAFINLAR.xml:S2:4134:3	B-AdverseReaction
)	TAFINLAR.xml:S2:4137:1	O
,	TAFINLAR.xml:S2:4138:1	O
including	TAFINLAR.xml:S2:4140:9	O
keratoacanthoma	TAFINLAR.xml:S2:4150:15	B-AdverseReaction
,	TAFINLAR.xml:S2:4165:1	O
occurred	TAFINLAR.xml:S2:4167:8	O
in	TAFINLAR.xml:S2:4176:2	O
7%	TAFINLAR.xml:S2:4179:2	O
of	TAFINLAR.xml:S2:4182:2	O
patients	TAFINLAR.xml:S2:4185:8	O
receiving	TAFINLAR.xml:S2:4194:9	O
TAFINLAR	TAFINLAR.xml:S2:4204:8	O
in	TAFINLAR.xml:S2:4213:2	O
combination	TAFINLAR.xml:S2:4216:11	O
with	TAFINLAR.xml:S2:4228:4	O
trametinib	TAFINLAR.xml:S2:4233:10	O
and	TAFINLAR.xml:S2:4244:3	O
19%	TAFINLAR.xml:S2:4248:3	O
of	TAFINLAR.xml:S2:4252:2	O
patients	TAFINLAR.xml:S2:4255:8	O
receiving	TAFINLAR.xml:S2:4264:9	O
TAFINLAR	TAFINLAR.xml:S2:4274:8	O
as	TAFINLAR.xml:S2:4283:2	O
a	TAFINLAR.xml:S2:4286:1	O
single	TAFINLAR.xml:S2:4288:6	O
agent	TAFINLAR.xml:S2:4295:5	O
.	TAFINLAR.xml:S2:4300:1	O

The	TAFINLAR.xml:S2:4302:3	O
range	TAFINLAR.xml:S2:4306:5	O
of	TAFINLAR.xml:S2:4312:2	O
time	TAFINLAR.xml:S2:4315:4	O
to	TAFINLAR.xml:S2:4320:2	O
diagnosis	TAFINLAR.xml:S2:4323:9	O
of	TAFINLAR.xml:S2:4333:2	O
cuSCC	TAFINLAR.xml:S2:4336:5	B-AdverseReaction
was	TAFINLAR.xml:S2:4342:3	O
136	TAFINLAR.xml:S2:4346:3	O
to197	TAFINLAR.xml:S2:4350:5	O
days	TAFINLAR.xml:S2:4356:4	O
in	TAFINLAR.xml:S2:4361:2	O
the	TAFINLAR.xml:S2:4364:3	O
combination	TAFINLAR.xml:S2:4368:11	O
arm	TAFINLAR.xml:S2:4380:3	O
and	TAFINLAR.xml:S2:4384:3	O
was	TAFINLAR.xml:S2:4388:3	O
9	TAFINLAR.xml:S2:4392:1	O
to	TAFINLAR.xml:S2:4394:2	O
197	TAFINLAR.xml:S2:4397:3	O
days	TAFINLAR.xml:S2:4401:4	O
in	TAFINLAR.xml:S2:4406:2	O
the	TAFINLAR.xml:S2:4409:3	O
arm	TAFINLAR.xml:S2:4413:3	O
receiving	TAFINLAR.xml:S2:4417:9	O
TAFINLAR	TAFINLAR.xml:S2:4427:8	O
as	TAFINLAR.xml:S2:4436:2	O
a	TAFINLAR.xml:S2:4439:1	O
single	TAFINLAR.xml:S2:4441:6	O
agent	TAFINLAR.xml:S2:4448:5	O
.	TAFINLAR.xml:S2:4453:1	O

New	TAFINLAR.xml:S2:4462:3	O
primary	TAFINLAR.xml:S2:4466:7	B-AdverseReaction
melanoma	TAFINLAR.xml:S2:4474:8	I-AdverseReaction
occurred	TAFINLAR.xml:S2:4483:8	O
in	TAFINLAR.xml:S2:4492:2	O
2%	TAFINLAR.xml:S2:4495:2	O
(	TAFINLAR.xml:S2:4498:1	O
1	TAFINLAR.xml:S2:4499:1	O
53	TAFINLAR.xml:S2:4501:2	O
)	TAFINLAR.xml:S2:4503:1	O
of	TAFINLAR.xml:S2:4505:2	O
patients	TAFINLAR.xml:S2:4508:8	O
receiving	TAFINLAR.xml:S2:4517:9	O
TAFINLAR	TAFINLAR.xml:S2:4527:8	O
as	TAFINLAR.xml:S2:4536:2	O
a	TAFINLAR.xml:S2:4539:1	O
single	TAFINLAR.xml:S2:4541:6	O
agent	TAFINLAR.xml:S2:4548:5	O
and	TAFINLAR.xml:S2:4554:3	O
in	TAFINLAR.xml:S2:4558:2	O
none	TAFINLAR.xml:S2:4561:4	O
of	TAFINLAR.xml:S2:4566:2	O
the	TAFINLAR.xml:S2:4569:3	O
55	TAFINLAR.xml:S2:4573:2	O
patients	TAFINLAR.xml:S2:4576:8	O
receiving	TAFINLAR.xml:S2:4585:9	O
TAFINLAR	TAFINLAR.xml:S2:4595:8	O
in	TAFINLAR.xml:S2:4604:2	O
combination	TAFINLAR.xml:S2:4607:11	O
with	TAFINLAR.xml:S2:4619:4	O
trametinib	TAFINLAR.xml:S2:4624:10	O
.	TAFINLAR.xml:S2:4634:1	O

Perform	TAFINLAR.xml:S2:4643:7	O
dermatologic	TAFINLAR.xml:S2:4651:12	O
evaluations	TAFINLAR.xml:S2:4664:11	O
prior	TAFINLAR.xml:S2:4676:5	O
to	TAFINLAR.xml:S2:4682:2	O
initiation	TAFINLAR.xml:S2:4685:10	O
of	TAFINLAR.xml:S2:4696:2	O
TAFINLAR	TAFINLAR.xml:S2:4699:8	O
as	TAFINLAR.xml:S2:4708:2	O
a	TAFINLAR.xml:S2:4711:1	O
single	TAFINLAR.xml:S2:4713:6	O
agent	TAFINLAR.xml:S2:4720:5	O
or	TAFINLAR.xml:S2:4726:2	O
in	TAFINLAR.xml:S2:4729:2	O
combination	TAFINLAR.xml:S2:4732:11	O
with	TAFINLAR.xml:S2:4744:4	O
trametinib	TAFINLAR.xml:S2:4749:10	O
,	TAFINLAR.xml:S2:4759:1	O
every	TAFINLAR.xml:S2:4761:5	O
2	TAFINLAR.xml:S2:4767:1	O
months	TAFINLAR.xml:S2:4769:6	O
while	TAFINLAR.xml:S2:4776:5	O
on	TAFINLAR.xml:S2:4782:2	O
therapy	TAFINLAR.xml:S2:4785:7	O
,	TAFINLAR.xml:S2:4792:1	O
and	TAFINLAR.xml:S2:4794:3	O
for	TAFINLAR.xml:S2:4798:3	O
up	TAFINLAR.xml:S2:4802:2	O
to	TAFINLAR.xml:S2:4805:2	O
6	TAFINLAR.xml:S2:4808:1	O
months	TAFINLAR.xml:S2:4810:6	O
following	TAFINLAR.xml:S2:4817:9	O
discontinuation	TAFINLAR.xml:S2:4827:15	O
of	TAFINLAR.xml:S2:4843:2	O
TAFINLAR	TAFINLAR.xml:S2:4846:8	O
.	TAFINLAR.xml:S2:4854:1	O

No	TAFINLAR.xml:S2:4856:2	O
dose	TAFINLAR.xml:S2:4859:4	O
modifications	TAFINLAR.xml:S2:4864:13	O
of	TAFINLAR.xml:S2:4878:2	O
TAFINLAR	TAFINLAR.xml:S2:4881:8	O
or	TAFINLAR.xml:S2:4890:2	O
trametinib	TAFINLAR.xml:S2:4893:10	O
are	TAFINLAR.xml:S2:4904:3	O
required	TAFINLAR.xml:S2:4908:8	O
in	TAFINLAR.xml:S2:4917:2	O
patients	TAFINLAR.xml:S2:4920:8	O
who	TAFINLAR.xml:S2:4929:3	O
develop	TAFINLAR.xml:S2:4933:7	O
new	TAFINLAR.xml:S2:4941:3	O
primary	TAFINLAR.xml:S2:4945:7	O
cutaneous	TAFINLAR.xml:S2:4953:9	O
malignancies	TAFINLAR.xml:S2:4963:12	O
.	TAFINLAR.xml:S2:4975:1	O

Non	TAFINLAR.xml:S2:4985:3	O
-	TAFINLAR.xml:S2:4988:1	O
cutaneous	TAFINLAR.xml:S2:4989:9	O
Malignancies	TAFINLAR.xml:S2:4999:12	O
:	TAFINLAR.xml:S2:5011:1	O

Based	TAFINLAR.xml:S2:5022:5	O
on	TAFINLAR.xml:S2:5028:2	O
its	TAFINLAR.xml:S2:5031:3	O
mechanism	TAFINLAR.xml:S2:5035:9	O
of	TAFINLAR.xml:S2:5045:2	O
action	TAFINLAR.xml:S2:5048:6	O
,	TAFINLAR.xml:S2:5054:1	O
TAFINLAR	TAFINLAR.xml:S2:5056:8	O
may	TAFINLAR.xml:S2:5065:3	B-Factor
promote	TAFINLAR.xml:S2:5069:7	O
the	TAFINLAR.xml:S2:5077:3	O
growth	TAFINLAR.xml:S2:5081:6	O
and	TAFINLAR.xml:S2:5088:3	O
development	TAFINLAR.xml:S2:5092:11	O
of	TAFINLAR.xml:S2:5104:2	O
malignancies	TAFINLAR.xml:S2:5107:12	B-AdverseReaction
with	TAFINLAR.xml:S2:5120:4	O
activation	TAFINLAR.xml:S2:5125:10	O
of	TAFINLAR.xml:S2:5136:2	O
RAS	TAFINLAR.xml:S2:5139:3	O
through	TAFINLAR.xml:S2:5143:7	O
mutation	TAFINLAR.xml:S2:5151:8	O
or	TAFINLAR.xml:S2:5160:2	O
other	TAFINLAR.xml:S2:5163:5	O
mechanisms	TAFINLAR.xml:S2:5169:10	O
[	TAFINLAR.xml:S2:5180:1	O
see	TAFINLAR.xml:S2:5181:3	O
Warnings	TAFINLAR.xml:S2:5185:8	O
and	TAFINLAR.xml:S2:5194:3	O
Precautions	TAFINLAR.xml:S2:5198:11	O
(	TAFINLAR.xml:S2:5210:1	O
5.2	TAFINLAR.xml:S2:5211:3	O
)]	TAFINLAR.xml:S2:5214:2	O
.	TAFINLAR.xml:S2:5218:1	O

In	TAFINLAR.xml:S2:5220:2	O
patients	TAFINLAR.xml:S2:5223:8	O
receiving	TAFINLAR.xml:S2:5232:9	O
TAFINLAR	TAFINLAR.xml:S2:5242:8	O
in	TAFINLAR.xml:S2:5251:2	O
combination	TAFINLAR.xml:S2:5254:11	O
with	TAFINLAR.xml:S2:5266:4	O
trametinib	TAFINLAR.xml:S2:5271:10	O
four	TAFINLAR.xml:S2:5282:4	O
cases	TAFINLAR.xml:S2:5287:5	O
of	TAFINLAR.xml:S2:5293:2	O
non	TAFINLAR.xml:S2:5296:3	B-AdverseReaction
-	TAFINLAR.xml:S2:5299:1	I-AdverseReaction
cutaneous	TAFINLAR.xml:S2:5300:9	I-AdverseReaction
malignancies	TAFINLAR.xml:S2:5310:12	I-AdverseReaction
were	TAFINLAR.xml:S2:5323:4	O
identified	TAFINLAR.xml:S2:5328:10	O
:	TAFINLAR.xml:S2:5338:1	O
KRAS	TAFINLAR.xml:S2:5340:4	B-AdverseReaction
mutation	TAFINLAR.xml:S2:5345:8	I-AdverseReaction
-	TAFINLAR.xml:S2:5353:1	I-AdverseReaction
positive	TAFINLAR.xml:S2:5354:8	I-AdverseReaction
pancreatic	TAFINLAR.xml:S2:5363:10	I-AdverseReaction
adenocarcinoma	TAFINLAR.xml:S2:5374:14	I-AdverseReaction
(	TAFINLAR.xml:S2:5389:1	O
n	TAFINLAR.xml:S2:5390:1	O
1	TAFINLAR.xml:S2:5394:1	O
)	TAFINLAR.xml:S2:5395:1	O
,	TAFINLAR.xml:S2:5396:1	O
recurrent	TAFINLAR.xml:S2:5398:9	B-AdverseReaction
NRAS	TAFINLAR.xml:S2:5408:4	I-AdverseReaction
mutation	TAFINLAR.xml:S2:5413:8	I-AdverseReaction
-	TAFINLAR.xml:S2:5421:1	I-AdverseReaction
positive	TAFINLAR.xml:S2:5422:8	I-AdverseReaction
colorectal	TAFINLAR.xml:S2:5431:10	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:5442:9	I-AdverseReaction
(	TAFINLAR.xml:S2:5452:1	O
n	TAFINLAR.xml:S2:5453:1	O
1	TAFINLAR.xml:S2:5457:1	O
)	TAFINLAR.xml:S2:5458:1	O
,	TAFINLAR.xml:S2:5459:1	O
head	TAFINLAR.xml:S2:5461:4	B-AdverseReaction
and	TAFINLAR.xml:S2:5466:3	I-AdverseReaction
neck	TAFINLAR.xml:S2:5470:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:5475:9	I-AdverseReaction
(	TAFINLAR.xml:S2:5485:1	O
n	TAFINLAR.xml:S2:5486:1	O
1	TAFINLAR.xml:S2:5490:1	O
)	TAFINLAR.xml:S2:5491:1	O
,	TAFINLAR.xml:S2:5492:1	O
and	TAFINLAR.xml:S2:5494:3	O
glioblastoma	TAFINLAR.xml:S2:5498:12	B-AdverseReaction
(	TAFINLAR.xml:S2:5511:1	O
n	TAFINLAR.xml:S2:5512:1	O
1	TAFINLAR.xml:S2:5516:1	O
)	TAFINLAR.xml:S2:5517:1	O
.	TAFINLAR.xml:S2:5518:1	O

Monitor	TAFINLAR.xml:S2:5520:7	O
patients	TAFINLAR.xml:S2:5528:8	O
receiving	TAFINLAR.xml:S2:5537:9	O
the	TAFINLAR.xml:S2:5547:3	O
combination	TAFINLAR.xml:S2:5551:11	O
closely	TAFINLAR.xml:S2:5563:7	O
for	TAFINLAR.xml:S2:5571:3	O
signs	TAFINLAR.xml:S2:5575:5	O
or	TAFINLAR.xml:S2:5581:2	O
symptoms	TAFINLAR.xml:S2:5584:8	O
of	TAFINLAR.xml:S2:5593:2	O
non	TAFINLAR.xml:S2:5596:3	O
-	TAFINLAR.xml:S2:5599:1	O
cutaneous	TAFINLAR.xml:S2:5600:9	O
malignancies	TAFINLAR.xml:S2:5610:12	O
.	TAFINLAR.xml:S2:5622:1	O

Permanently	TAFINLAR.xml:S2:5624:11	O
discontinue	TAFINLAR.xml:S2:5636:11	O
TAFINLAR	TAFINLAR.xml:S2:5648:8	O
for	TAFINLAR.xml:S2:5657:3	O
RAS	TAFINLAR.xml:S2:5661:3	O
mutation	TAFINLAR.xml:S2:5665:8	O
-	TAFINLAR.xml:S2:5673:1	O
positive	TAFINLAR.xml:S2:5674:8	O
non	TAFINLAR.xml:S2:5683:3	O
-	TAFINLAR.xml:S2:5686:1	O
cutaneous	TAFINLAR.xml:S2:5687:9	O
malignancies	TAFINLAR.xml:S2:5697:12	O
.	TAFINLAR.xml:S2:5709:1	O

If	TAFINLAR.xml:S2:5711:2	O
used	TAFINLAR.xml:S2:5714:4	O
in	TAFINLAR.xml:S2:5719:2	O
combination	TAFINLAR.xml:S2:5722:11	O
with	TAFINLAR.xml:S2:5734:4	O
trametinib	TAFINLAR.xml:S2:5739:10	O
,	TAFINLAR.xml:S2:5749:1	O
no	TAFINLAR.xml:S2:5751:2	O
dose	TAFINLAR.xml:S2:5754:4	O
modification	TAFINLAR.xml:S2:5759:12	O
of	TAFINLAR.xml:S2:5772:2	O
trametinib	TAFINLAR.xml:S2:5775:10	O
is	TAFINLAR.xml:S2:5786:2	O
required	TAFINLAR.xml:S2:5789:8	O
for	TAFINLAR.xml:S2:5798:3	O
patients	TAFINLAR.xml:S2:5802:8	O
who	TAFINLAR.xml:S2:5811:3	O
develop	TAFINLAR.xml:S2:5815:7	O
non	TAFINLAR.xml:S2:5823:3	O
-	TAFINLAR.xml:S2:5826:1	O
cutaneous	TAFINLAR.xml:S2:5827:9	O
malignancies	TAFINLAR.xml:S2:5837:12	O
.	TAFINLAR.xml:S2:5849:1	O

5.2	TAFINLAR.xml:S2:5860:3	O
Tumor	TAFINLAR.xml:S2:5864:5	O
Promotion	TAFINLAR.xml:S2:5870:9	O
in	TAFINLAR.xml:S2:5880:2	O
BRAF	TAFINLAR.xml:S2:5883:4	O
Wild	TAFINLAR.xml:S2:5888:4	O
-	TAFINLAR.xml:S2:5892:1	O
Type	TAFINLAR.xml:S2:5893:4	O
Melanoma	TAFINLAR.xml:S2:5898:8	O

In	TAFINLAR.xml:S2:5912:2	O
vitro	TAFINLAR.xml:S2:5915:5	O
experiments	TAFINLAR.xml:S2:5921:11	O
have	TAFINLAR.xml:S2:5933:4	O
demonstrated	TAFINLAR.xml:S2:5938:12	O
paradoxical	TAFINLAR.xml:S2:5951:11	O
activation	TAFINLAR.xml:S2:5963:10	O
of	TAFINLAR.xml:S2:5974:2	O
MAP	TAFINLAR.xml:S2:5977:3	O
-	TAFINLAR.xml:S2:5980:1	O
kinase	TAFINLAR.xml:S2:5981:6	O
signaling	TAFINLAR.xml:S2:5988:9	O
and	TAFINLAR.xml:S2:5998:3	O
increased	TAFINLAR.xml:S2:6002:9	B-AdverseReaction
cell	TAFINLAR.xml:S2:6012:4	I-AdverseReaction
proliferation	TAFINLAR.xml:S2:6017:13	I-AdverseReaction
in	TAFINLAR.xml:S2:6031:2	O
BRAF	TAFINLAR.xml:S2:6034:4	O
wild	TAFINLAR.xml:S2:6039:4	O
-	TAFINLAR.xml:S2:6043:1	O
type	TAFINLAR.xml:S2:6044:4	O
cells	TAFINLAR.xml:S2:6049:5	O
which	TAFINLAR.xml:S2:6055:5	O
are	TAFINLAR.xml:S2:6061:3	O
exposed	TAFINLAR.xml:S2:6065:7	O
to	TAFINLAR.xml:S2:6073:2	O
BRAF	TAFINLAR.xml:S2:6076:4	B-DrugClass
inhibitors	TAFINLAR.xml:S2:6081:10	I-DrugClass
.	TAFINLAR.xml:S2:6091:1	O

Confirm	TAFINLAR.xml:S2:6093:7	O
evidence	TAFINLAR.xml:S2:6101:8	O
of	TAFINLAR.xml:S2:6110:2	O
BRAF	TAFINLAR.xml:S2:6113:4	O
V600E	TAFINLAR.xml:S2:6118:5	O
or	TAFINLAR.xml:S2:6124:2	O
V600K	TAFINLAR.xml:S2:6127:5	O
mutation	TAFINLAR.xml:S2:6134:8	O
status	TAFINLAR.xml:S2:6143:6	O
prior	TAFINLAR.xml:S2:6150:5	O
to	TAFINLAR.xml:S2:6156:2	O
initiation	TAFINLAR.xml:S2:6159:10	O
of	TAFINLAR.xml:S2:6170:2	O
TAFINLAR	TAFINLAR.xml:S2:6173:8	O
as	TAFINLAR.xml:S2:6182:2	O
a	TAFINLAR.xml:S2:6186:1	O
single	TAFINLAR.xml:S2:6188:6	O
agent	TAFINLAR.xml:S2:6195:5	O
or	TAFINLAR.xml:S2:6201:2	O
combination	TAFINLAR.xml:S2:6204:11	O
therapy	TAFINLAR.xml:S2:6216:7	O
[	TAFINLAR.xml:S2:6226:1	O
see	TAFINLAR.xml:S2:6227:3	O
Indications	TAFINLAR.xml:S2:6231:11	O
and	TAFINLAR.xml:S2:6243:3	O
Usage	TAFINLAR.xml:S2:6247:5	O
(	TAFINLAR.xml:S2:6253:1	O
1	TAFINLAR.xml:S2:6254:1	O
)	TAFINLAR.xml:S2:6255:1	O
,	TAFINLAR.xml:S2:6256:1	O
Dosage	TAFINLAR.xml:S2:6258:6	O
and	TAFINLAR.xml:S2:6265:3	O
Administration	TAFINLAR.xml:S2:6269:14	O
(	TAFINLAR.xml:S2:6284:1	O
2.1	TAFINLAR.xml:S2:6285:3	O
)]	TAFINLAR.xml:S2:6288:2	O
.	TAFINLAR.xml:S2:6292:1	O

5.3	TAFINLAR.xml:S2:6302:3	O
Hemorrhage	TAFINLAR.xml:S2:6306:10	O

Hemorrhages	TAFINLAR.xml:S2:6325:11	B-AdverseReaction
,	TAFINLAR.xml:S2:6336:1	O
including	TAFINLAR.xml:S2:6338:9	O
major	TAFINLAR.xml:S2:6348:5	B-Severity
hemorrhages	TAFINLAR.xml:S2:6354:11	B-AdverseReaction
defined	TAFINLAR.xml:S2:6366:7	O
as	TAFINLAR.xml:S2:6374:2	O
symptomatic	TAFINLAR.xml:S2:6377:11	B-AdverseReaction
bleeding	TAFINLAR.xml:S2:6389:8	I-AdverseReaction
in	TAFINLAR.xml:S2:6398:2	O
a	TAFINLAR.xml:S2:6401:1	O
critical	TAFINLAR.xml:S2:6403:8	O
area	TAFINLAR.xml:S2:6412:4	O
or	TAFINLAR.xml:S2:6417:2	O
organ	TAFINLAR.xml:S2:6420:5	O
,	TAFINLAR.xml:S2:6425:1	O
can	TAFINLAR.xml:S2:6427:3	B-Factor
occur	TAFINLAR.xml:S2:6431:5	O
when	TAFINLAR.xml:S2:6437:4	O
TAFINLAR	TAFINLAR.xml:S2:6442:8	O
is	TAFINLAR.xml:S2:6451:2	O
used	TAFINLAR.xml:S2:6454:4	O
in	TAFINLAR.xml:S2:6459:2	O
combination	TAFINLAR.xml:S2:6462:11	O
with	TAFINLAR.xml:S2:6474:4	O
trametinib	TAFINLAR.xml:S2:6479:10	O
.	TAFINLAR.xml:S2:6489:1	O

In	TAFINLAR.xml:S2:6498:2	O
Trial	TAFINLAR.xml:S2:6501:5	O
2	TAFINLAR.xml:S2:6507:1	O
,	TAFINLAR.xml:S2:6508:1	O
treatment	TAFINLAR.xml:S2:6510:9	O
with	TAFINLAR.xml:S2:6520:4	O
TAFINLAR	TAFINLAR.xml:S2:6525:8	O
in	TAFINLAR.xml:S2:6534:2	O
combination	TAFINLAR.xml:S2:6537:11	O
with	TAFINLAR.xml:S2:6549:4	O
trametinib	TAFINLAR.xml:S2:6554:10	O
resulted	TAFINLAR.xml:S2:6565:8	O
in	TAFINLAR.xml:S2:6574:2	O
an	TAFINLAR.xml:S2:6577:2	O
increased	TAFINLAR.xml:S2:6580:9	O
incidence	TAFINLAR.xml:S2:6590:9	O
and	TAFINLAR.xml:S2:6600:3	O
severity	TAFINLAR.xml:S2:6604:8	O
of	TAFINLAR.xml:S2:6613:2	O
any	TAFINLAR.xml:S2:6616:3	O
hemorrhagic	TAFINLAR.xml:S2:6620:11	B-AdverseReaction
event	TAFINLAR.xml:S2:6632:5	I-AdverseReaction
:	TAFINLAR.xml:S2:6637:1	O
16%	TAFINLAR.xml:S2:6639:3	O
(	TAFINLAR.xml:S2:6643:1	O
9	TAFINLAR.xml:S2:6644:1	O
55	TAFINLAR.xml:S2:6646:2	O
)	TAFINLAR.xml:S2:6648:1	O
of	TAFINLAR.xml:S2:6650:2	O
patients	TAFINLAR.xml:S2:6653:8	O
treated	TAFINLAR.xml:S2:6662:7	O
with	TAFINLAR.xml:S2:6670:4	O
TAFINLAR	TAFINLAR.xml:S2:6675:8	O
in	TAFINLAR.xml:S2:6684:2	O
combination	TAFINLAR.xml:S2:6687:11	O
with	TAFINLAR.xml:S2:6699:4	O
trametinib	TAFINLAR.xml:S2:6704:10	O
compared	TAFINLAR.xml:S2:6715:8	O
with	TAFINLAR.xml:S2:6724:4	O
2%	TAFINLAR.xml:S2:6729:2	O
(	TAFINLAR.xml:S2:6732:1	O
1	TAFINLAR.xml:S2:6733:1	O
53	TAFINLAR.xml:S2:6735:2	O
)	TAFINLAR.xml:S2:6737:1	O
of	TAFINLAR.xml:S2:6739:2	O
patients	TAFINLAR.xml:S2:6742:8	O
treated	TAFINLAR.xml:S2:6751:7	O
with	TAFINLAR.xml:S2:6759:4	O
TAFINLAR	TAFINLAR.xml:S2:6764:8	O
as	TAFINLAR.xml:S2:6773:2	O
a	TAFINLAR.xml:S2:6776:1	O
single	TAFINLAR.xml:S2:6778:6	O
agent	TAFINLAR.xml:S2:6785:5	O
.	TAFINLAR.xml:S2:6790:1	O

The	TAFINLAR.xml:S2:6792:3	O
major	TAFINLAR.xml:S2:6796:5	B-Severity
hemorrhagic	TAFINLAR.xml:S2:6802:11	B-AdverseReaction
events	TAFINLAR.xml:S2:6814:6	I-AdverseReaction
of	TAFINLAR.xml:S2:6821:2	O
intracranial	TAFINLAR.xml:S2:6824:12	B-AdverseReaction
or	TAFINLAR.xml:S2:6837:2	O
gastric	TAFINLAR.xml:S2:6840:7	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S2:6848:10	I-AdverseReaction
occurred	TAFINLAR.xml:S2:6859:8	O
in	TAFINLAR.xml:S2:6868:2	O
5%	TAFINLAR.xml:S2:6871:2	O
(	TAFINLAR.xml:S2:6874:1	O
3	TAFINLAR.xml:S2:6875:1	O
55	TAFINLAR.xml:S2:6877:2	O
)	TAFINLAR.xml:S2:6879:1	O
of	TAFINLAR.xml:S2:6881:2	O
patients	TAFINLAR.xml:S2:6884:8	O
treated	TAFINLAR.xml:S2:6893:7	O
with	TAFINLAR.xml:S2:6901:4	O
TAFINLAR	TAFINLAR.xml:S2:6906:8	O
in	TAFINLAR.xml:S2:6915:2	O
combination	TAFINLAR.xml:S2:6918:11	O
with	TAFINLAR.xml:S2:6930:4	O
trametinib	TAFINLAR.xml:S2:6935:10	O
compared	TAFINLAR.xml:S2:6946:8	O
with	TAFINLAR.xml:S2:6955:4	O
none	TAFINLAR.xml:S2:6960:4	O
of	TAFINLAR.xml:S2:6965:2	O
the	TAFINLAR.xml:S2:6968:3	O
53	TAFINLAR.xml:S2:6972:2	O
patients	TAFINLAR.xml:S2:6975:8	O
treated	TAFINLAR.xml:S2:6984:7	O
with	TAFINLAR.xml:S2:6992:4	O
TAFINLAR	TAFINLAR.xml:S2:6997:8	O
as	TAFINLAR.xml:S2:7006:2	O
a	TAFINLAR.xml:S2:7009:1	O
single	TAFINLAR.xml:S2:7011:6	O
agent	TAFINLAR.xml:S2:7018:5	O
.	TAFINLAR.xml:S2:7023:1	O

Intracranial	TAFINLAR.xml:S2:7025:12	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S2:7038:10	I-AdverseReaction
was	TAFINLAR.xml:S2:7049:3	O
fatal	TAFINLAR.xml:S2:7053:5	B-AdverseReaction
in	TAFINLAR.xml:S2:7059:2	O
4%	TAFINLAR.xml:S2:7062:2	O
(	TAFINLAR.xml:S2:7065:1	O
2	TAFINLAR.xml:S2:7066:1	O
55	TAFINLAR.xml:S2:7068:2	O
)	TAFINLAR.xml:S2:7070:1	O
of	TAFINLAR.xml:S2:7072:2	O
patients	TAFINLAR.xml:S2:7075:8	O
receiving	TAFINLAR.xml:S2:7084:9	O
TAFINLAR	TAFINLAR.xml:S2:7094:8	O
in	TAFINLAR.xml:S2:7103:2	O
combination	TAFINLAR.xml:S2:7106:11	O
with	TAFINLAR.xml:S2:7118:4	O
trametinib	TAFINLAR.xml:S2:7123:10	O
.	TAFINLAR.xml:S2:7133:1	O

Permanently	TAFINLAR.xml:S2:7142:11	O
discontinue	TAFINLAR.xml:S2:7154:11	O
TAFINLAR	TAFINLAR.xml:S2:7166:8	O
and	TAFINLAR.xml:S2:7175:3	O
trametinib	TAFINLAR.xml:S2:7179:10	O
for	TAFINLAR.xml:S2:7190:3	O
all	TAFINLAR.xml:S2:7194:3	O
Grade	TAFINLAR.xml:S2:7198:5	O
4	TAFINLAR.xml:S2:7204:1	O
hemorrhagic	TAFINLAR.xml:S2:7206:11	O
events	TAFINLAR.xml:S2:7218:6	O
and	TAFINLAR.xml:S2:7225:3	O
for	TAFINLAR.xml:S2:7229:3	O
any	TAFINLAR.xml:S2:7233:3	O
Grade	TAFINLAR.xml:S2:7237:5	O
3	TAFINLAR.xml:S2:7243:1	O
hemorrhagic	TAFINLAR.xml:S2:7245:11	O
events	TAFINLAR.xml:S2:7257:6	O
that	TAFINLAR.xml:S2:7264:4	O
do	TAFINLAR.xml:S2:7269:2	O
not	TAFINLAR.xml:S2:7272:3	O
improve	TAFINLAR.xml:S2:7276:7	O
.	TAFINLAR.xml:S2:7283:1	O

Withhold	TAFINLAR.xml:S2:7285:8	O
TAFINLAR	TAFINLAR.xml:S2:7294:8	O
for	TAFINLAR.xml:S2:7303:3	O
Grade	TAFINLAR.xml:S2:7307:5	O
3	TAFINLAR.xml:S2:7313:1	O
hemorrhagic	TAFINLAR.xml:S2:7315:11	O
events	TAFINLAR.xml:S2:7327:6	O
;	TAFINLAR.xml:S2:7333:1	O
if	TAFINLAR.xml:S2:7335:2	O
improved	TAFINLAR.xml:S2:7338:8	O
resume	TAFINLAR.xml:S2:7347:6	O
at	TAFINLAR.xml:S2:7354:2	O
a	TAFINLAR.xml:S2:7357:1	O
lower	TAFINLAR.xml:S2:7359:5	O
dose	TAFINLAR.xml:S2:7365:4	O
level	TAFINLAR.xml:S2:7370:5	O
.	TAFINLAR.xml:S2:7375:1	O

Withhold	TAFINLAR.xml:S2:7377:8	O
trametinib	TAFINLAR.xml:S2:7386:10	O
for	TAFINLAR.xml:S2:7397:3	O
up	TAFINLAR.xml:S2:7401:2	O
to	TAFINLAR.xml:S2:7404:2	O
3	TAFINLAR.xml:S2:7407:1	O
weeks	TAFINLAR.xml:S2:7409:5	O
for	TAFINLAR.xml:S2:7415:3	O
Grade	TAFINLAR.xml:S2:7419:5	O
3	TAFINLAR.xml:S2:7425:1	O
hemorrhagic	TAFINLAR.xml:S2:7427:11	O
events	TAFINLAR.xml:S2:7439:6	O
;	TAFINLAR.xml:S2:7445:1	O
if	TAFINLAR.xml:S2:7447:2	O
improved	TAFINLAR.xml:S2:7450:8	O
,	TAFINLAR.xml:S2:7458:1	O
resume	TAFINLAR.xml:S2:7460:6	O
at	TAFINLAR.xml:S2:7467:2	O
a	TAFINLAR.xml:S2:7470:1	O
lower	TAFINLAR.xml:S2:7472:5	O
dose	TAFINLAR.xml:S2:7478:4	O
level	TAFINLAR.xml:S2:7483:5	O
.	TAFINLAR.xml:S2:7488:1	O

5.4	TAFINLAR.xml:S2:7500:3	O
Venous	TAFINLAR.xml:S2:7504:6	O
Thromboembolism	TAFINLAR.xml:S2:7511:15	O

Venous	TAFINLAR.xml:S2:7535:6	B-AdverseReaction
thromboembolism	TAFINLAR.xml:S2:7542:15	I-AdverseReaction
can	TAFINLAR.xml:S2:7558:3	B-Factor
occur	TAFINLAR.xml:S2:7562:5	O
when	TAFINLAR.xml:S2:7568:4	O
TAFINLAR	TAFINLAR.xml:S2:7573:8	O
is	TAFINLAR.xml:S2:7582:2	O
used	TAFINLAR.xml:S2:7585:4	O
in	TAFINLAR.xml:S2:7590:2	O
combination	TAFINLAR.xml:S2:7593:11	O
with	TAFINLAR.xml:S2:7605:4	O
trametinib	TAFINLAR.xml:S2:7610:10	O
.	TAFINLAR.xml:S2:7620:1	O

In	TAFINLAR.xml:S2:7629:2	O
Trial	TAFINLAR.xml:S2:7632:5	O
2	TAFINLAR.xml:S2:7638:1	O
,	TAFINLAR.xml:S2:7639:1	O
treatment	TAFINLAR.xml:S2:7641:9	O
with	TAFINLAR.xml:S2:7651:4	O
TAFINLAR	TAFINLAR.xml:S2:7656:8	O
in	TAFINLAR.xml:S2:7665:2	O
combination	TAFINLAR.xml:S2:7668:11	O
with	TAFINLAR.xml:S2:7680:4	O
trametinib	TAFINLAR.xml:S2:7685:10	O
resulted	TAFINLAR.xml:S2:7696:8	O
in	TAFINLAR.xml:S2:7705:2	O
an	TAFINLAR.xml:S2:7708:2	O
increased	TAFINLAR.xml:S2:7711:9	O
incidence	TAFINLAR.xml:S2:7721:9	O
of	TAFINLAR.xml:S2:7731:2	O
deep	TAFINLAR.xml:S2:7734:4	B-AdverseReaction
venous	TAFINLAR.xml:S2:7739:6	I-AdverseReaction
thrombosis	TAFINLAR.xml:S2:7746:10	I-AdverseReaction
(	TAFINLAR.xml:S2:7757:1	O
DVT	TAFINLAR.xml:S2:7758:3	B-AdverseReaction
)	TAFINLAR.xml:S2:7761:1	O
and	TAFINLAR.xml:S2:7763:3	O
pulmonary	TAFINLAR.xml:S2:7767:9	B-AdverseReaction
embolism	TAFINLAR.xml:S2:7777:8	I-AdverseReaction
(	TAFINLAR.xml:S2:7786:1	O
PE	TAFINLAR.xml:S2:7787:2	B-AdverseReaction
)	TAFINLAR.xml:S2:7789:1	O
:	TAFINLAR.xml:S2:7790:1	O
7%	TAFINLAR.xml:S2:7792:2	O
(	TAFINLAR.xml:S2:7795:1	O
4	TAFINLAR.xml:S2:7796:1	O
55	TAFINLAR.xml:S2:7798:2	O
)	TAFINLAR.xml:S2:7800:1	O
of	TAFINLAR.xml:S2:7802:2	O
patients	TAFINLAR.xml:S2:7805:8	O
treated	TAFINLAR.xml:S2:7814:7	O
with	TAFINLAR.xml:S2:7822:4	O
TAFINLAR	TAFINLAR.xml:S2:7827:8	O
in	TAFINLAR.xml:S2:7836:2	O
combination	TAFINLAR.xml:S2:7839:11	O
with	TAFINLAR.xml:S2:7851:4	O
trametinib	TAFINLAR.xml:S2:7856:10	O
compared	TAFINLAR.xml:S2:7867:8	O
with	TAFINLAR.xml:S2:7876:4	O
none	TAFINLAR.xml:S2:7881:4	O
of	TAFINLAR.xml:S2:7886:2	O
the	TAFINLAR.xml:S2:7889:3	O
53	TAFINLAR.xml:S2:7893:2	O
patients	TAFINLAR.xml:S2:7896:8	O
treated	TAFINLAR.xml:S2:7905:7	O
with	TAFINLAR.xml:S2:7913:4	O
TAFINLAR	TAFINLAR.xml:S2:7918:8	O
as	TAFINLAR.xml:S2:7927:2	O
a	TAFINLAR.xml:S2:7930:1	O
single	TAFINLAR.xml:S2:7932:6	O
agent	TAFINLAR.xml:S2:7939:5	O
.	TAFINLAR.xml:S2:7944:1	O

Pulmonary	TAFINLAR.xml:S2:7946:9	B-AdverseReaction
embolism	TAFINLAR.xml:S2:7956:8	I-AdverseReaction
was	TAFINLAR.xml:S2:7965:3	O
fatal	TAFINLAR.xml:S2:7969:5	B-AdverseReaction
in	TAFINLAR.xml:S2:7975:2	O
2%	TAFINLAR.xml:S2:7978:2	O
(	TAFINLAR.xml:S2:7981:1	O
1	TAFINLAR.xml:S2:7982:1	O
55	TAFINLAR.xml:S2:7984:2	O
)	TAFINLAR.xml:S2:7986:1	O
of	TAFINLAR.xml:S2:7988:2	O
patients	TAFINLAR.xml:S2:7991:8	O
receiving	TAFINLAR.xml:S2:8000:9	O
TAFINLAR	TAFINLAR.xml:S2:8010:8	O
in	TAFINLAR.xml:S2:8019:2	O
combination	TAFINLAR.xml:S2:8022:11	O
with	TAFINLAR.xml:S2:8034:4	O
trametinib	TAFINLAR.xml:S2:8039:10	O
.	TAFINLAR.xml:S2:8049:1	O

Advise	TAFINLAR.xml:S2:8058:6	O
patients	TAFINLAR.xml:S2:8065:8	O
to	TAFINLAR.xml:S2:8074:2	O
immediately	TAFINLAR.xml:S2:8077:11	O
seek	TAFINLAR.xml:S2:8089:4	O
medical	TAFINLAR.xml:S2:8094:7	O
care	TAFINLAR.xml:S2:8102:4	O
if	TAFINLAR.xml:S2:8107:2	O
they	TAFINLAR.xml:S2:8110:4	O
develop	TAFINLAR.xml:S2:8115:7	O
symptoms	TAFINLAR.xml:S2:8123:8	O
of	TAFINLAR.xml:S2:8132:2	O
DVT	TAFINLAR.xml:S2:8135:3	O
or	TAFINLAR.xml:S2:8139:2	O
PE	TAFINLAR.xml:S2:8142:2	O
,	TAFINLAR.xml:S2:8144:1	O
such	TAFINLAR.xml:S2:8146:4	O
as	TAFINLAR.xml:S2:8151:2	O
shortness	TAFINLAR.xml:S2:8154:9	O
of	TAFINLAR.xml:S2:8164:2	O
breath	TAFINLAR.xml:S2:8167:6	O
,	TAFINLAR.xml:S2:8173:1	O
chest	TAFINLAR.xml:S2:8175:5	O
pain	TAFINLAR.xml:S2:8181:4	O
,	TAFINLAR.xml:S2:8185:1	O
or	TAFINLAR.xml:S2:8187:2	O
arm	TAFINLAR.xml:S2:8190:3	O
or	TAFINLAR.xml:S2:8194:2	O
leg	TAFINLAR.xml:S2:8197:3	O
swelling	TAFINLAR.xml:S2:8201:8	O
.	TAFINLAR.xml:S2:8209:1	O

Permanently	TAFINLAR.xml:S2:8211:11	O
discontinue	TAFINLAR.xml:S2:8223:11	O
TAFINLAR	TAFINLAR.xml:S2:8235:8	O
and	TAFINLAR.xml:S2:8244:3	O
trametinib	TAFINLAR.xml:S2:8248:10	O
for	TAFINLAR.xml:S2:8259:3	O
life	TAFINLAR.xml:S2:8263:4	O
-	TAFINLAR.xml:S2:8267:1	O
threatening	TAFINLAR.xml:S2:8268:11	O
PE	TAFINLAR.xml:S2:8280:2	O
.	TAFINLAR.xml:S2:8282:1	O

Withhold	TAFINLAR.xml:S2:8284:8	O
trametinib	TAFINLAR.xml:S2:8293:10	O
and	TAFINLAR.xml:S2:8304:3	O
continue	TAFINLAR.xml:S2:8308:8	O
TAFINLAR	TAFINLAR.xml:S2:8317:8	O
at	TAFINLAR.xml:S2:8326:2	O
the	TAFINLAR.xml:S2:8329:3	O
same	TAFINLAR.xml:S2:8333:4	O
dose	TAFINLAR.xml:S2:8338:4	O
for	TAFINLAR.xml:S2:8343:3	O
uncomplicated	TAFINLAR.xml:S2:8347:13	O
DVT	TAFINLAR.xml:S2:8361:3	O
or	TAFINLAR.xml:S2:8365:2	O
PE	TAFINLAR.xml:S2:8368:2	O
;	TAFINLAR.xml:S2:8370:1	O
if	TAFINLAR.xml:S2:8372:2	O
improved	TAFINLAR.xml:S2:8375:8	O
within	TAFINLAR.xml:S2:8384:6	O
3	TAFINLAR.xml:S2:8391:1	O
weeks	TAFINLAR.xml:S2:8393:5	O
,	TAFINLAR.xml:S2:8398:1	O
trametinib	TAFINLAR.xml:S2:8400:10	O
may	TAFINLAR.xml:S2:8411:3	O
be	TAFINLAR.xml:S2:8415:2	O
resumed	TAFINLAR.xml:S2:8418:7	O
at	TAFINLAR.xml:S2:8426:2	O
a	TAFINLAR.xml:S2:8429:1	O
lower	TAFINLAR.xml:S2:8431:5	O
dose	TAFINLAR.xml:S2:8437:4	O
level	TAFINLAR.xml:S2:8442:5	O
[	TAFINLAR.xml:S2:8448:1	O
see	TAFINLAR.xml:S2:8449:3	O
Dosage	TAFINLAR.xml:S2:8453:6	O
and	TAFINLAR.xml:S2:8460:3	O
Administration	TAFINLAR.xml:S2:8464:14	O
(	TAFINLAR.xml:S2:8479:1	O
2.3	TAFINLAR.xml:S2:8480:3	O
)]	TAFINLAR.xml:S2:8483:2	O
.	TAFINLAR.xml:S2:8489:1	O

5.5	TAFINLAR.xml:S2:8499:3	O
Cardiomyopathy	TAFINLAR.xml:S2:8503:14	O

Cardiomyopathy	TAFINLAR.xml:S2:8526:14	B-AdverseReaction
can	TAFINLAR.xml:S2:8541:3	B-Factor
occur	TAFINLAR.xml:S2:8545:5	O
when	TAFINLAR.xml:S2:8551:4	O
TAFINLAR	TAFINLAR.xml:S2:8556:8	O
is	TAFINLAR.xml:S2:8565:2	O
used	TAFINLAR.xml:S2:8568:4	O
in	TAFINLAR.xml:S2:8573:2	O
combination	TAFINLAR.xml:S2:8576:11	O
with	TAFINLAR.xml:S2:8588:4	O
trametinib	TAFINLAR.xml:S2:8593:10	O
and	TAFINLAR.xml:S2:8604:3	O
with	TAFINLAR.xml:S2:8608:4	O
trametinib	TAFINLAR.xml:S2:8613:10	O
as	TAFINLAR.xml:S2:8624:2	O
a	TAFINLAR.xml:S2:8627:1	O
single	TAFINLAR.xml:S2:8629:6	O
agent	TAFINLAR.xml:S2:8636:5	O
[	TAFINLAR.xml:S2:8642:1	O
refer	TAFINLAR.xml:S2:8643:5	O
to	TAFINLAR.xml:S2:8649:2	O
Full	TAFINLAR.xml:S2:8652:4	O
Prescribing	TAFINLAR.xml:S2:8657:11	O
Information	TAFINLAR.xml:S2:8669:11	O
for	TAFINLAR.xml:S2:8681:3	O
trametinib	TAFINLAR.xml:S2:8685:10	O
]	TAFINLAR.xml:S2:8695:1	O
.	TAFINLAR.xml:S2:8698:1	O

In	TAFINLAR.xml:S2:8707:2	O
Trial	TAFINLAR.xml:S2:8710:5	O
2	TAFINLAR.xml:S2:8716:1	O
,	TAFINLAR.xml:S2:8717:1	O
cardiomyopathy	TAFINLAR.xml:S2:8719:14	B-AdverseReaction
occurred	TAFINLAR.xml:S2:8734:8	O
in	TAFINLAR.xml:S2:8743:2	O
9%	TAFINLAR.xml:S2:8746:2	O
(	TAFINLAR.xml:S2:8749:1	O
5	TAFINLAR.xml:S2:8750:1	O
55	TAFINLAR.xml:S2:8752:2	O
)	TAFINLAR.xml:S2:8754:1	O
of	TAFINLAR.xml:S2:8756:2	O
patients	TAFINLAR.xml:S2:8759:8	O
treated	TAFINLAR.xml:S2:8768:7	O
with	TAFINLAR.xml:S2:8776:4	O
TAFINLAR	TAFINLAR.xml:S2:8781:8	O
in	TAFINLAR.xml:S2:8790:2	O
combination	TAFINLAR.xml:S2:8793:11	O
with	TAFINLAR.xml:S2:8805:4	O
trametinib	TAFINLAR.xml:S2:8810:10	O
and	TAFINLAR.xml:S2:8821:3	O
in	TAFINLAR.xml:S2:8825:2	O
none	TAFINLAR.xml:S2:8828:4	O
of	TAFINLAR.xml:S2:8833:2	O
patients	TAFINLAR.xml:S2:8836:8	O
treated	TAFINLAR.xml:S2:8845:7	O
with	TAFINLAR.xml:S2:8853:4	O
TAFINLAR	TAFINLAR.xml:S2:8858:8	O
as	TAFINLAR.xml:S2:8867:2	O
a	TAFINLAR.xml:S2:8870:1	O
single	TAFINLAR.xml:S2:8872:6	O
agent	TAFINLAR.xml:S2:8879:5	O
.	TAFINLAR.xml:S2:8884:1	O

The	TAFINLAR.xml:S2:8886:3	O
median	TAFINLAR.xml:S2:8890:6	O
time	TAFINLAR.xml:S2:8897:4	O
to	TAFINLAR.xml:S2:8902:2	O
onset	TAFINLAR.xml:S2:8905:5	O
of	TAFINLAR.xml:S2:8911:2	O
cardiomyopathy	TAFINLAR.xml:S2:8914:14	B-AdverseReaction
in	TAFINLAR.xml:S2:8929:2	O
patients	TAFINLAR.xml:S2:8932:8	O
treated	TAFINLAR.xml:S2:8941:7	O
with	TAFINLAR.xml:S2:8949:4	O
TAFINLAR	TAFINLAR.xml:S2:8954:8	O
in	TAFINLAR.xml:S2:8963:2	O
combination	TAFINLAR.xml:S2:8966:11	O
with	TAFINLAR.xml:S2:8978:4	O
trametinib	TAFINLAR.xml:S2:8983:10	O
was	TAFINLAR.xml:S2:8994:3	O
86	TAFINLAR.xml:S2:8998:2	O
days	TAFINLAR.xml:S2:9001:4	O
(	TAFINLAR.xml:S2:9006:1	O
range	TAFINLAR.xml:S2:9007:5	O
:	TAFINLAR.xml:S2:9012:1	O
27	TAFINLAR.xml:S2:9014:2	O
to	TAFINLAR.xml:S2:9017:2	O
253	TAFINLAR.xml:S2:9020:3	O
days	TAFINLAR.xml:S2:9024:4	O
)	TAFINLAR.xml:S2:9028:1	O
.	TAFINLAR.xml:S2:9029:1	O

Cardiomyopathy	TAFINLAR.xml:S2:9031:14	B-AdverseReaction
was	TAFINLAR.xml:S2:9046:3	O
identified	TAFINLAR.xml:S2:9050:10	O
within	TAFINLAR.xml:S2:9061:6	O
the	TAFINLAR.xml:S2:9068:3	O
first	TAFINLAR.xml:S2:9072:5	O
month	TAFINLAR.xml:S2:9078:5	O
of	TAFINLAR.xml:S2:9084:2	O
treatment	TAFINLAR.xml:S2:9087:9	O
with	TAFINLAR.xml:S2:9097:4	O
TAFINLAR	TAFINLAR.xml:S2:9102:8	O
in	TAFINLAR.xml:S2:9111:2	O
combination	TAFINLAR.xml:S2:9114:11	O
with	TAFINLAR.xml:S2:9126:4	O
trametinib	TAFINLAR.xml:S2:9131:10	O
in	TAFINLAR.xml:S2:9142:2	O
two	TAFINLAR.xml:S2:9145:3	O
of	TAFINLAR.xml:S2:9149:2	O
five	TAFINLAR.xml:S2:9152:4	O
patients	TAFINLAR.xml:S2:9157:8	O
.	TAFINLAR.xml:S2:9165:1	O

Development	TAFINLAR.xml:S2:9167:11	O
of	TAFINLAR.xml:S2:9179:2	O
cardiomyopathy	TAFINLAR.xml:S2:9182:14	B-AdverseReaction
resolved	TAFINLAR.xml:S2:9197:8	O
in	TAFINLAR.xml:S2:9206:2	O
all	TAFINLAR.xml:S2:9209:3	O
five	TAFINLAR.xml:S2:9213:4	O
patients	TAFINLAR.xml:S2:9218:8	O
following	TAFINLAR.xml:S2:9227:9	O
dose	TAFINLAR.xml:S2:9237:4	O
reduction	TAFINLAR.xml:S2:9242:9	O
(	TAFINLAR.xml:S2:9252:1	O
4	TAFINLAR.xml:S2:9253:1	O
55	TAFINLAR.xml:S2:9255:2	O
)	TAFINLAR.xml:S2:9257:1	O
and	TAFINLAR.xml:S2:9259:3	O
or	TAFINLAR.xml:S2:9263:2	O
dose	TAFINLAR.xml:S2:9266:4	O
interruption	TAFINLAR.xml:S2:9271:12	O
(	TAFINLAR.xml:S2:9284:1	O
1	TAFINLAR.xml:S2:9285:1	O
55	TAFINLAR.xml:S2:9287:2	O
)	TAFINLAR.xml:S2:9289:1	O
.	TAFINLAR.xml:S2:9290:1	O

Across	TAFINLAR.xml:S2:9299:6	O
clinical	TAFINLAR.xml:S2:9306:8	O
trials	TAFINLAR.xml:S2:9315:6	O
of	TAFINLAR.xml:S2:9322:2	O
TAFINLAR	TAFINLAR.xml:S2:9325:8	O
administered	TAFINLAR.xml:S2:9334:12	O
in	TAFINLAR.xml:S2:9347:2	O
combination	TAFINLAR.xml:S2:9350:11	O
with	TAFINLAR.xml:S2:9362:4	O
trametinib	TAFINLAR.xml:S2:9367:10	O
(	TAFINLAR.xml:S2:9378:1	O
N	TAFINLAR.xml:S2:9379:1	O
202	TAFINLAR.xml:S2:9383:3	O
)	TAFINLAR.xml:S2:9386:1	O
,	TAFINLAR.xml:S2:9387:1	O
8%	TAFINLAR.xml:S2:9389:2	O
of	TAFINLAR.xml:S2:9392:2	O
patients	TAFINLAR.xml:S2:9395:8	O
developed	TAFINLAR.xml:S2:9404:9	O
evidence	TAFINLAR.xml:S2:9414:8	O
of	TAFINLAR.xml:S2:9423:2	O
cardiomyopathy	TAFINLAR.xml:S2:9426:14	B-AdverseReaction
(	TAFINLAR.xml:S2:9441:1	O
decrease	TAFINLAR.xml:S2:9442:8	B-AdverseReaction
in	TAFINLAR.xml:S2:9451:2	I-AdverseReaction
LVEF	TAFINLAR.xml:S2:9454:4	I-AdverseReaction
below	TAFINLAR.xml:S2:9459:5	O
institutional	TAFINLAR.xml:S2:9465:13	B-Severity
lower	TAFINLAR.xml:S2:9479:5	I-Severity
limits	TAFINLAR.xml:S2:9485:6	I-Severity
of	TAFINLAR.xml:S2:9492:2	I-Severity
normal	TAFINLAR.xml:S2:9495:6	I-Severity
with	TAFINLAR.xml:S2:9502:4	O
an	TAFINLAR.xml:S2:9507:2	O
absolute	TAFINLAR.xml:S2:9510:8	B-AdverseReaction
decrease	TAFINLAR.xml:S2:9519:8	I-AdverseReaction
in	TAFINLAR.xml:S2:9528:2	I-AdverseReaction
LVEF	TAFINLAR.xml:S2:9531:4	I-AdverseReaction
10%	TAFINLAR.xml:S2:9538:3	B-Severity
below	TAFINLAR.xml:S2:9542:5	I-Severity
baseline	TAFINLAR.xml:S2:9548:8	I-Severity
)	TAFINLAR.xml:S2:9556:1	O
.	TAFINLAR.xml:S2:9557:1	O

Two	TAFINLAR.xml:S2:9559:3	O
percent	TAFINLAR.xml:S2:9563:7	O
demonstrated	TAFINLAR.xml:S2:9571:12	O
a	TAFINLAR.xml:S2:9584:1	O
decrease	TAFINLAR.xml:S2:9586:8	B-AdverseReaction
in	TAFINLAR.xml:S2:9595:2	I-AdverseReaction
LVEF	TAFINLAR.xml:S2:9598:4	I-AdverseReaction
below	TAFINLAR.xml:S2:9603:5	O
institutional	TAFINLAR.xml:S2:9609:13	B-Severity
lower	TAFINLAR.xml:S2:9623:5	I-Severity
limits	TAFINLAR.xml:S2:9629:6	I-Severity
of	TAFINLAR.xml:S2:9636:2	I-Severity
normal	TAFINLAR.xml:S2:9639:6	I-Severity
with	TAFINLAR.xml:S2:9646:4	O
an	TAFINLAR.xml:S2:9651:2	O
absolute	TAFINLAR.xml:S2:9654:8	B-AdverseReaction
decrease	TAFINLAR.xml:S2:9663:8	I-AdverseReaction
in	TAFINLAR.xml:S2:9672:2	I-AdverseReaction
LVEF	TAFINLAR.xml:S2:9675:4	I-AdverseReaction
of	TAFINLAR.xml:S2:9680:2	O
20%	TAFINLAR.xml:S2:9685:3	B-Severity
below	TAFINLAR.xml:S2:9689:5	I-Severity
baseline	TAFINLAR.xml:S2:9695:8	I-Severity
.	TAFINLAR.xml:S2:9703:1	O

Assess	TAFINLAR.xml:S2:9712:6	O
LVEF	TAFINLAR.xml:S2:9719:4	O
by	TAFINLAR.xml:S2:9724:2	O
echocardiogram	TAFINLAR.xml:S2:9727:14	O
or	TAFINLAR.xml:S2:9742:2	O
multigated	TAFINLAR.xml:S2:9745:10	O
acquisition	TAFINLAR.xml:S2:9756:11	O
(	TAFINLAR.xml:S2:9768:1	O
MUGA	TAFINLAR.xml:S2:9769:4	O
)	TAFINLAR.xml:S2:9773:1	O
scan	TAFINLAR.xml:S2:9775:4	O
before	TAFINLAR.xml:S2:9780:6	O
initiation	TAFINLAR.xml:S2:9787:10	O
of	TAFINLAR.xml:S2:9798:2	O
TAFINLAR	TAFINLAR.xml:S2:9801:8	O
in	TAFINLAR.xml:S2:9810:2	O
combination	TAFINLAR.xml:S2:9813:11	O
with	TAFINLAR.xml:S2:9825:4	O
trametinib	TAFINLAR.xml:S2:9830:10	O
,	TAFINLAR.xml:S2:9840:1	O
one	TAFINLAR.xml:S2:9842:3	O
month	TAFINLAR.xml:S2:9846:5	O
after	TAFINLAR.xml:S2:9852:5	O
initiation	TAFINLAR.xml:S2:9858:10	O
,	TAFINLAR.xml:S2:9868:1	O
and	TAFINLAR.xml:S2:9870:3	O
then	TAFINLAR.xml:S2:9874:4	O
at	TAFINLAR.xml:S2:9879:2	O
2	TAFINLAR.xml:S2:9882:1	O
-	TAFINLAR.xml:S2:9883:1	O
to	TAFINLAR.xml:S2:9885:2	O
3	TAFINLAR.xml:S2:9888:1	O
-	TAFINLAR.xml:S2:9889:1	O
month	TAFINLAR.xml:S2:9890:5	O
intervals	TAFINLAR.xml:S2:9896:9	O
while	TAFINLAR.xml:S2:9906:5	O
on	TAFINLAR.xml:S2:9912:2	O
treatment	TAFINLAR.xml:S2:9915:9	O
with	TAFINLAR.xml:S2:9925:4	O
the	TAFINLAR.xml:S2:9930:3	O
combination	TAFINLAR.xml:S2:9934:11	O
.	TAFINLAR.xml:S2:9945:1	O

Withhold	TAFINLAR.xml:S2:9947:8	O
treatment	TAFINLAR.xml:S2:9956:9	O
with	TAFINLAR.xml:S2:9966:4	O
trametinib	TAFINLAR.xml:S2:9971:10	O
and	TAFINLAR.xml:S2:9982:3	O
continue	TAFINLAR.xml:S2:9986:8	O
TAFINLAR	TAFINLAR.xml:S2:9995:8	O
at	TAFINLAR.xml:S2:10004:2	O
the	TAFINLAR.xml:S2:10007:3	O
same	TAFINLAR.xml:S2:10011:4	O
dose	TAFINLAR.xml:S2:10016:4	O
if	TAFINLAR.xml:S2:10021:2	O
absolute	TAFINLAR.xml:S2:10024:8	O
LVEF	TAFINLAR.xml:S2:10033:4	O
value	TAFINLAR.xml:S2:10038:5	O
decreases	TAFINLAR.xml:S2:10044:9	O
by	TAFINLAR.xml:S2:10054:2	O
10%	TAFINLAR.xml:S2:10057:3	O
from	TAFINLAR.xml:S2:10061:4	O
pretreatment	TAFINLAR.xml:S2:10066:12	O
values	TAFINLAR.xml:S2:10079:6	O
and	TAFINLAR.xml:S2:10086:3	O
is	TAFINLAR.xml:S2:10090:2	O
less	TAFINLAR.xml:S2:10093:4	O
than	TAFINLAR.xml:S2:10098:4	O
the	TAFINLAR.xml:S2:10103:3	O
lower	TAFINLAR.xml:S2:10107:5	O
limit	TAFINLAR.xml:S2:10113:5	O
of	TAFINLAR.xml:S2:10119:2	O
normal	TAFINLAR.xml:S2:10122:6	O
.	TAFINLAR.xml:S2:10128:1	O

For	TAFINLAR.xml:S2:10130:3	O
symptomatic	TAFINLAR.xml:S2:10134:11	O
cardiomyopathy	TAFINLAR.xml:S2:10146:14	O
or	TAFINLAR.xml:S2:10161:2	O
persistent	TAFINLAR.xml:S2:10164:10	O
,	TAFINLAR.xml:S2:10174:1	O
asymptomatic	TAFINLAR.xml:S2:10176:12	O
LV	TAFINLAR.xml:S2:10189:2	O
dysfunction	TAFINLAR.xml:S2:10192:11	O
that	TAFINLAR.xml:S2:10204:4	O
does	TAFINLAR.xml:S2:10209:4	O
not	TAFINLAR.xml:S2:10214:3	O
resolve	TAFINLAR.xml:S2:10218:7	O
within	TAFINLAR.xml:S2:10226:6	O
4	TAFINLAR.xml:S2:10233:1	O
weeks	TAFINLAR.xml:S2:10235:5	O
,	TAFINLAR.xml:S2:10240:1	O
permanently	TAFINLAR.xml:S2:10242:11	O
discontinue	TAFINLAR.xml:S2:10254:11	O
trametinib	TAFINLAR.xml:S2:10266:10	O
and	TAFINLAR.xml:S2:10277:3	O
withhold	TAFINLAR.xml:S2:10281:8	O
TAFINLAR	TAFINLAR.xml:S2:10290:8	O
.	TAFINLAR.xml:S2:10298:1	O

Resume	TAFINLAR.xml:S2:10300:6	O
TAFINLAR	TAFINLAR.xml:S2:10307:8	O
at	TAFINLAR.xml:S2:10316:2	O
the	TAFINLAR.xml:S2:10319:3	O
same	TAFINLAR.xml:S2:10323:4	O
dose	TAFINLAR.xml:S2:10328:4	O
level	TAFINLAR.xml:S2:10333:5	O
upon	TAFINLAR.xml:S2:10339:4	O
recovery	TAFINLAR.xml:S2:10344:8	O
of	TAFINLAR.xml:S2:10353:2	O
cardiac	TAFINLAR.xml:S2:10356:7	O
function	TAFINLAR.xml:S2:10364:8	O
[	TAFINLAR.xml:S2:10373:1	O
see	TAFINLAR.xml:S2:10374:3	O
Dosage	TAFINLAR.xml:S2:10378:6	O
and	TAFINLAR.xml:S2:10385:3	O
Administration	TAFINLAR.xml:S2:10389:14	O
(	TAFINLAR.xml:S2:10404:1	O
2.3	TAFINLAR.xml:S2:10405:3	O
)]	TAFINLAR.xml:S2:10408:2	O
.	TAFINLAR.xml:S2:10414:1	O

5.6	TAFINLAR.xml:S2:10424:3	O
Ocular	TAFINLAR.xml:S2:10428:6	O
Toxicities	TAFINLAR.xml:S2:10435:10	O

Retinal	TAFINLAR.xml:S2:10455:7	O
Pigment	TAFINLAR.xml:S2:10463:7	O
Epithelial	TAFINLAR.xml:S2:10471:10	O
Detachment	TAFINLAR.xml:S2:10482:10	O
(	TAFINLAR.xml:S2:10493:1	O
RPED	TAFINLAR.xml:S2:10494:4	O
)	TAFINLAR.xml:S2:10498:1	O
:	TAFINLAR.xml:S2:10499:1	O

Retinal	TAFINLAR.xml:S2:10510:7	B-AdverseReaction
pigment	TAFINLAR.xml:S2:10518:7	I-AdverseReaction
epithelial	TAFINLAR.xml:S2:10526:10	I-AdverseReaction
detachments	TAFINLAR.xml:S2:10537:11	I-AdverseReaction
(	TAFINLAR.xml:S2:10549:1	O
RPED	TAFINLAR.xml:S2:10550:4	B-AdverseReaction
)	TAFINLAR.xml:S2:10554:1	O
can	TAFINLAR.xml:S2:10556:3	B-Factor
occur	TAFINLAR.xml:S2:10560:5	O
when	TAFINLAR.xml:S2:10566:4	O
TAFINLAR	TAFINLAR.xml:S2:10571:8	O
is	TAFINLAR.xml:S2:10580:2	O
used	TAFINLAR.xml:S2:10583:4	O
in	TAFINLAR.xml:S2:10588:2	O
combination	TAFINLAR.xml:S2:10591:11	O
with	TAFINLAR.xml:S2:10603:4	O
trametinib	TAFINLAR.xml:S2:10608:10	O
and	TAFINLAR.xml:S2:10619:3	O
with	TAFINLAR.xml:S2:10623:4	O
trametinib	TAFINLAR.xml:S2:10628:10	O
as	TAFINLAR.xml:S2:10639:2	O
a	TAFINLAR.xml:S2:10642:1	O
single	TAFINLAR.xml:S2:10644:6	O
agent	TAFINLAR.xml:S2:10651:5	O
[	TAFINLAR.xml:S2:10657:1	O
refer	TAFINLAR.xml:S2:10658:5	O
to	TAFINLAR.xml:S2:10664:2	O
Full	TAFINLAR.xml:S2:10667:4	O
Prescribing	TAFINLAR.xml:S2:10672:11	O
Information	TAFINLAR.xml:S2:10684:11	O
for	TAFINLAR.xml:S2:10696:3	O
trametinib	TAFINLAR.xml:S2:10700:10	O
]	TAFINLAR.xml:S2:10710:1	O
.	TAFINLAR.xml:S2:10713:1	O

Retinal	TAFINLAR.xml:S2:10715:7	B-AdverseReaction
detachments	TAFINLAR.xml:S2:10723:11	I-AdverseReaction
resulting	TAFINLAR.xml:S2:10735:9	O
from	TAFINLAR.xml:S2:10745:4	O
trametinib	TAFINLAR.xml:S2:10750:10	O
are	TAFINLAR.xml:S2:10761:3	O
often	TAFINLAR.xml:S2:10765:5	O
bilateral	TAFINLAR.xml:S2:10771:9	O
and	TAFINLAR.xml:S2:10781:3	O
multifocal	TAFINLAR.xml:S2:10785:10	O
,	TAFINLAR.xml:S2:10795:1	O
occurring	TAFINLAR.xml:S2:10797:9	O
in	TAFINLAR.xml:S2:10807:2	O
the	TAFINLAR.xml:S2:10810:3	O
macular	TAFINLAR.xml:S2:10814:7	O
region	TAFINLAR.xml:S2:10822:6	O
of	TAFINLAR.xml:S2:10829:2	O
the	TAFINLAR.xml:S2:10832:3	O
retina	TAFINLAR.xml:S2:10836:6	O
.	TAFINLAR.xml:S2:10842:1	O

In	TAFINLAR.xml:S2:10851:2	O
Trial	TAFINLAR.xml:S2:10854:5	O
2	TAFINLAR.xml:S2:10860:1	O
,	TAFINLAR.xml:S2:10861:1	O
ophthalmologic	TAFINLAR.xml:S2:10863:14	O
examinations	TAFINLAR.xml:S2:10878:12	O
including	TAFINLAR.xml:S2:10891:9	O
retinal	TAFINLAR.xml:S2:10901:7	O
evaluation	TAFINLAR.xml:S2:10909:10	O
were	TAFINLAR.xml:S2:10920:4	O
performed	TAFINLAR.xml:S2:10925:9	O
pretreatment	TAFINLAR.xml:S2:10935:12	O
and	TAFINLAR.xml:S2:10948:3	O
at	TAFINLAR.xml:S2:10952:2	O
regular	TAFINLAR.xml:S2:10955:7	O
intervals	TAFINLAR.xml:S2:10963:9	O
during	TAFINLAR.xml:S2:10973:6	O
treatment	TAFINLAR.xml:S2:10980:9	O
.	TAFINLAR.xml:S2:10989:1	O

RPED	TAFINLAR.xml:S2:10991:4	B-AdverseReaction
occurred	TAFINLAR.xml:S2:10996:8	O
in	TAFINLAR.xml:S2:11005:2	O
2%	TAFINLAR.xml:S2:11008:2	O
(	TAFINLAR.xml:S2:11011:1	O
1	TAFINLAR.xml:S2:11012:1	O
55	TAFINLAR.xml:S2:11014:2	O
)	TAFINLAR.xml:S2:11016:1	O
of	TAFINLAR.xml:S2:11018:2	O
patients	TAFINLAR.xml:S2:11021:8	O
receiving	TAFINLAR.xml:S2:11030:9	O
TAFINLAR	TAFINLAR.xml:S2:11040:8	O
in	TAFINLAR.xml:S2:11049:2	O
combination	TAFINLAR.xml:S2:11052:11	O
with	TAFINLAR.xml:S2:11064:4	O
trametinib	TAFINLAR.xml:S2:11069:10	O
.	TAFINLAR.xml:S2:11079:1	O

Across	TAFINLAR.xml:S2:11081:6	O
clinical	TAFINLAR.xml:S2:11088:8	O
trials	TAFINLAR.xml:S2:11097:6	O
of	TAFINLAR.xml:S2:11104:2	O
TAFINLAR	TAFINLAR.xml:S2:11107:8	O
administered	TAFINLAR.xml:S2:11116:12	O
in	TAFINLAR.xml:S2:11129:2	O
combination	TAFINLAR.xml:S2:11132:11	O
with	TAFINLAR.xml:S2:11144:4	O
trametinib	TAFINLAR.xml:S2:11149:10	O
(	TAFINLAR.xml:S2:11160:1	O
N	TAFINLAR.xml:S2:11161:1	O
202	TAFINLAR.xml:S2:11165:3	O
)	TAFINLAR.xml:S2:11168:1	O
,	TAFINLAR.xml:S2:11169:1	O
the	TAFINLAR.xml:S2:11171:3	O
incidence	TAFINLAR.xml:S2:11175:9	O
of	TAFINLAR.xml:S2:11185:2	O
RPED	TAFINLAR.xml:S2:11188:4	B-AdverseReaction
was	TAFINLAR.xml:S2:11193:3	O
1%	TAFINLAR.xml:S2:11197:2	O
(	TAFINLAR.xml:S2:11200:1	O
2	TAFINLAR.xml:S2:11201:1	O
202	TAFINLAR.xml:S2:11203:3	O
)	TAFINLAR.xml:S2:11206:1	O
.	TAFINLAR.xml:S2:11207:1	O

Perform	TAFINLAR.xml:S2:11216:7	O
ophthalmological	TAFINLAR.xml:S2:11224:16	O
evaluation	TAFINLAR.xml:S2:11241:10	O
at	TAFINLAR.xml:S2:11252:2	O
any	TAFINLAR.xml:S2:11255:3	O
time	TAFINLAR.xml:S2:11259:4	O
a	TAFINLAR.xml:S2:11264:1	O
patient	TAFINLAR.xml:S2:11266:7	O
reports	TAFINLAR.xml:S2:11274:7	O
visual	TAFINLAR.xml:S2:11282:6	O
disturbances	TAFINLAR.xml:S2:11289:12	O
and	TAFINLAR.xml:S2:11302:3	O
compare	TAFINLAR.xml:S2:11306:7	O
with	TAFINLAR.xml:S2:11314:4	O
baseline	TAFINLAR.xml:S2:11319:8	O
,	TAFINLAR.xml:S2:11327:1	O
if	TAFINLAR.xml:S2:11329:2	O
available	TAFINLAR.xml:S2:11332:9	O
.	TAFINLAR.xml:S2:11341:1	O

If	TAFINLAR.xml:S2:11343:2	O
TAFINLAR	TAFINLAR.xml:S2:11346:8	O
is	TAFINLAR.xml:S2:11355:2	O
used	TAFINLAR.xml:S2:11358:4	O
in	TAFINLAR.xml:S2:11363:2	O
combination	TAFINLAR.xml:S2:11366:11	O
with	TAFINLAR.xml:S2:11378:4	O
trametinib	TAFINLAR.xml:S2:11383:10	O
,	TAFINLAR.xml:S2:11393:1	O
do	TAFINLAR.xml:S2:11395:2	O
not	TAFINLAR.xml:S2:11398:3	O
modify	TAFINLAR.xml:S2:11402:6	O
the	TAFINLAR.xml:S2:11409:3	O
dose	TAFINLAR.xml:S2:11413:4	O
of	TAFINLAR.xml:S2:11418:2	O
TAFINLAR	TAFINLAR.xml:S2:11421:8	O
.	TAFINLAR.xml:S2:11429:1	O

Withhold	TAFINLAR.xml:S2:11431:8	O
trametinib	TAFINLAR.xml:S2:11440:10	O
if	TAFINLAR.xml:S2:11451:2	O
RPED	TAFINLAR.xml:S2:11454:4	O
is	TAFINLAR.xml:S2:11459:2	O
diagnosed	TAFINLAR.xml:S2:11462:9	O
.	TAFINLAR.xml:S2:11471:1	O

If	TAFINLAR.xml:S2:11473:2	O
resolution	TAFINLAR.xml:S2:11476:10	O
of	TAFINLAR.xml:S2:11487:2	O
the	TAFINLAR.xml:S2:11490:3	O
RPED	TAFINLAR.xml:S2:11494:4	O
is	TAFINLAR.xml:S2:11499:2	O
documented	TAFINLAR.xml:S2:11502:10	O
on	TAFINLAR.xml:S2:11513:2	O
repeat	TAFINLAR.xml:S2:11516:6	O
ophthalmological	TAFINLAR.xml:S2:11523:16	O
evaluation	TAFINLAR.xml:S2:11540:10	O
within	TAFINLAR.xml:S2:11551:6	O
3	TAFINLAR.xml:S2:11558:1	O
weeks	TAFINLAR.xml:S2:11560:5	O
,	TAFINLAR.xml:S2:11565:1	O
resume	TAFINLAR.xml:S2:11567:6	O
trametinib	TAFINLAR.xml:S2:11574:10	O
at	TAFINLAR.xml:S2:11585:2	O
a	TAFINLAR.xml:S2:11588:1	O
lower	TAFINLAR.xml:S2:11590:5	O
dose	TAFINLAR.xml:S2:11596:4	O
level	TAFINLAR.xml:S2:11601:5	O
.	TAFINLAR.xml:S2:11606:1	O

Discontinue	TAFINLAR.xml:S2:11608:11	O
trametinib	TAFINLAR.xml:S2:11620:10	O
if	TAFINLAR.xml:S2:11631:2	O
no	TAFINLAR.xml:S2:11634:2	O
improvement	TAFINLAR.xml:S2:11637:11	O
after	TAFINLAR.xml:S2:11649:5	O
3	TAFINLAR.xml:S2:11655:1	O
weeks	TAFINLAR.xml:S2:11657:5	O
[	TAFINLAR.xml:S2:11663:1	O
see	TAFINLAR.xml:S2:11664:3	O
Dosage	TAFINLAR.xml:S2:11668:6	O
and	TAFINLAR.xml:S2:11675:3	O
Administration	TAFINLAR.xml:S2:11679:14	O
(	TAFINLAR.xml:S2:11694:1	O
2.3	TAFINLAR.xml:S2:11695:3	O
)]	TAFINLAR.xml:S2:11698:2	O
.	TAFINLAR.xml:S2:11700:1	O

Uveitis	TAFINLAR.xml:S2:11712:7	O
and	TAFINLAR.xml:S2:11720:3	O
Iritis	TAFINLAR.xml:S2:11724:6	O
:	TAFINLAR.xml:S2:11730:1	O

Uveitis	TAFINLAR.xml:S2:11741:7	B-AdverseReaction
and	TAFINLAR.xml:S2:11749:3	O
iritis	TAFINLAR.xml:S2:11753:6	B-AdverseReaction
can	TAFINLAR.xml:S2:11760:3	B-Factor
occur	TAFINLAR.xml:S2:11764:5	O
when	TAFINLAR.xml:S2:11770:4	O
TAFINLAR	TAFINLAR.xml:S2:11775:8	O
is	TAFINLAR.xml:S2:11784:2	O
administered	TAFINLAR.xml:S2:11787:12	O
as	TAFINLAR.xml:S2:11800:2	O
a	TAFINLAR.xml:S2:11803:1	O
single	TAFINLAR.xml:S2:11805:6	O
agent	TAFINLAR.xml:S2:11812:5	O
or	TAFINLAR.xml:S2:11818:2	O
when	TAFINLAR.xml:S2:11821:4	O
used	TAFINLAR.xml:S2:11826:4	O
in	TAFINLAR.xml:S2:11831:2	O
combination	TAFINLAR.xml:S2:11834:11	O
with	TAFINLAR.xml:S2:11846:4	O
trametinib	TAFINLAR.xml:S2:11851:10	O
.	TAFINLAR.xml:S2:11861:1	O

Uveitis	TAFINLAR.xml:S2:11870:7	B-AdverseReaction
(	TAFINLAR.xml:S2:11878:1	O
including	TAFINLAR.xml:S2:11879:9	O
iritis	TAFINLAR.xml:S2:11889:6	B-AdverseReaction
)	TAFINLAR.xml:S2:11895:1	O
occurred	TAFINLAR.xml:S2:11897:8	O
in	TAFINLAR.xml:S2:11906:2	O
1%	TAFINLAR.xml:S2:11909:2	O
(	TAFINLAR.xml:S2:11912:1	O
6	TAFINLAR.xml:S2:11913:1	O
586	TAFINLAR.xml:S2:11915:3	O
)	TAFINLAR.xml:S2:11918:1	O
of	TAFINLAR.xml:S2:11920:2	O
patients	TAFINLAR.xml:S2:11923:8	O
treated	TAFINLAR.xml:S2:11932:7	O
with	TAFINLAR.xml:S2:11940:4	O
TAFINLAR	TAFINLAR.xml:S2:11945:8	O
as	TAFINLAR.xml:S2:11954:2	O
a	TAFINLAR.xml:S2:11957:1	O
single	TAFINLAR.xml:S2:11959:6	O
agent	TAFINLAR.xml:S2:11966:5	O
and	TAFINLAR.xml:S2:11972:3	O
uveitis	TAFINLAR.xml:S2:11976:7	B-AdverseReaction
occurred	TAFINLAR.xml:S2:11984:8	O
in	TAFINLAR.xml:S2:11993:2	O
1%	TAFINLAR.xml:S2:11996:2	O
(	TAFINLAR.xml:S2:11999:1	O
2	TAFINLAR.xml:S2:12000:1	O
202	TAFINLAR.xml:S2:12002:3	O
)	TAFINLAR.xml:S2:12005:1	O
of	TAFINLAR.xml:S2:12007:2	O
patients	TAFINLAR.xml:S2:12010:8	O
treated	TAFINLAR.xml:S2:12019:7	O
with	TAFINLAR.xml:S2:12027:4	O
TAFINLAR	TAFINLAR.xml:S2:12032:8	O
in	TAFINLAR.xml:S2:12041:2	O
combination	TAFINLAR.xml:S2:12044:11	O
with	TAFINLAR.xml:S2:12056:4	O
trametinib	TAFINLAR.xml:S2:12061:10	O
.	TAFINLAR.xml:S2:12071:1	O

Symptomatic	TAFINLAR.xml:S2:12073:11	O
treatment	TAFINLAR.xml:S2:12085:9	O
employed	TAFINLAR.xml:S2:12095:8	O
in	TAFINLAR.xml:S2:12104:2	O
clinical	TAFINLAR.xml:S2:12107:8	O
trials	TAFINLAR.xml:S2:12116:6	O
included	TAFINLAR.xml:S2:12123:8	O
steroid	TAFINLAR.xml:S2:12132:7	O
and	TAFINLAR.xml:S2:12140:3	O
mydriatic	TAFINLAR.xml:S2:12144:9	O
ophthalmic	TAFINLAR.xml:S2:12154:10	O
drops	TAFINLAR.xml:S2:12165:5	O
.	TAFINLAR.xml:S2:12170:1	O

Monitor	TAFINLAR.xml:S2:12172:7	O
patients	TAFINLAR.xml:S2:12180:8	O
for	TAFINLAR.xml:S2:12189:3	O
visual	TAFINLAR.xml:S2:12193:6	O
signs	TAFINLAR.xml:S2:12200:5	O
and	TAFINLAR.xml:S2:12206:3	O
symptoms	TAFINLAR.xml:S2:12210:8	O
of	TAFINLAR.xml:S2:12219:2	O
uveitis	TAFINLAR.xml:S2:12222:7	O
(	TAFINLAR.xml:S2:12230:1	O
e	TAFINLAR.xml:S2:12231:1	O
.	TAFINLAR.xml:S2:12232:1	O
g	TAFINLAR.xml:S2:12233:1	O
.	TAFINLAR.xml:S2:12234:1	O
,	TAFINLAR.xml:S2:12235:1	O
change	TAFINLAR.xml:S2:12237:6	O
in	TAFINLAR.xml:S2:12244:2	O
vision	TAFINLAR.xml:S2:12247:6	O
,	TAFINLAR.xml:S2:12253:1	O
photophobia	TAFINLAR.xml:S2:12255:11	O
,	TAFINLAR.xml:S2:12266:1	O
eye	TAFINLAR.xml:S2:12268:3	O
pain	TAFINLAR.xml:S2:12272:4	O
)	TAFINLAR.xml:S2:12276:1	O
.	TAFINLAR.xml:S2:12277:1	O

If	TAFINLAR.xml:S2:12279:2	O
diagnosed	TAFINLAR.xml:S2:12282:9	O
,	TAFINLAR.xml:S2:12291:1	O
withhold	TAFINLAR.xml:S2:12293:8	O
TAFINLAR	TAFINLAR.xml:S2:12302:8	O
for	TAFINLAR.xml:S2:12311:3	O
up	TAFINLAR.xml:S2:12315:2	O
to	TAFINLAR.xml:S2:12318:2	O
6	TAFINLAR.xml:S2:12321:1	O
weeks	TAFINLAR.xml:S2:12323:5	O
until	TAFINLAR.xml:S2:12329:5	O
uveitis	TAFINLAR.xml:S2:12335:7	O
iritis	TAFINLAR.xml:S2:12343:6	O
resolves	TAFINLAR.xml:S2:12350:8	O
to	TAFINLAR.xml:S2:12359:2	O
Grade	TAFINLAR.xml:S2:12362:5	O
0	TAFINLAR.xml:S2:12368:1	O
-	TAFINLAR.xml:S2:12369:1	O
1	TAFINLAR.xml:S2:12370:1	O
.	TAFINLAR.xml:S2:12371:1	O

If	TAFINLAR.xml:S2:12373:2	O
TAFINLAR	TAFINLAR.xml:S2:12376:8	O
is	TAFINLAR.xml:S2:12385:2	O
used	TAFINLAR.xml:S2:12388:4	O
in	TAFINLAR.xml:S2:12393:2	O
combination	TAFINLAR.xml:S2:12396:11	O
with	TAFINLAR.xml:S2:12408:4	O
trametinib	TAFINLAR.xml:S2:12413:10	O
,	TAFINLAR.xml:S2:12423:1	O
do	TAFINLAR.xml:S2:12425:2	O
not	TAFINLAR.xml:S2:12428:3	O
modify	TAFINLAR.xml:S2:12432:6	O
the	TAFINLAR.xml:S2:12439:3	O
dose	TAFINLAR.xml:S2:12443:4	O
of	TAFINLAR.xml:S2:12448:2	O
trametinib	TAFINLAR.xml:S2:12451:10	O
.	TAFINLAR.xml:S2:12461:1	O

5.7	TAFINLAR.xml:S2:12472:3	O
Serious	TAFINLAR.xml:S2:12476:7	O
Febrile	TAFINLAR.xml:S2:12484:7	O
Reactions	TAFINLAR.xml:S2:12492:9	O

Serious	TAFINLAR.xml:S2:12508:7	B-Severity
febrile	TAFINLAR.xml:S2:12516:7	B-AdverseReaction
reactions	TAFINLAR.xml:S2:12524:9	I-AdverseReaction
and	TAFINLAR.xml:S2:12534:3	O
fever	TAFINLAR.xml:S2:12538:5	B-AdverseReaction
of	TAFINLAR.xml:S2:12544:2	O
any	TAFINLAR.xml:S2:12547:3	O
severity	TAFINLAR.xml:S2:12551:8	O
complicated	TAFINLAR.xml:S2:12560:11	O
by	TAFINLAR.xml:S2:12572:2	O
hypotension	TAFINLAR.xml:S2:12575:11	B-AdverseReaction
,	TAFINLAR.xml:S2:12586:1	O
rigors	TAFINLAR.xml:S2:12588:6	B-AdverseReaction
or	TAFINLAR.xml:S2:12595:2	O
chills	TAFINLAR.xml:S2:12598:6	B-AdverseReaction
,	TAFINLAR.xml:S2:12604:1	O
dehydration	TAFINLAR.xml:S2:12606:11	B-AdverseReaction
,	TAFINLAR.xml:S2:12617:1	O
or	TAFINLAR.xml:S2:12619:2	O
renal	TAFINLAR.xml:S2:12622:5	B-AdverseReaction
failure	TAFINLAR.xml:S2:12628:7	I-AdverseReaction
,	TAFINLAR.xml:S2:12635:1	O
can	TAFINLAR.xml:S2:12637:3	B-Factor
occur	TAFINLAR.xml:S2:12641:5	O
when	TAFINLAR.xml:S2:12647:4	O
TAFINLAR	TAFINLAR.xml:S2:12652:8	O
is	TAFINLAR.xml:S2:12661:2	O
administered	TAFINLAR.xml:S2:12664:12	O
as	TAFINLAR.xml:S2:12677:2	O
a	TAFINLAR.xml:S2:12680:1	O
single	TAFINLAR.xml:S2:12682:6	O
agent	TAFINLAR.xml:S2:12689:5	O
or	TAFINLAR.xml:S2:12695:2	O
when	TAFINLAR.xml:S2:12698:4	O
used	TAFINLAR.xml:S2:12703:4	O
in	TAFINLAR.xml:S2:12708:2	O
combination	TAFINLAR.xml:S2:12711:11	O
with	TAFINLAR.xml:S2:12723:4	O
trametinib	TAFINLAR.xml:S2:12728:10	O
.	TAFINLAR.xml:S2:12738:1	O

The	TAFINLAR.xml:S2:12740:3	O
incidence	TAFINLAR.xml:S2:12744:9	O
and	TAFINLAR.xml:S2:12754:3	O
severity	TAFINLAR.xml:S2:12758:8	O
of	TAFINLAR.xml:S2:12767:2	O
pyrexia	TAFINLAR.xml:S2:12770:7	B-AdverseReaction
are	TAFINLAR.xml:S2:12778:3	O
increased	TAFINLAR.xml:S2:12782:9	O
when	TAFINLAR.xml:S2:12792:4	O
TAFINLAR	TAFINLAR.xml:S2:12797:8	O
is	TAFINLAR.xml:S2:12806:2	O
used	TAFINLAR.xml:S2:12809:4	O
in	TAFINLAR.xml:S2:12814:2	O
combination	TAFINLAR.xml:S2:12817:11	O
with	TAFINLAR.xml:S2:12829:4	O
trametinib	TAFINLAR.xml:S2:12834:10	O
compared	TAFINLAR.xml:S2:12845:8	O
with	TAFINLAR.xml:S2:12854:4	O
TAFINLAR	TAFINLAR.xml:S2:12859:8	O
as	TAFINLAR.xml:S2:12868:2	O
a	TAFINLAR.xml:S2:12871:1	O
single	TAFINLAR.xml:S2:12873:6	O
agent	TAFINLAR.xml:S2:12880:5	O
[	TAFINLAR.xml:S2:12886:1	O
see	TAFINLAR.xml:S2:12887:3	O
Adverse	TAFINLAR.xml:S2:12891:7	O
Reactions	TAFINLAR.xml:S2:12899:9	O
(	TAFINLAR.xml:S2:12909:1	O
6.1	TAFINLAR.xml:S2:12910:3	O
)]	TAFINLAR.xml:S2:12913:2	O
.	TAFINLAR.xml:S2:12915:1	O

In	TAFINLAR.xml:S2:12925:2	O
Trial	TAFINLAR.xml:S2:12928:5	O
1	TAFINLAR.xml:S2:12934:1	O
,	TAFINLAR.xml:S2:12935:1	O
the	TAFINLAR.xml:S2:12937:3	O
incidence	TAFINLAR.xml:S2:12941:9	O
of	TAFINLAR.xml:S2:12951:2	O
fever	TAFINLAR.xml:S2:12954:5	B-AdverseReaction
(	TAFINLAR.xml:S2:12960:1	O
serious	TAFINLAR.xml:S2:12961:7	B-Severity
and	TAFINLAR.xml:S2:12969:3	O
non	TAFINLAR.xml:S2:12973:3	O
-	TAFINLAR.xml:S2:12976:1	O
serious	TAFINLAR.xml:S2:12977:7	O
)	TAFINLAR.xml:S2:12984:1	O
was	TAFINLAR.xml:S2:12986:3	O
28%	TAFINLAR.xml:S2:12990:3	O
in	TAFINLAR.xml:S2:12994:2	O
patients	TAFINLAR.xml:S2:12997:8	O
treated	TAFINLAR.xml:S2:13006:7	O
with	TAFINLAR.xml:S2:13014:4	O
TAFINLAR	TAFINLAR.xml:S2:13019:8	O
and	TAFINLAR.xml:S2:13028:3	O
10%	TAFINLAR.xml:S2:13032:3	O
in	TAFINLAR.xml:S2:13036:2	O
patients	TAFINLAR.xml:S2:13039:8	O
treated	TAFINLAR.xml:S2:13048:7	O
with	TAFINLAR.xml:S2:13056:4	O
dacarbazine	TAFINLAR.xml:S2:13061:11	O
.	TAFINLAR.xml:S2:13072:1	O

In	TAFINLAR.xml:S2:13074:2	O
patients	TAFINLAR.xml:S2:13077:8	O
treated	TAFINLAR.xml:S2:13086:7	O
with	TAFINLAR.xml:S2:13094:4	O
TAFINLAR	TAFINLAR.xml:S2:13099:8	O
,	TAFINLAR.xml:S2:13107:1	O
the	TAFINLAR.xml:S2:13109:3	O
median	TAFINLAR.xml:S2:13113:6	O
time	TAFINLAR.xml:S2:13120:4	O
to	TAFINLAR.xml:S2:13125:2	O
initial	TAFINLAR.xml:S2:13128:7	O
onset	TAFINLAR.xml:S2:13136:5	O
of	TAFINLAR.xml:S2:13142:2	O
fever	TAFINLAR.xml:S2:13145:5	B-AdverseReaction
(	TAFINLAR.xml:S2:13151:1	O
any	TAFINLAR.xml:S2:13152:3	O
severity	TAFINLAR.xml:S2:13156:8	O
)	TAFINLAR.xml:S2:13164:1	O
was	TAFINLAR.xml:S2:13166:3	O
11	TAFINLAR.xml:S2:13170:2	O
days	TAFINLAR.xml:S2:13173:4	O
(	TAFINLAR.xml:S2:13178:1	O
range	TAFINLAR.xml:S2:13179:5	O
:	TAFINLAR.xml:S2:13184:1	O
1	TAFINLAR.xml:S2:13186:1	O
to	TAFINLAR.xml:S2:13188:2	O
202	TAFINLAR.xml:S2:13191:3	O
days	TAFINLAR.xml:S2:13195:4	O
)	TAFINLAR.xml:S2:13199:1	O
and	TAFINLAR.xml:S2:13201:3	O
the	TAFINLAR.xml:S2:13205:3	O
median	TAFINLAR.xml:S2:13209:6	O
duration	TAFINLAR.xml:S2:13216:8	O
of	TAFINLAR.xml:S2:13225:2	O
fever	TAFINLAR.xml:S2:13228:5	B-AdverseReaction
was	TAFINLAR.xml:S2:13234:3	O
3	TAFINLAR.xml:S2:13238:1	O
days	TAFINLAR.xml:S2:13240:4	O
(	TAFINLAR.xml:S2:13245:1	O
range	TAFINLAR.xml:S2:13246:5	O
:	TAFINLAR.xml:S2:13251:1	O
1	TAFINLAR.xml:S2:13253:1	O
to	TAFINLAR.xml:S2:13255:2	O
129	TAFINLAR.xml:S2:13258:3	O
days	TAFINLAR.xml:S2:13262:4	O
)	TAFINLAR.xml:S2:13266:1	O
.	TAFINLAR.xml:S2:13267:1	O

Serious	TAFINLAR.xml:S2:13269:7	B-Severity
febrile	TAFINLAR.xml:S2:13277:7	B-AdverseReaction
reactions	TAFINLAR.xml:S2:13285:9	I-AdverseReaction
and	TAFINLAR.xml:S2:13295:3	O
fever	TAFINLAR.xml:S2:13299:5	B-AdverseReaction
of	TAFINLAR.xml:S2:13305:2	O
any	TAFINLAR.xml:S2:13308:3	O
severity	TAFINLAR.xml:S2:13312:8	O
complicated	TAFINLAR.xml:S2:13321:11	O
by	TAFINLAR.xml:S2:13333:2	O
hypotension	TAFINLAR.xml:S2:13336:11	B-AdverseReaction
,	TAFINLAR.xml:S2:13347:1	O
rigors	TAFINLAR.xml:S2:13349:6	B-AdverseReaction
or	TAFINLAR.xml:S2:13356:2	O
chills	TAFINLAR.xml:S2:13359:6	B-AdverseReaction
occurred	TAFINLAR.xml:S2:13366:8	O
in	TAFINLAR.xml:S2:13375:2	O
3.7%	TAFINLAR.xml:S2:13378:4	O
(	TAFINLAR.xml:S2:13383:1	O
7	TAFINLAR.xml:S2:13384:1	O
187	TAFINLAR.xml:S2:13386:3	O
)	TAFINLAR.xml:S2:13389:1	O
of	TAFINLAR.xml:S2:13391:2	O
patients	TAFINLAR.xml:S2:13394:8	O
treated	TAFINLAR.xml:S2:13403:7	O
with	TAFINLAR.xml:S2:13411:4	O
TAFINLAR	TAFINLAR.xml:S2:13416:8	O
and	TAFINLAR.xml:S2:13425:3	O
in	TAFINLAR.xml:S2:13429:2	O
none	TAFINLAR.xml:S2:13432:4	O
of	TAFINLAR.xml:S2:13437:2	O
the	TAFINLAR.xml:S2:13440:3	O
59	TAFINLAR.xml:S2:13444:2	O
patients	TAFINLAR.xml:S2:13447:8	O
treated	TAFINLAR.xml:S2:13456:7	O
with	TAFINLAR.xml:S2:13464:4	O
dacarbazine	TAFINLAR.xml:S2:13469:11	O
.	TAFINLAR.xml:S2:13480:1	O

In	TAFINLAR.xml:S2:13489:2	O
Trial	TAFINLAR.xml:S2:13492:5	O
2	TAFINLAR.xml:S2:13498:1	O
,	TAFINLAR.xml:S2:13499:1	O
the	TAFINLAR.xml:S2:13501:3	O
incidence	TAFINLAR.xml:S2:13505:9	O
of	TAFINLAR.xml:S2:13515:2	O
fever	TAFINLAR.xml:S2:13518:5	B-AdverseReaction
(	TAFINLAR.xml:S2:13524:1	O
serious	TAFINLAR.xml:S2:13525:7	B-Severity
and	TAFINLAR.xml:S2:13533:3	O
non	TAFINLAR.xml:S2:13537:3	O
-	TAFINLAR.xml:S2:13540:1	O
serious	TAFINLAR.xml:S2:13541:7	O
)	TAFINLAR.xml:S2:13548:1	O
was	TAFINLAR.xml:S2:13550:3	O
71%	TAFINLAR.xml:S2:13554:3	O
(	TAFINLAR.xml:S2:13558:1	O
39	TAFINLAR.xml:S2:13559:2	O
55	TAFINLAR.xml:S2:13562:2	O
)	TAFINLAR.xml:S2:13564:1	O
in	TAFINLAR.xml:S2:13566:2	O
patients	TAFINLAR.xml:S2:13569:8	O
treated	TAFINLAR.xml:S2:13578:7	O
with	TAFINLAR.xml:S2:13586:4	O
TAFINLAR	TAFINLAR.xml:S2:13591:8	O
in	TAFINLAR.xml:S2:13600:2	O
combination	TAFINLAR.xml:S2:13603:11	O
with	TAFINLAR.xml:S2:13615:4	O
trametinib	TAFINLAR.xml:S2:13620:10	O
and	TAFINLAR.xml:S2:13631:3	O
26%	TAFINLAR.xml:S2:13635:3	O
(	TAFINLAR.xml:S2:13639:1	O
14	TAFINLAR.xml:S2:13640:2	O
53	TAFINLAR.xml:S2:13643:2	O
)	TAFINLAR.xml:S2:13645:1	O
in	TAFINLAR.xml:S2:13647:2	O
patients	TAFINLAR.xml:S2:13650:8	O
treated	TAFINLAR.xml:S2:13659:7	O
with	TAFINLAR.xml:S2:13667:4	O
TAFINLAR	TAFINLAR.xml:S2:13672:8	O
as	TAFINLAR.xml:S2:13681:2	O
a	TAFINLAR.xml:S2:13684:1	O
single	TAFINLAR.xml:S2:13686:6	O
agent	TAFINLAR.xml:S2:13693:5	O
.	TAFINLAR.xml:S2:13698:1	O

Serious	TAFINLAR.xml:S2:13700:7	B-Severity
febrile	TAFINLAR.xml:S2:13708:7	B-AdverseReaction
reactions	TAFINLAR.xml:S2:13716:9	I-AdverseReaction
and	TAFINLAR.xml:S2:13726:3	O
fever	TAFINLAR.xml:S2:13730:5	B-AdverseReaction
of	TAFINLAR.xml:S2:13736:2	O
any	TAFINLAR.xml:S2:13739:3	O
severity	TAFINLAR.xml:S2:13743:8	O
complicated	TAFINLAR.xml:S2:13752:11	O
by	TAFINLAR.xml:S2:13764:2	O
hypotension	TAFINLAR.xml:S2:13767:11	B-AdverseReaction
,	TAFINLAR.xml:S2:13778:1	O
rigors	TAFINLAR.xml:S2:13780:6	B-AdverseReaction
or	TAFINLAR.xml:S2:13787:2	O
chills	TAFINLAR.xml:S2:13790:6	B-AdverseReaction
occurred	TAFINLAR.xml:S2:13797:8	O
in	TAFINLAR.xml:S2:13806:2	O
25%	TAFINLAR.xml:S2:13809:3	O
(	TAFINLAR.xml:S2:13813:1	O
14	TAFINLAR.xml:S2:13814:2	O
55	TAFINLAR.xml:S2:13817:2	O
)	TAFINLAR.xml:S2:13819:1	O
of	TAFINLAR.xml:S2:13821:2	O
patients	TAFINLAR.xml:S2:13824:8	O
treated	TAFINLAR.xml:S2:13833:7	O
with	TAFINLAR.xml:S2:13841:4	O
TAFINLAR	TAFINLAR.xml:S2:13846:8	O
in	TAFINLAR.xml:S2:13855:2	O
combination	TAFINLAR.xml:S2:13858:11	O
with	TAFINLAR.xml:S2:13870:4	O
trametinib	TAFINLAR.xml:S2:13875:10	O
compared	TAFINLAR.xml:S2:13886:8	O
with	TAFINLAR.xml:S2:13895:4	O
2%	TAFINLAR.xml:S2:13900:2	O
(	TAFINLAR.xml:S2:13903:1	O
1	TAFINLAR.xml:S2:13904:1	O
53	TAFINLAR.xml:S2:13906:2	O
)	TAFINLAR.xml:S2:13908:1	O
of	TAFINLAR.xml:S2:13910:2	O
patients	TAFINLAR.xml:S2:13913:8	O
treated	TAFINLAR.xml:S2:13922:7	O
with	TAFINLAR.xml:S2:13930:4	O
TAFINLAR	TAFINLAR.xml:S2:13935:8	O
as	TAFINLAR.xml:S2:13944:2	O
a	TAFINLAR.xml:S2:13947:1	O
single	TAFINLAR.xml:S2:13949:6	O
agent	TAFINLAR.xml:S2:13956:5	O
.	TAFINLAR.xml:S2:13961:1	O

Fever	TAFINLAR.xml:S2:13963:5	B-AdverseReaction
was	TAFINLAR.xml:S2:13969:3	O
complicated	TAFINLAR.xml:S2:13973:11	O
with	TAFINLAR.xml:S2:13985:4	O
chills	TAFINLAR.xml:S2:13990:6	B-AdverseReaction
rigors	TAFINLAR.xml:S2:13997:6	B-AdverseReaction
in	TAFINLAR.xml:S2:14004:2	O
51%	TAFINLAR.xml:S2:14007:3	O
(	TAFINLAR.xml:S2:14011:1	O
28	TAFINLAR.xml:S2:14012:2	O
55	TAFINLAR.xml:S2:14015:2	O
)	TAFINLAR.xml:S2:14017:1	O
,	TAFINLAR.xml:S2:14018:1	O
dehydration	TAFINLAR.xml:S2:14020:11	B-AdverseReaction
in	TAFINLAR.xml:S2:14032:2	O
9%	TAFINLAR.xml:S2:14035:2	O
(	TAFINLAR.xml:S2:14038:1	O
5	TAFINLAR.xml:S2:14039:1	O
55	TAFINLAR.xml:S2:14041:2	O
)	TAFINLAR.xml:S2:14043:1	O
,	TAFINLAR.xml:S2:14044:1	O
renal	TAFINLAR.xml:S2:14046:5	B-AdverseReaction
failure	TAFINLAR.xml:S2:14052:7	I-AdverseReaction
in	TAFINLAR.xml:S2:14060:2	O
4%	TAFINLAR.xml:S2:14063:2	O
(	TAFINLAR.xml:S2:14066:1	O
2	TAFINLAR.xml:S2:14067:1	O
55	TAFINLAR.xml:S2:14069:2	O
)	TAFINLAR.xml:S2:14071:1	O
,	TAFINLAR.xml:S2:14072:1	O
and	TAFINLAR.xml:S2:14074:3	O
syncope	TAFINLAR.xml:S2:14078:7	B-AdverseReaction
in	TAFINLAR.xml:S2:14086:2	O
4%	TAFINLAR.xml:S2:14089:2	O
(	TAFINLAR.xml:S2:14092:1	O
2	TAFINLAR.xml:S2:14093:1	O
55	TAFINLAR.xml:S2:14095:2	O
)	TAFINLAR.xml:S2:14097:1	O
of	TAFINLAR.xml:S2:14099:2	O
patients	TAFINLAR.xml:S2:14102:8	O
in	TAFINLAR.xml:S2:14111:2	O
Trial	TAFINLAR.xml:S2:14114:5	O
2	TAFINLAR.xml:S2:14120:1	O
.	TAFINLAR.xml:S2:14121:1	O

In	TAFINLAR.xml:S2:14130:2	O
patients	TAFINLAR.xml:S2:14133:8	O
treated	TAFINLAR.xml:S2:14142:7	O
with	TAFINLAR.xml:S2:14150:4	O
TAFINLAR	TAFINLAR.xml:S2:14155:8	O
in	TAFINLAR.xml:S2:14164:2	O
combination	TAFINLAR.xml:S2:14167:11	O
with	TAFINLAR.xml:S2:14179:4	O
trametinib	TAFINLAR.xml:S2:14184:10	O
,	TAFINLAR.xml:S2:14194:1	O
the	TAFINLAR.xml:S2:14196:3	O
median	TAFINLAR.xml:S2:14200:6	O
time	TAFINLAR.xml:S2:14207:4	O
to	TAFINLAR.xml:S2:14212:2	O
initial	TAFINLAR.xml:S2:14215:7	O
onset	TAFINLAR.xml:S2:14223:5	O
of	TAFINLAR.xml:S2:14229:2	O
fever	TAFINLAR.xml:S2:14232:5	B-AdverseReaction
was	TAFINLAR.xml:S2:14238:3	O
30	TAFINLAR.xml:S2:14242:2	O
days	TAFINLAR.xml:S2:14245:4	O
compared	TAFINLAR.xml:S2:14250:8	O
with	TAFINLAR.xml:S2:14259:4	O
19	TAFINLAR.xml:S2:14264:2	O
days	TAFINLAR.xml:S2:14267:4	O
in	TAFINLAR.xml:S2:14272:2	O
patients	TAFINLAR.xml:S2:14275:8	O
treated	TAFINLAR.xml:S2:14284:7	O
with	TAFINLAR.xml:S2:14292:4	O
TAFINLAR	TAFINLAR.xml:S2:14297:8	O
as	TAFINLAR.xml:S2:14306:2	O
a	TAFINLAR.xml:S2:14309:1	O
single	TAFINLAR.xml:S2:14311:6	O
agent	TAFINLAR.xml:S2:14318:5	O
;	TAFINLAR.xml:S2:14323:1	O
the	TAFINLAR.xml:S2:14325:3	O
median	TAFINLAR.xml:S2:14329:6	O
duration	TAFINLAR.xml:S2:14336:8	O
of	TAFINLAR.xml:S2:14345:2	O
fever	TAFINLAR.xml:S2:14348:5	B-AdverseReaction
was	TAFINLAR.xml:S2:14354:3	O
6	TAFINLAR.xml:S2:14358:1	O
days	TAFINLAR.xml:S2:14360:4	O
with	TAFINLAR.xml:S2:14365:4	O
the	TAFINLAR.xml:S2:14370:3	O
combination	TAFINLAR.xml:S2:14374:11	O
compared	TAFINLAR.xml:S2:14386:8	O
with	TAFINLAR.xml:S2:14395:4	O
4	TAFINLAR.xml:S2:14400:1	O
days	TAFINLAR.xml:S2:14402:4	O
with	TAFINLAR.xml:S2:14407:4	O
TAFINLAR	TAFINLAR.xml:S2:14412:8	O
as	TAFINLAR.xml:S2:14421:2	O
a	TAFINLAR.xml:S2:14424:1	O
single	TAFINLAR.xml:S2:14426:6	O
agent	TAFINLAR.xml:S2:14433:5	O
.	TAFINLAR.xml:S2:14438:1	O

Across	TAFINLAR.xml:S2:14447:6	O
clinical	TAFINLAR.xml:S2:14454:8	O
trials	TAFINLAR.xml:S2:14463:6	O
of	TAFINLAR.xml:S2:14470:2	O
TAFINLAR	TAFINLAR.xml:S2:14473:8	O
administered	TAFINLAR.xml:S2:14482:12	O
in	TAFINLAR.xml:S2:14495:2	O
combination	TAFINLAR.xml:S2:14498:11	O
with	TAFINLAR.xml:S2:14510:4	O
trametinib	TAFINLAR.xml:S2:14515:10	O
(	TAFINLAR.xml:S2:14526:1	O
N	TAFINLAR.xml:S2:14527:1	O
202	TAFINLAR.xml:S2:14531:3	O
)	TAFINLAR.xml:S2:14534:1	O
,	TAFINLAR.xml:S2:14535:1	O
the	TAFINLAR.xml:S2:14537:3	O
incidence	TAFINLAR.xml:S2:14541:9	O
of	TAFINLAR.xml:S2:14551:2	O
pyrexia	TAFINLAR.xml:S2:14554:7	B-AdverseReaction
was	TAFINLAR.xml:S2:14562:3	O
57%	TAFINLAR.xml:S2:14566:3	O
(	TAFINLAR.xml:S2:14570:1	O
116	TAFINLAR.xml:S2:14571:3	O
202	TAFINLAR.xml:S2:14575:3	O
)	TAFINLAR.xml:S2:14578:1	O
.	TAFINLAR.xml:S2:14579:1	O

Withhold	TAFINLAR.xml:S2:14587:8	O
TAFINLAR	TAFINLAR.xml:S2:14596:8	O
for	TAFINLAR.xml:S2:14605:3	O
fever	TAFINLAR.xml:S2:14609:5	O
of	TAFINLAR.xml:S2:14615:2	O
101.3	TAFINLAR.xml:S2:14618:5	O
oF	TAFINLAR.xml:S2:14623:2	O
or	TAFINLAR.xml:S2:14626:2	O
higher	TAFINLAR.xml:S2:14629:6	O
.	TAFINLAR.xml:S2:14635:1	O

Withhold	TAFINLAR.xml:S2:14637:8	O
trametinib	TAFINLAR.xml:S2:14646:10	O
for	TAFINLAR.xml:S2:14657:3	O
any	TAFINLAR.xml:S2:14661:3	O
fever	TAFINLAR.xml:S2:14665:5	O
higher	TAFINLAR.xml:S2:14671:6	O
than	TAFINLAR.xml:S2:14678:4	O
104	TAFINLAR.xml:S2:14683:3	O
oF	TAFINLAR.xml:S2:14686:2	O
.	TAFINLAR.xml:S2:14688:1	O

Withhold	TAFINLAR.xml:S2:14690:8	O
TAFINLAR	TAFINLAR.xml:S2:14699:8	O
,	TAFINLAR.xml:S2:14707:1	O
and	TAFINLAR.xml:S2:14709:3	O
trametinib	TAFINLAR.xml:S2:14713:10	O
if	TAFINLAR.xml:S2:14724:2	O
used	TAFINLAR.xml:S2:14727:4	O
in	TAFINLAR.xml:S2:14732:2	O
combination	TAFINLAR.xml:S2:14735:11	O
,	TAFINLAR.xml:S2:14746:1	O
for	TAFINLAR.xml:S2:14748:3	O
any	TAFINLAR.xml:S2:14752:3	O
serious	TAFINLAR.xml:S2:14756:7	O
febrile	TAFINLAR.xml:S2:14764:7	O
reaction	TAFINLAR.xml:S2:14772:8	O
or	TAFINLAR.xml:S2:14781:2	O
fever	TAFINLAR.xml:S2:14784:5	O
complicated	TAFINLAR.xml:S2:14790:11	O
by	TAFINLAR.xml:S2:14802:2	O
hypotension	TAFINLAR.xml:S2:14805:11	O
,	TAFINLAR.xml:S2:14816:1	O
rigors	TAFINLAR.xml:S2:14818:6	O
or	TAFINLAR.xml:S2:14825:2	O
chills	TAFINLAR.xml:S2:14828:6	O
,	TAFINLAR.xml:S2:14834:1	O
dehydration	TAFINLAR.xml:S2:14836:11	O
,	TAFINLAR.xml:S2:14847:1	O
or	TAFINLAR.xml:S2:14849:2	O
renal	TAFINLAR.xml:S2:14852:5	O
failure	TAFINLAR.xml:S2:14858:7	O
and	TAFINLAR.xml:S2:14866:3	O
evaluate	TAFINLAR.xml:S2:14870:8	O
for	TAFINLAR.xml:S2:14879:3	O
signs	TAFINLAR.xml:S2:14883:5	O
and	TAFINLAR.xml:S2:14889:3	O
symptoms	TAFINLAR.xml:S2:14893:8	O
of	TAFINLAR.xml:S2:14902:2	O
infection	TAFINLAR.xml:S2:14905:9	O
.	TAFINLAR.xml:S2:14914:1	O

Refer	TAFINLAR.xml:S2:14916:5	O
to	TAFINLAR.xml:S2:14922:2	O
Table	TAFINLAR.xml:S2:14925:5	O
2	TAFINLAR.xml:S2:14931:1	O
for	TAFINLAR.xml:S2:14933:3	O
recommended	TAFINLAR.xml:S2:14937:11	O
dose	TAFINLAR.xml:S2:14949:4	O
modifications	TAFINLAR.xml:S2:14954:13	O
for	TAFINLAR.xml:S2:14968:3	O
adverse	TAFINLAR.xml:S2:14972:7	O
reactions	TAFINLAR.xml:S2:14980:9	O
[	TAFINLAR.xml:S2:14990:1	O
see	TAFINLAR.xml:S2:14991:3	O
Dosage	TAFINLAR.xml:S2:14995:6	O
and	TAFINLAR.xml:S2:15002:3	O
Administration	TAFINLAR.xml:S2:15006:14	O
(	TAFINLAR.xml:S2:15021:1	O
2.3	TAFINLAR.xml:S2:15022:3	O
)]	TAFINLAR.xml:S2:15025:2	O
.	TAFINLAR.xml:S2:15027:1	O

Prophylaxis	TAFINLAR.xml:S2:15030:11	O
with	TAFINLAR.xml:S2:15042:4	O
antipyretics	TAFINLAR.xml:S2:15047:12	O
may	TAFINLAR.xml:S2:15060:3	O
be	TAFINLAR.xml:S2:15064:2	O
required	TAFINLAR.xml:S2:15067:8	O
when	TAFINLAR.xml:S2:15076:4	O
resuming	TAFINLAR.xml:S2:15081:8	O
TAFINLAR	TAFINLAR.xml:S2:15090:8	O
or	TAFINLAR.xml:S2:15099:2	O
trametinib	TAFINLAR.xml:S2:15102:10	O
.	TAFINLAR.xml:S2:15112:1	O

5.8	TAFINLAR.xml:S2:15124:3	O
Serious	TAFINLAR.xml:S2:15128:7	O
Skin	TAFINLAR.xml:S2:15136:4	O
Toxicity	TAFINLAR.xml:S2:15141:8	O

Serious	TAFINLAR.xml:S2:15158:7	B-Severity
skin	TAFINLAR.xml:S2:15166:4	B-AdverseReaction
toxicity	TAFINLAR.xml:S2:15171:8	I-AdverseReaction
can	TAFINLAR.xml:S2:15180:3	B-Factor
occur	TAFINLAR.xml:S2:15184:5	O
when	TAFINLAR.xml:S2:15190:4	O
TAFINLAR	TAFINLAR.xml:S2:15195:8	O
is	TAFINLAR.xml:S2:15204:2	O
used	TAFINLAR.xml:S2:15207:4	O
in	TAFINLAR.xml:S2:15212:2	O
combination	TAFINLAR.xml:S2:15215:11	O
with	TAFINLAR.xml:S2:15227:4	O
trametinib	TAFINLAR.xml:S2:15232:10	O
and	TAFINLAR.xml:S2:15243:3	O
with	TAFINLAR.xml:S2:15247:4	O
trametinib	TAFINLAR.xml:S2:15252:10	O
as	TAFINLAR.xml:S2:15263:2	O
a	TAFINLAR.xml:S2:15266:1	O
single	TAFINLAR.xml:S2:15268:6	O
agent	TAFINLAR.xml:S2:15275:5	O
[	TAFINLAR.xml:S2:15281:1	O
refer	TAFINLAR.xml:S2:15282:5	O
to	TAFINLAR.xml:S2:15288:2	O
Full	TAFINLAR.xml:S2:15291:4	O
Prescribing	TAFINLAR.xml:S2:15296:11	O
Information	TAFINLAR.xml:S2:15308:11	O
for	TAFINLAR.xml:S2:15320:3	O
trametinib	TAFINLAR.xml:S2:15324:10	O
]	TAFINLAR.xml:S2:15334:1	O
.	TAFINLAR.xml:S2:15337:1	O

In	TAFINLAR.xml:S2:15346:2	O
Trial	TAFINLAR.xml:S2:15349:5	O
2	TAFINLAR.xml:S2:15355:1	O
,	TAFINLAR.xml:S2:15356:1	O
the	TAFINLAR.xml:S2:15358:3	O
incidence	TAFINLAR.xml:S2:15362:9	O
of	TAFINLAR.xml:S2:15372:2	O
any	TAFINLAR.xml:S2:15375:3	O
skin	TAFINLAR.xml:S2:15379:4	B-AdverseReaction
toxicity	TAFINLAR.xml:S2:15384:8	I-AdverseReaction
was	TAFINLAR.xml:S2:15393:3	O
similar	TAFINLAR.xml:S2:15397:7	O
for	TAFINLAR.xml:S2:15405:3	O
patients	TAFINLAR.xml:S2:15409:8	O
receiving	TAFINLAR.xml:S2:15418:9	O
TAFINLAR	TAFINLAR.xml:S2:15428:8	O
in	TAFINLAR.xml:S2:15437:2	O
combination	TAFINLAR.xml:S2:15440:11	O
with	TAFINLAR.xml:S2:15452:4	O
trametinib	TAFINLAR.xml:S2:15457:10	O
(	TAFINLAR.xml:S2:15468:1	O
65%	TAFINLAR.xml:S2:15469:3	O
[	TAFINLAR.xml:S2:15473:1	O
36	TAFINLAR.xml:S2:15474:2	O
55	TAFINLAR.xml:S2:15477:2	O
])	TAFINLAR.xml:S2:15479:2	O
compared	TAFINLAR.xml:S2:15482:8	O
with	TAFINLAR.xml:S2:15491:4	O
patients	TAFINLAR.xml:S2:15496:8	O
receiving	TAFINLAR.xml:S2:15505:9	O
TAFINLAR	TAFINLAR.xml:S2:15515:8	O
as	TAFINLAR.xml:S2:15524:2	O
a	TAFINLAR.xml:S2:15527:1	O
single	TAFINLAR.xml:S2:15529:6	O
agent	TAFINLAR.xml:S2:15536:5	O
(	TAFINLAR.xml:S2:15542:1	O
68%	TAFINLAR.xml:S2:15543:3	O
[	TAFINLAR.xml:S2:15547:1	O
36	TAFINLAR.xml:S2:15548:2	O
53	TAFINLAR.xml:S2:15551:2	O
])	TAFINLAR.xml:S2:15553:2	O
.	TAFINLAR.xml:S2:15555:1	O

The	TAFINLAR.xml:S2:15557:3	O
median	TAFINLAR.xml:S2:15561:6	O
time	TAFINLAR.xml:S2:15568:4	O
to	TAFINLAR.xml:S2:15573:2	O
onset	TAFINLAR.xml:S2:15576:5	O
of	TAFINLAR.xml:S2:15582:2	O
skin	TAFINLAR.xml:S2:15585:4	B-AdverseReaction
toxicity	TAFINLAR.xml:S2:15590:8	I-AdverseReaction
in	TAFINLAR.xml:S2:15599:2	O
patients	TAFINLAR.xml:S2:15602:8	O
treated	TAFINLAR.xml:S2:15611:7	O
with	TAFINLAR.xml:S2:15619:4	O
TAFINLAR	TAFINLAR.xml:S2:15624:8	O
in	TAFINLAR.xml:S2:15633:2	O
combination	TAFINLAR.xml:S2:15636:11	O
with	TAFINLAR.xml:S2:15648:4	O
trametinib	TAFINLAR.xml:S2:15653:10	O
was	TAFINLAR.xml:S2:15664:3	O
37	TAFINLAR.xml:S2:15668:2	O
days	TAFINLAR.xml:S2:15671:4	O
(	TAFINLAR.xml:S2:15676:1	O
range	TAFINLAR.xml:S2:15677:5	O
:	TAFINLAR.xml:S2:15682:1	O
1	TAFINLAR.xml:S2:15684:1	O
to	TAFINLAR.xml:S2:15686:2	O
225	TAFINLAR.xml:S2:15689:3	O
days	TAFINLAR.xml:S2:15693:4	O
)	TAFINLAR.xml:S2:15697:1	O
and	TAFINLAR.xml:S2:15699:3	O
median	TAFINLAR.xml:S2:15703:6	O
time	TAFINLAR.xml:S2:15710:4	O
to	TAFINLAR.xml:S2:15715:2	O
resolution	TAFINLAR.xml:S2:15718:10	O
of	TAFINLAR.xml:S2:15729:2	O
skin	TAFINLAR.xml:S2:15732:4	B-AdverseReaction
toxicity	TAFINLAR.xml:S2:15737:8	I-AdverseReaction
was	TAFINLAR.xml:S2:15746:3	O
33	TAFINLAR.xml:S2:15750:2	O
days	TAFINLAR.xml:S2:15753:4	O
(	TAFINLAR.xml:S2:15758:1	O
range	TAFINLAR.xml:S2:15759:5	O
:	TAFINLAR.xml:S2:15764:1	O
3	TAFINLAR.xml:S2:15766:1	O
to	TAFINLAR.xml:S2:15768:2	O
421	TAFINLAR.xml:S2:15771:3	O
days	TAFINLAR.xml:S2:15775:4	O
)	TAFINLAR.xml:S2:15779:1	O
.	TAFINLAR.xml:S2:15780:1	O

No	TAFINLAR.xml:S2:15782:2	O
patient	TAFINLAR.xml:S2:15785:7	O
required	TAFINLAR.xml:S2:15793:8	O
dose	TAFINLAR.xml:S2:15802:4	O
reduction	TAFINLAR.xml:S2:15807:9	O
or	TAFINLAR.xml:S2:15817:2	O
permanent	TAFINLAR.xml:S2:15820:9	O
discontinuation	TAFINLAR.xml:S2:15830:15	O
of	TAFINLAR.xml:S2:15846:2	O
TAFINLAR	TAFINLAR.xml:S2:15849:8	O
or	TAFINLAR.xml:S2:15858:2	O
trametinib	TAFINLAR.xml:S2:15861:10	O
for	TAFINLAR.xml:S2:15872:3	O
skin	TAFINLAR.xml:S2:15876:4	O
toxicity	TAFINLAR.xml:S2:15881:8	O
.	TAFINLAR.xml:S2:15889:1	O

Across	TAFINLAR.xml:S2:15898:6	O
clinical	TAFINLAR.xml:S2:15905:8	O
trials	TAFINLAR.xml:S2:15914:6	O
of	TAFINLAR.xml:S2:15921:2	O
TAFINLAR	TAFINLAR.xml:S2:15924:8	O
in	TAFINLAR.xml:S2:15933:2	O
combination	TAFINLAR.xml:S2:15936:11	O
with	TAFINLAR.xml:S2:15948:4	O
trametinib	TAFINLAR.xml:S2:15953:10	O
(	TAFINLAR.xml:S2:15964:1	O
N	TAFINLAR.xml:S2:15965:1	O
202	TAFINLAR.xml:S2:15969:3	O
)	TAFINLAR.xml:S2:15972:1	O
,	TAFINLAR.xml:S2:15973:1	O
severe	TAFINLAR.xml:S2:15975:6	B-Severity
skin	TAFINLAR.xml:S2:15982:4	B-AdverseReaction
toxicity	TAFINLAR.xml:S2:15987:8	I-AdverseReaction
and	TAFINLAR.xml:S2:15996:3	O
secondary	TAFINLAR.xml:S2:16000:9	B-AdverseReaction
infections	TAFINLAR.xml:S2:16010:10	I-AdverseReaction
of	TAFINLAR.xml:S2:16021:2	I-AdverseReaction
the	TAFINLAR.xml:S2:16024:3	I-AdverseReaction
skin	TAFINLAR.xml:S2:16028:4	I-AdverseReaction
requiring	TAFINLAR.xml:S2:16033:9	O
hospitalization	TAFINLAR.xml:S2:16043:15	O
occurred	TAFINLAR.xml:S2:16059:8	O
in	TAFINLAR.xml:S2:16068:2	O
2.5%	TAFINLAR.xml:S2:16071:4	O
(	TAFINLAR.xml:S2:16076:1	O
5	TAFINLAR.xml:S2:16077:1	O
202	TAFINLAR.xml:S2:16079:3	O
)	TAFINLAR.xml:S2:16082:1	O
of	TAFINLAR.xml:S2:16084:2	O
patients	TAFINLAR.xml:S2:16087:8	O
treated	TAFINLAR.xml:S2:16096:7	O
with	TAFINLAR.xml:S2:16104:4	O
TAFINLAR	TAFINLAR.xml:S2:16109:8	O
in	TAFINLAR.xml:S2:16118:2	O
combination	TAFINLAR.xml:S2:16121:11	O
with	TAFINLAR.xml:S2:16133:4	O
trametinib	TAFINLAR.xml:S2:16138:10	O
.	TAFINLAR.xml:S2:16148:1	O

Withhold	TAFINLAR.xml:S2:16157:8	O
TAFINLAR	TAFINLAR.xml:S2:16166:8	O
,	TAFINLAR.xml:S2:16174:1	O
and	TAFINLAR.xml:S2:16176:3	O
trametinib	TAFINLAR.xml:S2:16180:10	O
if	TAFINLAR.xml:S2:16191:2	O
used	TAFINLAR.xml:S2:16194:4	O
in	TAFINLAR.xml:S2:16199:2	O
combination	TAFINLAR.xml:S2:16202:11	O
,	TAFINLAR.xml:S2:16213:1	O
for	TAFINLAR.xml:S2:16215:3	O
intolerable	TAFINLAR.xml:S2:16219:11	O
or	TAFINLAR.xml:S2:16231:2	O
severe	TAFINLAR.xml:S2:16234:6	O
skin	TAFINLAR.xml:S2:16241:4	O
toxicity	TAFINLAR.xml:S2:16246:8	O
.	TAFINLAR.xml:S2:16254:1	O

TAFINLAR	TAFINLAR.xml:S2:16256:8	O
and	TAFINLAR.xml:S2:16265:3	O
trametinib	TAFINLAR.xml:S2:16269:10	O
may	TAFINLAR.xml:S2:16280:3	O
be	TAFINLAR.xml:S2:16284:2	O
resumed	TAFINLAR.xml:S2:16287:7	O
at	TAFINLAR.xml:S2:16295:2	O
lower	TAFINLAR.xml:S2:16298:5	O
dose	TAFINLAR.xml:S2:16304:4	O
levels	TAFINLAR.xml:S2:16309:6	O
in	TAFINLAR.xml:S2:16316:2	O
patients	TAFINLAR.xml:S2:16319:8	O
with	TAFINLAR.xml:S2:16328:4	O
improvement	TAFINLAR.xml:S2:16333:11	O
or	TAFINLAR.xml:S2:16345:2	O
recovery	TAFINLAR.xml:S2:16348:8	O
from	TAFINLAR.xml:S2:16357:4	O
skin	TAFINLAR.xml:S2:16362:4	O
toxicity	TAFINLAR.xml:S2:16367:8	O
within	TAFINLAR.xml:S2:16376:6	O
3	TAFINLAR.xml:S2:16383:1	O
weeks	TAFINLAR.xml:S2:16385:5	O
[	TAFINLAR.xml:S2:16391:1	O
see	TAFINLAR.xml:S2:16392:3	O
Dosage	TAFINLAR.xml:S2:16396:6	O
and	TAFINLAR.xml:S2:16403:3	O
Administration	TAFINLAR.xml:S2:16407:14	O
(	TAFINLAR.xml:S2:16422:1	O
2.3	TAFINLAR.xml:S2:16423:3	O
)]	TAFINLAR.xml:S2:16426:2	O
.	TAFINLAR.xml:S2:16430:1	O

5.9	TAFINLAR.xml:S2:16441:3	O
Hyperglycemia	TAFINLAR.xml:S2:16445:13	O

Hyperglycemia	TAFINLAR.xml:S2:16465:13	B-AdverseReaction
can	TAFINLAR.xml:S2:16479:3	B-Factor
occur	TAFINLAR.xml:S2:16483:5	O
when	TAFINLAR.xml:S2:16489:4	O
TAFINLAR	TAFINLAR.xml:S2:16494:8	O
is	TAFINLAR.xml:S2:16503:2	O
administered	TAFINLAR.xml:S2:16506:12	O
as	TAFINLAR.xml:S2:16519:2	O
a	TAFINLAR.xml:S2:16522:1	O
single	TAFINLAR.xml:S2:16524:6	O
agent	TAFINLAR.xml:S2:16531:5	O
or	TAFINLAR.xml:S2:16537:2	O
when	TAFINLAR.xml:S2:16540:4	O
used	TAFINLAR.xml:S2:16545:4	O
in	TAFINLAR.xml:S2:16550:2	O
combination	TAFINLAR.xml:S2:16553:11	O
with	TAFINLAR.xml:S2:16565:4	O
trametinib	TAFINLAR.xml:S2:16570:10	O
.	TAFINLAR.xml:S2:16582:1	O

In	TAFINLAR.xml:S2:16588:2	O
Trial	TAFINLAR.xml:S2:16591:5	O
1	TAFINLAR.xml:S2:16597:1	O
,	TAFINLAR.xml:S2:16598:1	O
5	TAFINLAR.xml:S2:16600:1	O
of	TAFINLAR.xml:S2:16602:2	O
12	TAFINLAR.xml:S2:16605:2	O
patients	TAFINLAR.xml:S2:16608:8	O
with	TAFINLAR.xml:S2:16617:4	O
a	TAFINLAR.xml:S2:16622:1	O
history	TAFINLAR.xml:S2:16624:7	O
of	TAFINLAR.xml:S2:16632:2	O
diabetes	TAFINLAR.xml:S2:16635:8	O
required	TAFINLAR.xml:S2:16644:8	O
more	TAFINLAR.xml:S2:16653:4	O
intensive	TAFINLAR.xml:S2:16658:9	O
hypoglycemic	TAFINLAR.xml:S2:16668:12	O
therapy	TAFINLAR.xml:S2:16681:7	O
while	TAFINLAR.xml:S2:16689:5	O
taking	TAFINLAR.xml:S2:16695:6	O
TAFINLAR	TAFINLAR.xml:S2:16702:8	O
.	TAFINLAR.xml:S2:16710:1	O

The	TAFINLAR.xml:S2:16712:3	O
incidence	TAFINLAR.xml:S2:16716:9	O
of	TAFINLAR.xml:S2:16726:2	O
Grade	TAFINLAR.xml:S2:16729:5	B-Severity
3	TAFINLAR.xml:S2:16735:1	I-Severity
hyperglycemia	TAFINLAR.xml:S2:16737:13	B-AdverseReaction
based	TAFINLAR.xml:S2:16751:5	O
on	TAFINLAR.xml:S2:16757:2	O
laboratory	TAFINLAR.xml:S2:16760:10	O
values	TAFINLAR.xml:S2:16771:6	O
was	TAFINLAR.xml:S2:16778:3	O
6%	TAFINLAR.xml:S2:16782:2	O
(	TAFINLAR.xml:S2:16785:1	O
12	TAFINLAR.xml:S2:16786:2	O
187	TAFINLAR.xml:S2:16789:3	O
)	TAFINLAR.xml:S2:16792:1	O
in	TAFINLAR.xml:S2:16794:2	O
patients	TAFINLAR.xml:S2:16797:8	O
treated	TAFINLAR.xml:S2:16806:7	O
with	TAFINLAR.xml:S2:16814:4	O
TAFINLAR	TAFINLAR.xml:S2:16819:8	O
compared	TAFINLAR.xml:S2:16828:8	O
with	TAFINLAR.xml:S2:16837:4	O
none	TAFINLAR.xml:S2:16842:4	O
of	TAFINLAR.xml:S2:16847:2	O
the	TAFINLAR.xml:S2:16850:3	O
dacarbazine	TAFINLAR.xml:S2:16854:11	O
-	TAFINLAR.xml:S2:16865:1	O
treated	TAFINLAR.xml:S2:16866:7	O
patients	TAFINLAR.xml:S2:16874:8	O
.	TAFINLAR.xml:S2:16882:1	O

In	TAFINLAR.xml:S2:16889:2	O
Trial	TAFINLAR.xml:S2:16892:5	O
2	TAFINLAR.xml:S2:16898:1	O
,	TAFINLAR.xml:S2:16899:1	O
the	TAFINLAR.xml:S2:16901:3	O
incidence	TAFINLAR.xml:S2:16905:9	O
of	TAFINLAR.xml:S2:16915:2	O
Grade	TAFINLAR.xml:S2:16918:5	B-Severity
3	TAFINLAR.xml:S2:16924:1	I-Severity
hyperglycemia	TAFINLAR.xml:S2:16926:13	B-AdverseReaction
based	TAFINLAR.xml:S2:16940:5	O
on	TAFINLAR.xml:S2:16946:2	O
laboratory	TAFINLAR.xml:S2:16949:10	O
values	TAFINLAR.xml:S2:16960:6	O
was	TAFINLAR.xml:S2:16967:3	O
5%	TAFINLAR.xml:S2:16971:2	O
(	TAFINLAR.xml:S2:16974:1	O
3	TAFINLAR.xml:S2:16975:1	O
55	TAFINLAR.xml:S2:16977:2	O
)	TAFINLAR.xml:S2:16979:1	O
in	TAFINLAR.xml:S2:16981:2	O
patients	TAFINLAR.xml:S2:16984:8	O
treated	TAFINLAR.xml:S2:16993:7	O
with	TAFINLAR.xml:S2:17001:4	O
TAFINLAR	TAFINLAR.xml:S2:17006:8	O
in	TAFINLAR.xml:S2:17015:2	O
combination	TAFINLAR.xml:S2:17018:11	O
with	TAFINLAR.xml:S2:17030:4	O
trametinib	TAFINLAR.xml:S2:17035:10	O
compared	TAFINLAR.xml:S2:17046:8	O
with	TAFINLAR.xml:S2:17055:4	O
2%	TAFINLAR.xml:S2:17060:2	O
(	TAFINLAR.xml:S2:17063:1	O
1	TAFINLAR.xml:S2:17064:1	O
53	TAFINLAR.xml:S2:17066:2	O
)	TAFINLAR.xml:S2:17068:1	O
in	TAFINLAR.xml:S2:17070:2	O
patients	TAFINLAR.xml:S2:17073:8	O
treated	TAFINLAR.xml:S2:17082:7	O
with	TAFINLAR.xml:S2:17090:4	O
TAFINLAR	TAFINLAR.xml:S2:17095:8	O
as	TAFINLAR.xml:S2:17104:2	O
a	TAFINLAR.xml:S2:17107:1	O
single	TAFINLAR.xml:S2:17109:6	O
agent	TAFINLAR.xml:S2:17116:5	O
.	TAFINLAR.xml:S2:17121:1	O

Monitor	TAFINLAR.xml:S2:17130:7	O
serum	TAFINLAR.xml:S2:17138:5	O
glucose	TAFINLAR.xml:S2:17144:7	O
levels	TAFINLAR.xml:S2:17152:6	O
as	TAFINLAR.xml:S2:17159:2	O
clinically	TAFINLAR.xml:S2:17162:10	O
appropriate	TAFINLAR.xml:S2:17173:11	O
when	TAFINLAR.xml:S2:17185:4	O
TAFINLAR	TAFINLAR.xml:S2:17190:8	O
is	TAFINLAR.xml:S2:17199:2	O
administered	TAFINLAR.xml:S2:17202:12	O
as	TAFINLAR.xml:S2:17215:2	O
a	TAFINLAR.xml:S2:17218:1	O
single	TAFINLAR.xml:S2:17220:6	O
agent	TAFINLAR.xml:S2:17227:5	O
or	TAFINLAR.xml:S2:17233:2	O
when	TAFINLAR.xml:S2:17236:4	O
used	TAFINLAR.xml:S2:17241:4	O
in	TAFINLAR.xml:S2:17246:2	O
combination	TAFINLAR.xml:S2:17249:11	O
with	TAFINLAR.xml:S2:17261:4	O
trametinib	TAFINLAR.xml:S2:17266:10	O
in	TAFINLAR.xml:S2:17277:2	O
patients	TAFINLAR.xml:S2:17280:8	O
with	TAFINLAR.xml:S2:17289:4	O
pre	TAFINLAR.xml:S2:17294:3	O
-	TAFINLAR.xml:S2:17297:1	O
existing	TAFINLAR.xml:S2:17298:8	O
diabetes	TAFINLAR.xml:S2:17307:8	O
or	TAFINLAR.xml:S2:17316:2	O
hyperglycemia	TAFINLAR.xml:S2:17319:13	O
.	TAFINLAR.xml:S2:17332:1	O

Advise	TAFINLAR.xml:S2:17334:6	O
patients	TAFINLAR.xml:S2:17341:8	O
to	TAFINLAR.xml:S2:17350:2	O
report	TAFINLAR.xml:S2:17353:6	O
symptoms	TAFINLAR.xml:S2:17360:8	O
of	TAFINLAR.xml:S2:17369:2	O
severe	TAFINLAR.xml:S2:17372:6	O
hyperglycemia	TAFINLAR.xml:S2:17379:13	O
such	TAFINLAR.xml:S2:17393:4	O
as	TAFINLAR.xml:S2:17398:2	O
excessive	TAFINLAR.xml:S2:17401:9	O
thirst	TAFINLAR.xml:S2:17411:6	O
or	TAFINLAR.xml:S2:17418:2	O
any	TAFINLAR.xml:S2:17421:3	O
increase	TAFINLAR.xml:S2:17425:8	O
in	TAFINLAR.xml:S2:17434:2	O
the	TAFINLAR.xml:S2:17437:3	O
volume	TAFINLAR.xml:S2:17441:6	O
or	TAFINLAR.xml:S2:17448:2	O
frequency	TAFINLAR.xml:S2:17451:9	O
of	TAFINLAR.xml:S2:17461:2	O
urination	TAFINLAR.xml:S2:17464:9	O
.	TAFINLAR.xml:S2:17475:1	O

5.10	TAFINLAR.xml:S2:17484:4	O
Glucose	TAFINLAR.xml:S2:17489:7	O
-	TAFINLAR.xml:S2:17496:1	O
6	TAFINLAR.xml:S2:17497:1	O
-	TAFINLAR.xml:S2:17498:1	O
Phosphate	TAFINLAR.xml:S2:17499:9	O
Dehydrogenase	TAFINLAR.xml:S2:17509:13	O
Deficiency	TAFINLAR.xml:S2:17523:10	O

TAFINLAR	TAFINLAR.xml:S2:17539:8	O
,	TAFINLAR.xml:S2:17547:1	O
which	TAFINLAR.xml:S2:17549:5	O
contains	TAFINLAR.xml:S2:17555:8	O
a	TAFINLAR.xml:S2:17564:1	O
sulfonamide	TAFINLAR.xml:S2:17566:11	O
moiety	TAFINLAR.xml:S2:17578:6	O
,	TAFINLAR.xml:S2:17584:1	O
confers	TAFINLAR.xml:S2:17586:7	O
a	TAFINLAR.xml:S2:17594:1	O
potential	TAFINLAR.xml:S2:17596:9	O
risk	TAFINLAR.xml:S2:17606:4	B-Factor
of	TAFINLAR.xml:S2:17611:2	O
hemolytic	TAFINLAR.xml:S2:17614:9	B-AdverseReaction
anemia	TAFINLAR.xml:S2:17624:6	I-AdverseReaction
in	TAFINLAR.xml:S2:17631:2	O
patients	TAFINLAR.xml:S2:17634:8	O
with	TAFINLAR.xml:S2:17643:4	O
glucose	TAFINLAR.xml:S2:17648:7	O
-	TAFINLAR.xml:S2:17655:1	O
6	TAFINLAR.xml:S2:17656:1	O
-	TAFINLAR.xml:S2:17657:1	O
phosphate	TAFINLAR.xml:S2:17658:9	O
dehydrogenase	TAFINLAR.xml:S2:17668:13	O
(	TAFINLAR.xml:S2:17682:1	O
G6PD	TAFINLAR.xml:S2:17683:4	O
)	TAFINLAR.xml:S2:17687:1	O
deficiency	TAFINLAR.xml:S2:17689:10	O
.	TAFINLAR.xml:S2:17699:1	O

Closely	TAFINLAR.xml:S2:17701:7	O
observe	TAFINLAR.xml:S2:17709:7	O
patients	TAFINLAR.xml:S2:17717:8	O
with	TAFINLAR.xml:S2:17726:4	O
G6PD	TAFINLAR.xml:S2:17731:4	O
deficiency	TAFINLAR.xml:S2:17736:10	O
for	TAFINLAR.xml:S2:17747:3	O
signs	TAFINLAR.xml:S2:17751:5	O
of	TAFINLAR.xml:S2:17757:2	O
hemolytic	TAFINLAR.xml:S2:17760:9	O
anemia	TAFINLAR.xml:S2:17770:6	O
.	TAFINLAR.xml:S2:17776:1	O

5.11	TAFINLAR.xml:S2:17785:4	O
Embryofetal	TAFINLAR.xml:S2:17790:11	O
Toxicity	TAFINLAR.xml:S2:17802:8	O

Based	TAFINLAR.xml:S2:17816:5	O
on	TAFINLAR.xml:S2:17822:2	O
its	TAFINLAR.xml:S2:17825:3	O
mechanism	TAFINLAR.xml:S2:17829:9	O
of	TAFINLAR.xml:S2:17839:2	O
action	TAFINLAR.xml:S2:17842:6	O
,	TAFINLAR.xml:S2:17848:1	O
TAFINLAR	TAFINLAR.xml:S2:17850:8	O
can	TAFINLAR.xml:S2:17859:3	B-Factor
cause	TAFINLAR.xml:S2:17863:5	O
fetal	TAFINLAR.xml:S2:17869:5	B-AdverseReaction
harm	TAFINLAR.xml:S2:17875:4	I-AdverseReaction
when	TAFINLAR.xml:S2:17880:4	O
administered	TAFINLAR.xml:S2:17885:12	O
to	TAFINLAR.xml:S2:17898:2	O
a	TAFINLAR.xml:S2:17901:1	O
pregnant	TAFINLAR.xml:S2:17903:8	O
woman	TAFINLAR.xml:S2:17912:5	O
.	TAFINLAR.xml:S2:17917:1	O

Dabrafenib	TAFINLAR.xml:S2:17919:10	O
was	TAFINLAR.xml:S2:17930:3	O
teratogenic	TAFINLAR.xml:S2:17934:11	B-AdverseReaction
and	TAFINLAR.xml:S2:17946:3	O
embryotoxic	TAFINLAR.xml:S2:17950:11	B-AdverseReaction
in	TAFINLAR.xml:S2:17962:2	O
rats	TAFINLAR.xml:S2:17965:4	B-Animal
at	TAFINLAR.xml:S2:17970:2	O
doses	TAFINLAR.xml:S2:17973:5	O
three	TAFINLAR.xml:S2:17979:5	O
times	TAFINLAR.xml:S2:17985:5	O
greater	TAFINLAR.xml:S2:17991:7	O
than	TAFINLAR.xml:S2:17999:4	O
the	TAFINLAR.xml:S2:18004:3	O
human	TAFINLAR.xml:S2:18008:5	O
exposure	TAFINLAR.xml:S2:18014:8	O
at	TAFINLAR.xml:S2:18023:2	O
the	TAFINLAR.xml:S2:18026:3	O
recommended	TAFINLAR.xml:S2:18030:11	O
clinical	TAFINLAR.xml:S2:18042:8	O
dose	TAFINLAR.xml:S2:18051:4	O
.	TAFINLAR.xml:S2:18055:1	O

If	TAFINLAR.xml:S2:18057:2	O
this	TAFINLAR.xml:S2:18060:4	O
drug	TAFINLAR.xml:S2:18065:4	O
is	TAFINLAR.xml:S2:18070:2	O
used	TAFINLAR.xml:S2:18073:4	O
during	TAFINLAR.xml:S2:18078:6	O
pregnancy	TAFINLAR.xml:S2:18085:9	O
or	TAFINLAR.xml:S2:18095:2	O
if	TAFINLAR.xml:S2:18098:2	O
the	TAFINLAR.xml:S2:18101:3	O
patient	TAFINLAR.xml:S2:18105:7	O
becomes	TAFINLAR.xml:S2:18113:7	O
pregnant	TAFINLAR.xml:S2:18121:8	O
while	TAFINLAR.xml:S2:18130:5	O
taking	TAFINLAR.xml:S2:18136:6	O
this	TAFINLAR.xml:S2:18143:4	O
drug	TAFINLAR.xml:S2:18148:4	O
,	TAFINLAR.xml:S2:18152:1	O
the	TAFINLAR.xml:S2:18154:3	O
patient	TAFINLAR.xml:S2:18158:7	O
should	TAFINLAR.xml:S2:18166:6	O
be	TAFINLAR.xml:S2:18173:2	O
apprised	TAFINLAR.xml:S2:18176:8	O
of	TAFINLAR.xml:S2:18185:2	O
the	TAFINLAR.xml:S2:18188:3	O
potential	TAFINLAR.xml:S2:18192:9	O
hazard	TAFINLAR.xml:S2:18202:6	O
to	TAFINLAR.xml:S2:18209:2	O
a	TAFINLAR.xml:S2:18212:1	O
fetus	TAFINLAR.xml:S2:18214:5	O
[	TAFINLAR.xml:S2:18220:1	O
see	TAFINLAR.xml:S2:18221:3	O
Use	TAFINLAR.xml:S2:18225:3	O
in	TAFINLAR.xml:S2:18229:2	O
Specific	TAFINLAR.xml:S2:18232:8	O
Populations	TAFINLAR.xml:S2:18241:11	O
(	TAFINLAR.xml:S2:18253:1	O
8.1	TAFINLAR.xml:S2:18254:3	O
)]	TAFINLAR.xml:S2:18257:2	O
.	TAFINLAR.xml:S2:18261:1	O

Advise	TAFINLAR.xml:S2:18267:6	O
female	TAFINLAR.xml:S2:18274:6	O
patients	TAFINLAR.xml:S2:18281:8	O
of	TAFINLAR.xml:S2:18290:2	O
reproductive	TAFINLAR.xml:S2:18293:12	O
potential	TAFINLAR.xml:S2:18306:9	O
to	TAFINLAR.xml:S2:18316:2	O
use	TAFINLAR.xml:S2:18319:3	O
a	TAFINLAR.xml:S2:18323:1	O
highly	TAFINLAR.xml:S2:18325:6	O
effective	TAFINLAR.xml:S2:18332:9	O
non	TAFINLAR.xml:S2:18342:3	O
-	TAFINLAR.xml:S2:18345:1	O
hormonal	TAFINLAR.xml:S2:18346:8	O
method	TAFINLAR.xml:S2:18355:6	O
of	TAFINLAR.xml:S2:18362:2	O
contraception	TAFINLAR.xml:S2:18365:13	O
since	TAFINLAR.xml:S2:18379:5	O
TAFINLAR	TAFINLAR.xml:S2:18385:8	O
can	TAFINLAR.xml:S2:18394:3	O
render	TAFINLAR.xml:S2:18398:6	O
hormonal	TAFINLAR.xml:S2:18405:8	O
contraceptives	TAFINLAR.xml:S2:18414:14	O
ineffective	TAFINLAR.xml:S2:18429:11	O
,	TAFINLAR.xml:S2:18441:1	O
during	TAFINLAR.xml:S2:18443:6	O
treatment	TAFINLAR.xml:S2:18450:9	O
and	TAFINLAR.xml:S2:18460:3	O
for	TAFINLAR.xml:S2:18464:3	O
at	TAFINLAR.xml:S2:18468:2	O
least	TAFINLAR.xml:S2:18471:5	O
2	TAFINLAR.xml:S2:18477:1	O
weeks	TAFINLAR.xml:S2:18479:5	O
after	TAFINLAR.xml:S2:18485:5	O
treatment	TAFINLAR.xml:S2:18491:9	O
with	TAFINLAR.xml:S2:18501:4	O
TAFINLAR	TAFINLAR.xml:S2:18506:8	O
or	TAFINLAR.xml:S2:18515:2	O
for	TAFINLAR.xml:S2:18518:3	O
4	TAFINLAR.xml:S2:18522:1	O
months	TAFINLAR.xml:S2:18524:6	O
after	TAFINLAR.xml:S2:18531:5	O
treatment	TAFINLAR.xml:S2:18537:9	O
with	TAFINLAR.xml:S2:18547:4	O
TAFINLAR	TAFINLAR.xml:S2:18552:8	O
in	TAFINLAR.xml:S2:18561:2	O
combination	TAFINLAR.xml:S2:18564:11	O
with	TAFINLAR.xml:S2:18576:4	O
trametinib	TAFINLAR.xml:S2:18581:10	O
.	TAFINLAR.xml:S2:18593:1	O

Advise	TAFINLAR.xml:S2:18595:6	O
patients	TAFINLAR.xml:S2:18602:8	O
to	TAFINLAR.xml:S2:18611:2	O
contact	TAFINLAR.xml:S2:18614:7	O
their	TAFINLAR.xml:S2:18622:5	O
healthcare	TAFINLAR.xml:S2:18628:10	O
provider	TAFINLAR.xml:S2:18639:8	O
if	TAFINLAR.xml:S2:18648:2	O
they	TAFINLAR.xml:S2:18651:4	O
become	TAFINLAR.xml:S2:18656:6	O
pregnant	TAFINLAR.xml:S2:18663:8	O
,	TAFINLAR.xml:S2:18671:1	O
or	TAFINLAR.xml:S2:18673:2	O
if	TAFINLAR.xml:S2:18676:2	O
pregnancy	TAFINLAR.xml:S2:18679:9	O
is	TAFINLAR.xml:S2:18689:2	O
suspected	TAFINLAR.xml:S2:18692:9	O
,	TAFINLAR.xml:S2:18701:1	O
while	TAFINLAR.xml:S2:18703:5	O
taking	TAFINLAR.xml:S2:18709:6	O
TAFINLAR	TAFINLAR.xml:S2:18716:8	O
[	TAFINLAR.xml:S2:18725:1	O
see	TAFINLAR.xml:S2:18726:3	O
Drug	TAFINLAR.xml:S2:18730:4	O
Interactions	TAFINLAR.xml:S2:18735:12	O
(	TAFINLAR.xml:S2:18748:1	O
7.2	TAFINLAR.xml:S2:18749:3	O
)	TAFINLAR.xml:S2:18752:1	O
,	TAFINLAR.xml:S2:18753:1	O
Use	TAFINLAR.xml:S2:18755:3	O
in	TAFINLAR.xml:S2:18759:2	O
Specific	TAFINLAR.xml:S2:18762:8	O
Populations	TAFINLAR.xml:S2:18771:11	O
(	TAFINLAR.xml:S2:18783:1	O
8.6	TAFINLAR.xml:S2:18784:3	O
)]	TAFINLAR.xml:S2:18787:2	O
.	TAFINLAR.xml:S2:18789:1	O
